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Aims and Scope for Series
“Cancer Sensitizing Agents
for Chemotherapy”
Current cancer management strategies
fail to adequately treat malignancies with
chemotherapy, with multivariable dose-
restrictive factors such as systemic toxicity
and multidrug resistance; hence, limiting
therapeutic benefits, quality of life and
complete long-term remission rates. The
resistance of cancer cells to anticancer
drugs is one of the major reasons for the
failure of traditional cancer treatments.
Cellular components and dysregulation of
signaling pathways contribute to drug re-
sistance. If modulated, such perturbations
may restore the drug response and its effi-
cacy. The recent understanding of the mo-
lecular mechanisms and targets that are
implicated for cancer chemoresistance
have paved the way to develop a large bat-
tery of small molecules (sensitizing agents)
that can target resistance and, thus,
allowing their combination with chemo-
therapeutic drugs to be effective and to re-
verse chemoresistance. A large variety of
chemotherapy-sensitizing agents has been
developed and several have been shown
to be effective in experimental models
and in cancer patients.
The main objective of the proposed series
“Cancer Sensitizing Agents for Chemother-
apy” is topublish individualizedand focused
volumeswherebyeachvolume iseditedbyan
invited expert Editor(s). Each volume will
dwell on specific chemo-sensitizing agents
with similar targeting activities. The combi-
nation treatment of the sensitizing agentwith
chemotherapy may result in a synergistic/
additive activity and the reversal of tumor
cells resistance to drugs.
The Editor(s) will compile nonoverlapp-
ing review chapters on reported findings in
various cancers, both experimentally and
clinically, with particular emphases on un-
derlying biochemical, genetic, andmolecular
mechanisms of the sensitizing agent and the
combination treatment.
The scope of the Series is to provide scien-
tists and clinicians with updated and clinical
information that will be valuable in their
quest to investigate, develop, and apply
novel combination therapies to reverse drug
resistance and, thereby, prolonging survival
and even cure in cancer patients.
Dr. Benjamin Bonavida, PhD (Series Editor)
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Preface
One of the main goals in cancer research is
to improve survival outcomes for patients
and it frequently relies on the understanding
of biologic events. ALK-driven cancers are a
remarkable example of how the molecular
characterization and functional study of a re-
ceptor have allowed to reach such a goal. In
less than a decade, first, second, and third
generation ALK tyrosine kinase inhibitors
(TKIs) have dramatically raised quality of
life and outcome of ALK-driven cancers.
Nevertheless, resistance to ALK TKIs forces
clinicians to face a therapeutic impasse after
the exhaustion of multiple treatment lines.
The characterization of resistant cancer sam-
ples has led to the identification of multiple
resistance mechanisms and innovative strat-
egies trying to overcome these, but they have
not been exhaustively reviewed in a single
document for different cancer types. Facing
efficacy failure of ALK TKIs in oncology, cli-
nicians and researchers would benefit from
general guidelines on how to identify the
acquired resistance mechanism and how to
select optimal therapeutic strategies to over-
come the specific resistance.
Dr. Luc Friboulet is a cancer scientist at the
INSERM institute and the Gustave Roussy
Comprehensive Cancer Center in France.
He is renowned for several breakthroughs
in the understanding of acquired mecha-
nisms of ALK-driven lung cancer. Together
with the best experts in the world on the
topic, he has delivered a genius book
containing the most comprehensive over-
view on ALK and cancer to date. It presents
the structure and function of the ALK recep-
tor and its role, not only in ALK-rearranged
lung cancer, but also in ALK-positive pediat-
ric cancers. It is also an extraordinary lesson
and guidance into resistance mechanisms
and tumor drug adaptation. The book is also
a remarkable resource on drug combinations
able to enhance ALK TKI antitumor efficacy
in ALK-driven cancers and presents many
future perspectives in the field. Among can-
cer researchers, clinicians, members of the
biomedical community, and even students,
most of them will find new inspiration and
useful information in this text to face their
daily fight to treat ALK-driven cancers.
Ken A. Olaussen
Universite Paris-Saclay, Gif-sur-Yvette,
France
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C H A P T E R
1
The ALK receptor tyrosine kinase
journey: From physiological roles to
pathological disruptions
Fabrizio Tabbò, Luisella Righi, Riccardo Taulli,
and Silvia Novello
Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy
Abstract
The overwhelming path of Anaplastic Lymphoma Kinase (ALK) goes from the characterization of its physi-
ological functions as Receptor Tyrosine Kinase (RTK) to the identification of pathogenetic mechanisms spur-
ring neoplastic transformation. If ALK role in mammal development is partially understood, molecular
disruptions have been observed in a variety of cancers either at high frequency in rare tumors or with low
occurrence in more prevalent ones, such as Non-Small Cell Lung Cancer (NSCLC). Deciphering ALK
perturbing effects in cancer cells gave us mechanistic insights in the comprehension of its physiological roles
and the basis to develop multiple small Tyrosine Kinase Inhibitors (TKI) capable to restrain ALK-driven on-
cogenesis. A deep understating of ALK biology has, therefore, direct therapeutic implications: amplifications,
point-mutations and translocations differently affect human cells and influence patients’ response to TKI or
other treatment strategies.
Abbreviations
AKT protein kinase B
ALCL anaplastic large cell lymphoma
ALK anaplastic lymphoma kinase
ALKAL ALK and LTK ligands
AP1 activator protein 1
BIM1 B cell-specific Moloney murine leukemia virus integration site 1
CAS9 CRISPR-associated protein 9
CD4 cluster of differentiation 4
CGH comprehensive genomic hybridization
CRISPR clustered regularly interspaced short palindromic repeats
CRKL CRK-like protein
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CTLC clathrin heavy chain
DDR DNA damage response
DLBCL diffuse large B cell lymphoma
DNMT1 DNA methyltransferase 1
EML4 echinoderm microtubule-associated protein-like 4
EZH2 enhancer of zeste homolog 2
FAM augemntor alfa/beta
FDA Food and Drug Administration
GCS granular cytoplasmic staining
GEM genetically engineered model
GR glycine-rich
HEN1 hesitation behavior 1
IMT inflammatory myofibroblastic tumor
JAK Janus kinase
Jeb jelly belly
JNK c-Jun N-terminal kinase
JUNB transcription factor Jun-B
KD kinase domain
KIF5B kinesin family member 5B
LDLa low-density lipoprotein
lncRNA long non-coding RNA
LTK leucocyte tyrosine kinase
MAM meprin, A-5 protein, Mu protein
MAPK mitogen-activated protein kinase
MCL1 induced myeloid leukemia cell differentiation protein Mcl-1
MDM2 mouse double minute 2 homolog
miRNA micro RNA
MMR DNA mismatch repair
MSH MutS homolog
mTOR mammalian target of rapamycin
MYCN N-myc proto-oncogene protein
NB neuroblastoma
NF1 neurofibromatosis type 1
NGS next-generation sequencing
NHL non-Hodgkin lymphoma
NPM1 nucleophosmin 1
p16INK4a inhibitor of CDK4
PI3K phosphoinositide 3 kinase
PLC-γ phospholipase C Gamma
PRDM1 positive regulatory domain maturation 1
PTN pleiotrphin
RAP1 Ras-related protein 1
RB retinoblastoma
RET Ret proto-oncogene
RPTP receptor-like protein tyrosine phosphatase
SETD2 SET domain containing 2
SHP1 Src homology region 2 domain-containing phosphatase-1
SNP single nucleotide polymoprhism
STAT singal transducer and activator of transcription
TAPE tandem atypical propeller in EMLs
TGF-β transforming growth factor beta
TP53 tumor protein P53
TPM3 tropomyosin alpha-3 chain
TRAF1 TNF receptor associated factor 1
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Introduction
Receptors Tyrosine Kinases (RTKs) exert a crucial role in the cellular physiology orches-
trating fundamental mechanisms such as cell-cycle progression, proliferation, differentiation
andmigration. Their ligand-dependent activation allows a temporal and spatial control of the
catalytic function, whose final fate is to induce specific biological responses through a com-
plex and redundant signaling cascade [1]. Negative regulators exist to attenuate and block
intracellular firing when a new cell “status” is achieved; however, diverse disrupting events
are capable to sustain RTK enzymatic activity determining an hyperactive condition [2,3].
Structural alterations, either prompting a ligand-independent constitutive activation or
expressing uncontrolled kinases out of their physiological context, make RTKs well-
recognized oncogenes, from which cancer cells very often depend [4,5]. The Anaplastic Lym-
phoma Kinase (ALK) RTK, which plays key roles in organism development, belongs to this
family of growth-enhancing proteins that, if functionally or structurally altered,may promote
uncontrolled cancer growth [6]. Across different tumors, multiple ALK alterations have been
described: full-length receptor point mutations in neuroblastoma (NB) and gene transloca-
tions in Anaplastic Large Cell Lymphoma (ALCL) andNon-Small Cell Lung Cancer (NSCLC)
are the most relevant [7]. Characterization of these molecular defects, in terms of occurrence,
protein structure, signaling perturbation and cancer cell dependency had led to the under-
standing of their pathogenic role and development of a plethora of ALK inhibitors (ALKi)
available in the clinical arena.
The ALK proto-oncogene
The Anaplastic Lymphoma Kinase (ALK) was originally identified in Anaplastic Large-
Cell non-Hodgkin’s Lymphoma (ALCL) cell lines as the product of a chromosomal translo-
cation t(2;5; p23;q35) involving the Nucleophosmin (NPM1) partner [8,9]. The human ALK
locus is located at the 2p23.2–p23.1 chromosome region and encodes for 26 exons that result
in a 1620 amino acids protein of about 180 kDa, that is the extensively glycosylated [10,11]. At
the structural level the ALK tyrosine kinase receptor, together with the leukocyte tyrosine
kinase (LTK), belong to the insulin receptor superfamily due to their similarities in the kinase
domain (KD). In contrast to LTK, the extracellular region of human ALK consists of a glycine-
rich domain (GR), two meprin A-5 protein, receptor protein-tyrosine phosphatase μ regions
(MAM) and a low-density lipoprotein motif (LDLa) (Fig. 1) [10–13]. The biological signifi-
cance of LDLa is unknown, while at the structural level the MAM domain can potentially es-
tablish extracellular cell-to-cell interactions. The functional relevance ofMAMandGR regions
have been demonstrated in a series of Drosophila ALKmutants, in which specific amino acid
substitutions resulted in a lethal gut phenotype during development [14]. At the molecular
level, the activation loop includes an YxxxYY motif that is in common with the insulin
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receptor. Notwithstanding, a detailed molecular analysis has revealed that, specifically, the
ALK Tyr1278 is critical for KD activation and for oncogenic transformation [15,16].
ALK function relies on classical receptor tyrosine kinase mechanisms: via a ligand-
dependent dimerization and trans-phosphorylation of specific residues, its catalytic capabilities
are activated. In addition to Y1278, Y1282 and Y1283 also appear as relevant tyrosine residues
within the activation loop [13,17]. Like other tyrosine kinase receptors, phosphorylated ALK
generates a downstream signaling cascade. The vast majority of insights about ALK signaling
are gained by aberrant isoforms, mainly ALK fusions, where canonical and non-canonical
FIG. 1 The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase structure and its pathological alterations.
As other receptor tyrosine kinases, ALK is composed by an extracellular domain (with two MAM domains, one
LDLa domain and one glychin-rich region), an intracellular domain (the tyrosine kinase domain—TKD) and a
connecting trans-membrane region. Physiological activation of ALK receptor depends by ligand binding (light blue
star) then requires auto- and trans-phosphorylation of specific residues (red dots) and finally promotes signaling
to the nucleus. Intra-TKD mutations determine a constitutive ligand-independent activation, whereas ALK amp-
lification sustains an increased downstream signaling in a ligand-dependent manner. Truncated ALK mutants,
loosing extracellular domain, appear overexpressed within the cytoplasm and rearranged ALK proteins, with
TKD juxtaposed to a fusion partner with dimerization sites, aberrantly phosphorylates protein substrates and
constitutively sustain cell survival and proliferation.
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effectors are involved; in those conditions, the fusion partner dictates lots of the ALK chimeras’
biological properties, influencing spatial and temporal distributions. General signaling
pathways activated are: PLCγ, JAK-STAT, PI3K-AKT-mTOR, JUNB—as part of the AP1 com-
plex, CRKL-C3G-RAP1, MAPK signaling and a large number of other downstream targets
(Fig. 2) [7,18–20].
Although an active scientific debate is ongoing to establish a unique and specific human
ALK ligand [21–23], inD.melanogaster and inC. elegance, Jelly belly (Jeb) and hesitation behav-
ior 1 (HEN-1), bothcharacterizedbyapeculiarLDLadomain,havebeenrecognizedaseffective
ALK ligands [24–29].More recently, in vitro and in vivo studies validatedALKALs (FAM150A
and FAM150B) as ligands of ALK, since their binding to the ALK extra-cellular domain
activates the receptor and its signaling cascade. Also heparin has been claimed as activator
of ALK, since an heparin-binding motif is part of the ALK N-terminal region [22,30–32].
FIG. 2 Anaplastic lymphoma kinase (ALK) fusion protein and the signaling network. ALK chimeric proteins are
composed of ALK tyrosine kinase domain (orange) and the fusion partner (purple), which often contain a dimeriza-
tion domain (black lines). Once transactivation of catalytic domains is gained (red dots indicate phosphorylated sites)
ALK fusions activatemultiple canonical signaling pathways (PI3K/AKT/mTOR, JAK/STAT, PLCγ/PKC, and RAS/
MAPK/ERK) modulating different downstream mediators and transcriptional factors. Multiple perturbing events
are induced: epigenetic reprogramming by DNMTs expression and miRNA interference; cytoskeleton reshaping
and migration induced by CRKL/C3G/RAP1A axis; genomic integrity jeopardized counteracting DNA damage re-
sponse pathway and mismatch repair system. KD, kinase domain; DNMTs, DNA methyltransferases; miRNA,
microRNA.
5The ALK proto-oncogene
Defining ALK biology exploiting animal models
Pioneering studies in Drosophila have defined the relevance of ALK in gut development. In-
deed, during embryogenesis, Jeb is involved in the specification of founder cells that are respon-
sible of visceral musculature formation [14,24,25]. Other functional analyses have revealed a
critical role of the Jeb/ALK axis in cognitive functions and in the modulation of the body size
[33]. Interestingly, a recent study in Neurofibromin 1 (NF1) mouse model confirms the impor-
tance of ALK signaling in associative learning and sleep, proposing also the impairment of
ALKactivity as potentially beneficial in patients affected byNeurofibromatosis [34]. InDrosophila
the Jeb/ALKpathway is also involved in synapses and neuromuscular junction formation, in vi-
sual system development, sparing also organ growth during caloric restrictions [35–38]. More-
over, recent evidences support the involvement of ALK signaling in the phenomenon of
longevity and long-term memory modulation [39,40]. A functional crosstalk between ALK
and Transforming Growth Factor β (TGF-β) pathway has been observed in Drosophila during
gut development, an interplay then demonstrated also in C. elegans by an epistatic analysis
[29,41]. Moreover, in olfactory adaptation of C. elegans, the HEN-1 signaling contributes with
other pathways to the regulation of sensory responses and in particular to the proper forgetting
function [42]. In Zebrafish (Danio rerio) the ALK family is composed of two members: DrLtk and
DrAlk. The DrALK exhibits a smaller extracellular domain that lacks one MAM domain, while
DrLTK includes bothMAM regions, as the human counterpart [13]. Interestingly, the DrLtkmu-
tant (shady) exhibits profound defects in pigmentation [43]. As the mammalian ALK, DrLtk is
expressed in iridophores of the neural crest [13,43,44]. Thus, Zebrafish represents a useful model
to recapitulate human pathological alterations as recently demonstrated by the gain of function
phenotype observed in chimeric Zebrafish models harboring human cancer mutations [45]. Re-
cently, in vivo evidences support a functional interaction between DrLtk and alkal1, alkal2a and
alkal2b, which represent the homologs of the human secreted small activating proteins ALKAL1
and 2 [31]. In mammalian, pioneering studies on ALK have highlighted a specific pattern of
mRNAexpression in the central nervous systemduringmouse development [10,11,46]. Notably,
ALK expression decreases upon weaning, approximately at 3 weeks of age [11]. A similar mod-
ulation ofALK levels has also been confirmed in chicken, rat andhumans,where additionalALK
variants have been observed in other body districts as small intestine, colon, prostate and testis
[8,47,48].ALK loss of function studies reveal that, at least inmice,ALK is dispensable for survival
duringdevelopment; however, adeepanalysis of the central nervous systemhas recently showed
an increase of hippocampal performance and dopamine levels in these mutants [49,50].
Genetically engineered models (GEMs) of ALK pathogenesis
GEMs have actively contributed to define the oncogenic role of ALK in different tumor
types. The expression of the NPM1-ALK translocation under the control of the CD4 promoter
results in the spontaneous development of T-cell lymphomas and plasma cell tumors, show-
ing that bothALK and its effector Signal Transducer andActivator of Transcription 3 (STAT3)
act as critical drivers in this subset of hematological diseases [51–53]. In 2008, ALK KD mu-
tations were reported in familiar Neuroblastoma (NB), supporting a potential oncogenic role
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of the receptor in this malignancy (Fig. 3) [54–58]. These mutations were also observed in
commercial NB cell lines and trigger tumor growth in nude mice [55]. At the genomic level,
in NB, the ALK mutation F1174L co-segregates with N-myc proto-oncogene (MYCN). Ac-
cordingly, in both mouse and zebrafish models, the expression of this variant in the neural
crest, in concomitance with MYCN, results in more aggressive NB tumors in terms of devel-
opment, penetrance and lethality [59–61]. Importantly, the use of ALK inhibitors (ALKi) ex-
erts a dramatic effect on tumor growth, confirming the relevance of ALK-addiction in this
disease [60,61]. Molecular analysis on knock-in mice bearing the ALK F1178L or the
R1279Q mutations has also revealed that ALK is able to trigger Ret proto-oncogene (RET)
up-regulation during transformation. Indeed, RET inhibition reduces tumor growth in dou-
bleMYCN/ALK knock-inmodels, supporting also a pathogenetic role for this tyrosine kinase
receptor in ALK-mutated NB tumors [62]. Recently, a novel GEM model, in which the ALK
F1174L variant is temporally and conditionally controlled by the inducible Cre-loxP system,
has been generated. In this more physiological setting, tumor development is observed only
in association with MYCN, confirming that the two oncogenes actively cooperate in promot-
ing NB growth [63].
FIG. 3 Figurative summary of anaplastic lymphoma kinase (ALK) mutations. Gain-of-function mutations are
mainly point mutations occurring within the kinase domain of ALK receptor. The majority has been identified in
neuroblastoma (NB), either as congenital or acquired alterations, interesting, in the 80% of the cases, three hot spot
regions (in bold). Mutations have been identified also in anaplastic thyroid cancer (ATC) and cutaneous squamous
cell carcinoma (cSCC) cases. Truncating mutations that eliminate the extracellular domain have been described in
primary samples or cell lines of NB, anaplastic large cell lymphoma (ALCL) and synovial sarcoma (SS). Lastly, in
non-small cell lung cancer (NSCLC) ALK intra-kinase domain mutations are a well-known mechanism of acquired
resistance toALK inhibitors (ALKi). A large spectrumhas been reported,with peculiar difference based on the type of
administered ALKi. Less frequently identified after first-generation ALKi, their percentage augment after second-
generation inhibitors, being G1202R the most frequent. With the sequential administration of multiple ALKi, after
third-generation ALKi, so called compound mutations may occur.
7Genetically engineered models (GEMs) of ALK pathogenesis
The identification of the Echinoderm Microtubule-associated protein-Like 4 (EML4)-
ALK translocation in non-small cell lung cancer (NSCLC) patients, has pointed out the
potential oncogenic role of ALK also in this tumor type [64]. Thereby, several transgenic
animals expressing the EML4-ALK fusion, or other X-ALK fusions, under the control of
surfactant protein C gene, specifically in lung alveolar epithelial cells, have been generated
[65–67]. These models have been extensively exploited to investigate novel therapeutic
options for the treatment of ALK+ lung tumors, including targeted therapies, immunolog-
ical approaches or different combination regimens [67]. The improvements of next gener-
ation sequencing (NGS) methodologies have recently expanded the spectrum of ALK
fusion partners in NSCLC to about ninety different variants [68]. Since the majority of these
novel chimeric entities have not been investigated, but can exhibit different sensitivity to
anti-ALK directed therapies, innovative approaches are urgently required for in vivo func-
tional validation studies. Intriguingly, the use of CRISPR/Cas9 genome editing has been
proposed to engineer specific chromosomal rearrangements directly in murine lungs
[69]. This technology represents an extraordinary opportunity to faithfully recapitulate,
in a simple and effective manner, the plethora of ALK rearrangements found in lung cancer
patients [70]. Finally, this new generation of GEMs can be extremely useful to test ALKi in a
personalized setting, to investigate the mechanisms of acquired resistance and to explore
novel therapeutic regimens.
Aberrant forms and altered expression of ALK
ALK exists in multiple different conditions that may be physiological alternatives or, as
above described, pathological disruptions. As results of alternative transcription initiation
(ATI) site, three different isoforms (ALKATI) have been recognized. These ALKATI are
kinase-active, possess oncogenic capacity and their expression has been identified in certain
tumors: melanoma, lung adenocarcinoma and renal clear cell carcinoma [71]. Why these al-
ternative isoforms exist and how they signal is still not elucidated.
Mechanisms that alter ALK expression are substantially three: ALK amplification, ALK
mutations ad ALK fusions. Several groups have investigated ALK overexpression in neoplas-
tic tissues (e.g., thyroid carcinoma, NSCLC, breast cancer, melanoma, tumors of the central
nervous system, ewing- or rabdomyo-sarcoma andmalignant fibrous histocytoma), although
its significance at the molecular level remains elusive [72–76]. Evidences suggest a potential
role of ALK in breast cancer due to its strong expression, associated with the Pleiothropin
(PTN)/Receptor-like Protein Tyrosine Phosphatase (RPTP)β/ζ signaling, claiming an hypo-
thetical ALK oncogenic property in a patients’ subset [77]. Amplifications of chromosome 2,
encoding both for ALK and MYCN, play a relevant role in NB especially when associated
with ALK mutations [76,78]. For this reason, as discussed, ALK amplification and gain-of-
function mutations are deeply characterized in the pathogenesis of NB [79].
Mutations within “hot spot” regions of the tyrosine KD, disrupting the auto-inhibitory
mechanism, are able to determine a constitutively active full-length receptor. Almost 85%
of them occupy specific positions: R1275, F1174 and F1245, which are observed in a relevant
number of familial NB and also in sporadic cases [54–58,80,81]. Full-length receptor muta-
tions, which affect tissues physiologically expressing ALK rather than cause an ectopic
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expression like in ALK-rearranged tumors, are observed also in other cancer types, as ana-
plastic thyroid cancer (mutations in L1198F and G1201E), rhabdomyosarcoma, primitive
neuroectodermal tumor, osteosarcoma and cutaneous squamous cell cancer [82–84]. Mainly
three different classes of ALK receptor mutations may be identified: ligand-independent
gain-of-function, ligand-dependent and truncated activated ALKmutants. Among this latter
category, ALKΔ2-3,Δ1-5 andΔ4-11 have been identified in neuroblastoma-derived cell lines,
while other variants (ALK Δ2-17) in ALCL and synovial sarcoma cell lines as results of com-
plex genomic rearrangements [85–88]. Lastly, intra-ALK KD mutations may occur as an
acquired mechanism of resistance during treatment with ALKi: in NSCLC patients their ap-
pearance is influenced by inhibitors of different generations (Fig. 3) [89, 90].
Structure and origin of ALK chimeras
From the first identification of the NPM1-ALK fusion protein generated by the chromo-
somal translocation t(2;5; p23;q35) in ALCL in 1994, an overwhelming plethora of ALK chi-
meras has been characterized, often occurring as rare event in a wide range of different
tumors. Today ALK translocations play a relevant role in the group of tyrosine kinase fusions
as potential therapeutic targets [7,8,91]. Of note ALK detection and targeting is part of gold-
standard diagnostic-therapeutic protocols of specific tumors, like NSCLC. Even if reported as
a quite rare event (2–7%), the EML4-ALK fusion, generated by an intra-chromosomal inver-
sion inv.(2)(p21p23), represents the most prevalent ALK chimera due to the high prevalence
in NSCLC patients [64,92,93]. A relevant aspect in the generation of chimeric protein, either
created by inter- or intra-chromosomal rearrangements, is the forced oligomerization caused
by loss of inhibitory domains and due to the ALK fusion partner: for instance, the coiled-coil
domain of EML4 induces dimerization and activation of the fused protein (Fig. 2).
Breakpoints generating ALK fusions occur within exons coding for the juxta-membrane re-
gion (typically exon 20), thus creating a protein with the entire tyrosine KD. Since the trans-
membrane and the promoter region are lost, the fusion partner will dictate its localization and
ectopically expression. In addition, some of the ALK chimeras have multiple variants for the
same partner (i.e., EML4-ALKwithmore the 15 variants), therefore augmenting the biological
complexity of the fusion protein itself [94,95].
Tyrosine kinase fusions are well-recognized oncogenes, however multiple efforts have
been spent to clarify its role as simple passengers or drivers of the neoplastic transformation.
Observations that NPM1-ALK fusion transcripts are detectable also in non-neoplastic healthy
T lymphocytes or hematopoietic cells suggest that maybe fusions are necessary, but not suf-
ficient, to drive oncogenesis and other alterations are required [96]. In lung adenocarcinoma,
EML4-ALK fusions appear as events of early oncogenesis and the acquisition, only after long
latency, of other genetic defects (i.e., SETD2 mutations) determines the emergence of tumor
lesions [97]. Furthermore, a differential role in tumor development may be due to different
levels of ALK protein expression, which depend on different transcriptional activity of the
fusion partner and different patterns of translational regulation of the chimeric protein: these
evidences shed light on the concept of near-neutrality also for ALK rearrangements during
early phases of neoplastic transformation [98].
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ALK fusions and their partners: Biological implications
Chromosomal rearrangements are perturbing events within the cell, whichever they rep-
resent the inception of oncogenesis or just a step forward. The generated chimeric protein
alters the intracellular biology, accelerating transformation with multiple different modali-
ties: recruits molecular adaptors, phosphorylates signaling substrates, alters transcriptional
programs interacting with nuclear factors, influences epigenetic modifications and genomic
stability, determines its proper spatial localization and prevents fusion protein degradation
(Fig. 2). ALK fusions activate a plethora of signaling pathways, as above elucidated, and are
capable to potentiate oncogenic pathways directly, like in the case of the NF-kB signaling for
the TRAF1-ALK fusion [99]. NPM1-ALK tends to accumulate also into the nucleus, due to the
oligomerization with wild-type NPM1, an ubiquitously expressed protein with nucleocyto-
plasmatic shutting role [100]. Due partially to its sub-localization, NPM1-ALK influences di-
rectly and indirectly DNA damage response (DDR) pathway and DNA mismatch repair
(MMR) system. From one side, as other oncogenes, ALK fusions induce DNA damages
and curtail pathways capable to induce cellular senescence: NPM1-ALK inhibits p53 via
MDM2 and JNK and deregulates p16INK4a/RB. On the other side they alter function of
the MMR mechanism: MSH2 is a substrate of NPM1-ALK phosphorylations, thus blocking
theMSH2/MSH6 interaction and hindering DNA repair properties in presence of DNAdam-
age (Fig. 2) [101–103]. If we add that, in ALK+ ALCL patients, microsatellite instability and
loss of TP53 have been reported, we conclude that ALK fusions are able to perturb genomic
stability [103–105].
Skewing of the epigenetic pathways by NPM1-ALK happens through different mecha-
nisms; enhancement of gene silencing by promoting DNA methylation is mediated via
STAT3, a central node of ALK signaling, which induces expression of DNAmethyltrasferase
1 (DNMT1)—a central enzyme that maintainmethylation status [52,106]. In ALK+ALCL, dif-
ferent methylated genes, therefore repressed, have been identified: both positive regulators
for cellular proliferation (e.g., BIM) and negative controllers of signaling (e.g., SHP1,
STAT5A) that normally act as tumor suppressors [107–109]. Gene expression could also be
subverted by activity of miRNAs, facilitating malignant phenotype. Different studies have
tried to interrogate expression profiles of ALK+ versus ALK- ALCL, identifying keymiRNAs
in ALK+ cell lines and primary patients’ samples: among others, miR-17-92 cluster, which is
regulated by STAT3 and seems vital of ALK+ cells and miR-101, whose targets are mTOR,
MCL1 and EZH2 [110]. Moreover, long non-coding RNAs (lncRNAs), having role in post-
transcriptional regulation of mRNA, have been associated with ALK positivity, but their
significance is still matter of investigation. Lastly, epigenetic programs are diverted by
NPM1-ALK capacities to influence transcription factors: AP1 complexes and cJUN and JUNB
directly interact with chimeric protein at nuclear level and facilitate cell cycle progression
(Fig. 2) [111,112].
As discussed below, a vast variety of N-terminal partners has been discovered in a wide
range of cancers, mainly occurring at a very low frequency. EML4, the most characterized
one, with its different truncation sites and derived variants (v-1, -2, -3a/b, -5a/b) accounts
for the vast majority of ALK fusions in NSCLC. Different 50 ALK partners, and different var-
iants of the same chimeric protein, may influence functional aspects: localizationwithin the cell
(EML4 v1 is found in the cytoplasm whereas v3a/b is more associated with microtubules),
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intrinsic kinase activity, protein-protein interactions (TPM3-ALK impairs co-localization ofWT
TPM3 influencing cytoskeleton shaping) and protein stability (presence or absence of TAPE
moiety influences unstable forms recruiting heat shock proteins) [113–115]. Pre-clinical and
clinical retrospective studies highlighted therapeutic implications based on different partners
and variants: patients bearing EML4-ALKv1 tend to respond better to ALKi, resistance muta-
tions to next generation inhibitors are identified preferentially in EML4-ALKv3 and KIF5B-
ALK is less sensitive to crizotinib and lorlatinib. Conversely, large prospective studies are
reporting equal clinical responses—in terms of objective response, progression free survival
and duration of response—in ALK+ NSCLC bearing different EML4 variants [116–119].
ALK rearrangements in hematological cancers
NPM1-ALK fusion protein is expressed in the majority of ALCL, approximately 55% of
adult patients and more than 90% of pediatric ones. ALCL is a rare subtype of non-Hodgkin
lymphoma (NHL), most common in children and young adults, with a male predominance
(male/female ratio, 3.0) and accounting for 10–15% of pediatric and adolescent NHL, while it
represents approximately 3% of adult NHL [120]. ALK+ ALCL, expressing ALK protein due
to translocations that involve the 2p23 locus, represents a distinct type of peripheral T-cell
lymphoma in the World Health Organization (WHO) tumors’ classification [121,122]. The
more frequent fusion partner in ALK+ ALCL is NPM1, but an increasing number of ALK
fusion proteins are being identified in hematological neoplastic diseases (Table 1).
The localization of the ALK fusion protein in the lymphoma cells detected by immun-
ostaining differs depending on the partner gene. For the common NPM1-ALK fusion, immu-
nohistochemical detection of the ALK antigen shows both nuclear and cytoplasmic staining
due to the heterodimerization of NPM1-ALK with normal NPM1. Approximately 15% of
ALK+ ALCL cases and other ALK+ NHL lack the nuclear staining pattern, indicating that
aberrant ALK expression is due to a partner gene other than NPM1 (Table 1) [139,141]. Even
though the ALK fusion is a key oncogenic event in the pathogenesis of ALK+ ALCL, addi-
tional genetic imbalances have been described. By comprehensive genomic hybridization
(CGH) array, 58% of the ALK+ ALCL demonstrated chromosomal imbalances including
loss of 4q13-q28, 6q13-q22, 11q14-q23, and 13q and also gains of 7p11-pter and chromosome
17 [142]. By single nucleotide polymorphism (SNP) array analysis, ALK+ ALCL displayed
losses of 17p13.3-p12 and 6q21 in 35% of the case, and gains of 1q, 7q32.3 and 7p22.3-p21.3
were observed in 15% of samples. Positive Regulatory Domain Maturation 1 (PRDM1) gene,
a well-known tumor suppressor, located on 6q21, is less frequently inactivated in ALK+
ALCL compared to ALK- ALCL [104]. The role of these additional alterations in the patho-
genesis of the disease and prognosis is still unclear.
Diffuse Large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lym-
phoma diagnosed in adults and accounts for 30–40% of newly diagnosed lymphomas in the
United States [122]. ALK-positive large B-cell lymphoma (ALK+ DLBCL) is a rare subtype of
large B cell lymphoma defined as a neoplasm of ALK-positive large immunoblast-like B-cells,
resembling ALCL with occasional plasmablastic differentiation. The most frequent fusion
partner in ALK+ LBCL is Clathrin heavy Chain (CLTC) gene, followed by NPM1, associated
with a granular cytoplasmic and a nuclear/cytoplasmic immunostaining pattern, respectively.
11ALK rearrangements in hematological cancers
Tumor cells of rare cases harboring other gene fusions are characterized by different ALK
staining patterns (Table 1). Indeed, a prognostic role of ALK immunohistochemical pattern
was suggested: segregating cases with a granular cytoplasmic staining (GCS) pattern or a
non-GCS pattern showed lower survival in this latter category [140].
ALK rearrangements in solid cancers
Gene rearrangements are found in up to 3% of all human tumors [143]. Since ALK was
described in ALCL in 1994, several ALK fusion proteins have been identified in the next
two decades as oncogenic drivers in numerous different not-hematological malignancies. Al-
though the most relevant is the EML4-ALK, due its frequency in NSCLC, the advent of NGS-
based diagnostics led to the identification of a long list of different ALK fusion partner genes
TABLE 1 ALK translocations, their partners, and relative frequencies in hematological cancers.
ALK partner
Chromosomal
location Entity
Frequency
(%) ALK immunostaining Reference
NPM1 t(2;5)(p23;q35) ALCL,
DLBCL
75–80, N/A Nuclear and cytoplasmic [8,123]
RNF213/
ALO17
t(2;17)(p23;q25) ALCL <1 Diffuse cytoplasmic [124]
TFG t(2;3)(p23;q21) ALCL 2 Diffuse cytoplasmic [125]
MSN t(2;X)(p32;q11-12) ALCL <1 Membranous [126]
TPM3 t(1;2)(q25;p23) ALCL 12–18 Cytoplasmic and membranous [127]
TPM4 t(2;19)(p23;p13) ALCL <1 Diffuse cytoplasmic [128]
ATIC inv(2)(p23;q35) ALCL 2 Diffuse cytoplasmic [129]
MYH9 t(2;22)(p23;q11.2) ALCL <1 Diffuse cytoplasmic [130]
TRAF1 t(2;9)(p23;q33) ALCL <1 Diffuse cytoplasmic [131]
CLTC t(2;17)(p23;q23) ALCL,
DLBCL
2, N/A Granular cytoplasmic [132,133]
SQSTM1 t(2;5)(p23.1;q35.3) DLBCL N/A Diffuse cytoplasmic with spots [134]
SEC31A t(2;4)(p24;q21) DLBCL N/A Granular cytoplasmic [135]
RANBP2 inv(2)(p23;q13) AML,
DLBCL
<1, N/A Nuclear membrane with spots [136,137]
EEF1G t(2;11)(p23;q12.3) ALCL <1 Diffuse cytoplasmic [138]
GORASP2 inv(2)(p23;q31.1) DLBCL <1 Diffuse cytoplasmic with
perinuclear spots
[139]
EML4 inv(2)(p23;p21) DLBCL <1 Diffuse cytoplasmic [140]
ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B cell lymphoma; AML, acute myeloid leukemia; N/A, not applicable.
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across multiple solid neoplasms (Table 2). For example, the inflammatory myofibroblastic tu-
mor (IMT) is the first solid tumor found to harbor ALK rearrangements, which occur in up to
50% of cases; nevertheless, in ALK+ IMT EML4-ALK has not been reported, but a variety of
other fusion partners, not seen in NSCLC, have instead been identified [202,203]. NSCLC is
the second solid tumor in which oncogenic ALK fusions were detected, accounting for 3–7%
TABLE 2 ALK translocations, their partners, and relative frequencies in solid cancers.
ALK partner Chromosomal location Entity Frequency (%) Reference
IMT Up to 50
A2M 12p13.31 [144]
ATIC 2q35 [145]
CARS 11p15.5 [124]
CLTC 17q23.1 [146]
DES 2q35 [147]
HNRNPA1 12q13.13 [148]
IGFBP5 2q35 [149]
KIF5B 10p11.22 [150]
NUMA1 11q13.4 [151]
PPFIBP1 12p11 [152]
RANBP2 2q13 [153]
SEC31A 4q21.22 [154]
SQSTM1 5q35.3 [155]
THBS1 15q14 [149]
TPM3 1q21.2 [156]
TPM4 19p13.1 [156]
NSCLC 3–7
BCL11A 2p16.1 [157]
CLTC 17q23.1 [158]
CMTR1 6p21.2 [159]
CRIM1 2p22.2 [158]
CUX 7q22.1 [160]
DCTN1 2p13.1 [161]
EML4 2p21 [64]
Continued
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TABLE 2 ALK translocations, their partners, and relative frequencies in solid cancers—cont’d
ALK partner Chromosomal location Entity Frequency (%) Reference
GCC2 2q12.3 [162]
HIP1 7q11.2 [163]
KIF5B 10p11.22 [164]
KLC1 14q32.3 [165]
LCLAT 2p23.1 [166]
MREG 2q35 [167]
NLRC4 2p22.3 [168]
PTPN3 9q31.3 [169]
SEC31A 4q21 [170]
SOS1 2p22.1 [171]
SQSTM1 5q35.3 [161]
STRN 2p22.2 [172]
TFG 3q12.2 [173]
TNIP2 5q33.1 [174]
TPR 1q31.1 [175]
VIT 2p22.2 [176]
WDPCP 2p23.3 [177]
CLIP1 12q24.31 LUNG NET N/A [178]
CRC <1
WDCP/C2ORF44 2p23.3 [179]
CAD 2p23.3 [180]
EML4 2p21 [181]
SMEK2 2p16.1 [182]
RCC <1
EML4 2p21 [183]
HOOK1 1p32.1 [184]
STRN 2p22.2 [185]
TPM3 1q21.2 [186]
VCL 10q22.2 [187]
LMS <1
ACTG2 2p13.1 [188]
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TABLE 2 ALK translocations, their partners, and relative frequencies in solid cancers—cont’d
ALK partner Chromosomal location Entity Frequency (%) Reference
KANK2 19p13.2 [188]
TNS 2q35 [189]
MMyST N/A
FBXO28 1q42.11 [190]
NPAS2 2q11.2 [190]
TPM3 1q21.2 [190]
PPFIBP1 12p11 [190]
EFH N/A
MLPH 2q37.3 [191]
PRKAR2A 3p21.31 [191]
SQSTM1 5q35.3 [191]
VCL 10q22.2 [191]
TPM3 1q21.2 [191]
EML4 2p21 [191]
EML4 2p21 BC N/A [181]
TPM1 15q22.2 TCC N/A [182]
EML4 2p21 EC N/A [192]
TPM4 19p13.1 ESCC N/A [193]
A2M 12p13.31 FLIT N/A [194]
FN1 2q35 GIL N/A [195]
PPP1CB 2p23.2 HGG N/A [196]
FN1 2q35 OC N/A [197]
MPM N/A
STRN 2p22.2 [198]
TPM1 15q22.2 [198]
ATG16L1 2q37.1 [198]
ST N/A
MLPH 2q37.3 [199]
GTF3C2 2p23.3 [200]
CLIP1 12q24.31 [200]
TC <1%
Continued
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of lung cancers and being associated with non-smoking habit, younger age, and adenocarci-
noma histology [64,173,204]. Even though the relative proportion of NSCLC bearing an ALK
rearrangement is significantly lower compared toALCL or IMT, NSCLC constitute the largest
subset of tumor with an ALK rearrangement due to the high incidence of lung cancer world-
wide [93]. Notably, studies in NSCLC have identified several additional ALK fusion proteins,
which collectively occur less frequently than EML4-ALK (Table 2). The identification of ALK
rearrangements in lung cancer patients had sparked the development of a series of ALK TKI
fromdifferent companies. To date, five ALKTKI (crizotinib, ceritinib, alectinib, brigatinib and
lorlatinib), with different efficacy and resistance profiles, have received approval by the Food
and Drug Administration (FDA) for ALK+ NSCLC treatment [205,206].
At low frequency, ALK rearrangements have been detected in other solid cancers, includ-
ing colorectal, breast, renal cell, esophageal, ovarian, and anaplastic thyroid carcinoma
(Table 2). Due to the wide and routine use of NGS, more and more reports, even of single
case, of new ALK fusion partners have been described, sometimes associated with different
sensitivity to TKI [68]. The development of deep sequencing, coupled with immunohisto-
chemistry and fluorescent-in-situ-hybridization, had shed light on the complexity of ALK
rearrangements and how their occurrence is an heterogeneous event; multiple rearrange-
ments within the ALK locus in the same specimen, “not-productive” translocations without
a targetable protein or, even, nonreciprocal/reciprocal translocations with the retained 50
ALK domain determine multiple phenotypes with different clinical behaviors [207,208].
Conclusion
ALK structure and signaling investigation are propaedeutic to ALK targeting in the con-
text of human cancers. Structural alterations with pathological implications are detectable
across different tumor types and the administration of ALKi demonstrated unexpected clin-
ical impacts in the management of ALK+ cancers both in pediatric and adult patients
[119,209]. The comprehension of ALKmolecular biology, acquiredmainly leveraging disease
models driven by ALK mutations or translocations, represents the bedrock for the develop-
ment of therapeutic strategies targeting ALK aberrant activation. Today multiple ALKi, with
different activity profiles, are available in the clinic area and experimental or combinatorial
approaches, such as antibody-drug conjugate or vaccination strategies, are under develop-
ment [67,210]. Nevertheless, the management of ALK+ cancer patients still requires answers
TABLE 2 ALK translocations, their partners, and relative frequencies in solid cancers—cont’d
ALK partner Chromosomal location Entity Frequency (%) Reference
STRN 2p22.2 [201]
GTF2IRD1 7q11.23 [182]
IMT, imflammatory myofibroblastich tumor; NSCLC, non-small cell lung cancer; NET, neuroendocrine tumors; CRC, colorectal
cancer; RCC, renal cell cancer; LMS, leiomyosarcoma; MMyST, melanocytic myxoid spindle cell tumor; EFH, epithelioid fibrous
histiocytoma; BC, breast cancer; TCC, transitional cell cancer; EC, endometrial cancer; ESCC, esophageal squamous cell cancer; FLIT,
fetal lung interstitial tumor; GIL, gastro-intestinal leiomyoma; HGG, high-grade glioma; OC, ovarian cancer; MPM, malignant
peritoneal mesothelioma; ST, Spitz tumor; TC, thyroid cancer; N/A, not applicable.
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to open questions. Gene rearrangements are complex events that deeply alter cellular homeo-
stasis and their occurrence not always translates into a targetable event; moreover, the count-
less list of partner genes makes ALK fusion a proteiform molecule, whose impact in the
pathogenesis may differ notably from one cancer to others. Thus, correct patients’ selection
and identification is a first mandatory step to proper guide future decisions and NGS tech-
niques are widen our comprehension [68,117,207]. Then, the identification of precise seq-
uence of ALKi administration and the implementation of strategies to overcome resistance
mechanisms will help us reaching a better disease control in ALK+ cancer patients. Toward
this end, an extensive comprehension of ALK-related disrupting molecular events, and
derived pathogenetic modifications, is a crucial requirement to do not lag behind the
ALK enemy.
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[125] Hernández L, Pinyol M, Hernández S, Beà S, Pulford K, Rosenwald A, Lamant L, Falini B, Ott G, Mason DY,
Delsol G, Campo E. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma produc-
ing two structurally different TFG-ALK translocations. Blood 1999;94:3265–8.
[126] Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, Nayach I, Kluin-Nelemans HC, Kluin P, Touriol C,
Delsol G, Mason D, Campo E. Molecular characterization of a new ALK translocation involving moesin
(MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81:419–26. https://doi.org/10.1038/
labinvest.3780249.
[127] Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell
lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088–95.
24 1. The ALK receptor tyrosine kinase journey
[128] Meech SJ, McGavran L, Odom LF, Liang X, Meltesen L, Gump J, Wei Q, Carlsen S, Hunger SP. Unusual child-
hood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin
4 – anaplastic lymphoma kinase gene fusion. Blood 2001;98:1209–16. https://doi.org/10.1182/blood.
v98.4.1209.
[129] Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, DeWolf-Peeters C,Wlodarska I,
Morris SW. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase
(ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Blood 2000;95:2144–9.
[130] Lamant L, Gascoyne RD, DuplantierMM,Armstrong F, RaghabA, ChhanabhaiM, Rajcan-Separovic E, Raghab
J, Delsol G, Espinos E.Non-musclemyosin heavy chain (MYH9): a newpartner fused toALK in anaplastic large
cell lymphoma. Genes Chromosomes Cancer 2003;37:427–32. https://doi.org/10.1002/gcc.10232.
[131] Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, Eckloff BW, Johnson SH, Porcher JC, Ansell SM,
Caride A. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma.
Genes Chromosomes Cancer 2013;52:1097–102. https://doi.org/10.1002/gcc.22104.
[132] Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, Rousset T, Mason DY, Delsol G. Further demonstra-
tion of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing
ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204–7.
[133] De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P,
Vandenberghe P, Speleman F, Praet M, De Wolf-Peeters C, Marynen P, Wlodarska I. ALK activation by the
CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003;102:2638–41. https://doi.org/
10.1182/blood-2003-04-1050.
[134] Takeuchi K, SodaM, Togashi Y, Ota Y, Sekiguchi Y, Hatano S, Asaka R, NoguchiM,ManoH. Identification of a
novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011;96:464–7. https://
doi.org/10.3324/haematol.2010.033514.
[135] Bedwell C, Rowe D, Moulton D, Jones G, Bown N, Bacon CM. Cytogenetically complex SEC31A-ALK fusions
are recurrent inALK-positive large B-cell lymphomas. Haematologica 2011;96:343–6. https://doi.org/10.3324/
haematol.2010.031484.
[136] Maesako Y, Izumi K, Okamori S, Takeoka K, Kishimori C, Okumura A, Honjo G, Akasaka T, Ohno H. inv(2)
(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an el-
derly woman. Int J Hematol 2014;99:202–7. https://doi.org/10.1007/s12185-013-1482-x.
[137] Lee SE, Kang SY, Takeuchi K, Ko YH. Identification of RANBP2-ALK fusion in ALKpositive diffuse large B-cell
lymphoma. Hematol Oncol 2014;32:221–4. https://doi.org/10.1002/hon.2125.
[138] Palacios G, Shaw TI, Li Y, Singh RK, Valentine M, Sandlund JT, Lim MS, Mullighan CG, Leventaki V. Novel
ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1
complex. Leukemia 2017;31:743–7. https://doi.org/10.1038/leu.2016.331.
[139] Ise M, Kageyama H, Araki A, Itami M. Identification of a novel GORASP2-ALK fusion in an ALK-
positive large B-cell lymphoma. Leuk Lymphoma 2019;60:493–7. https://doi.org/10.1080/10428194.2018.
1493731.
[140] Sakamoto K, NakasoneH, Togashi Y, Sakata S, TsuyamaN, Baba S, Dobashi A, Asaka R, Tsai C-C, Chuang S-S,
IzutsuK, Kanda Y, Takeuchi K. ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review
of the literature focusing on the ALK immunohistochemical staining pattern. Int J Hematol 2016;103:399–408.
https://doi.org/10.1007/s12185-016-1934-1.
[141] Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s
lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol
1997;17:2312–25. https://doi.org/10.1128/mcb.17.4.2312.
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Abstract
Introduction of tyrosine kinase inhibitors (TKIs) have changed the treatment paradigm and improved the
prognosis of oncogenic addicted non-small cell lung cancer patients (NSCLC). Nowadays, for ALK-positive
lung cancers three ALK TKI have been approved: crizotinib, alectinib and brigatinib. Both, alectinib and
crizotinib are preferred first-line treatment options based on significant improvement in progression free sur-
vival and higher intracranial activity compared with crizotinib. However, the new ALK TKIs in first-line set-
ting are being explored such as brigatinib and lorlatinib, which may shift again the treatment paradigm of
ALK-positive NSCLC. The mechanisms of acquired resistance to ALK TKI and the most suitable approach
upfront as well as at progression, the role of ALK fusion partners for treatment decisions making and how
liquid biopsy may improve the knowledge for this disease are current challenges. In this chapter, we summa-
rize the current evidence for the efficacy of the different ALK TKIs in first-line setting and discuss current and
future challenges in this disease.
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Introduction
ALK gene rearrangements occur in 5% of patients with advanced non-small cell lung can-
cer (NSCLC). First-generation ALK tyrosine kinase inhibitor (TKI), crizotinib, and, more re-
cently next generation ALKTKIs (second generation: ceritinib, ensartinib, alectinib, brigatinib
and third generation: lorlatinib) have enlarged the therapeutic arsenal in this population. In
Table 1 we report the ALK activity of each of these compounds. Similar to other oncogenic
addicted lung adenocarcinomas, personalized treatment with ALK TKIs in the first-line set-
ting is the standard of care in daily clinical practice [1,2], and initiating personalized treatment
in a timely manner in ALK-positive tumors may have a positive impact on survival outcomes
[3]. Table 2 summarizes the outcome of ALK TKI in first-line setting in ALK-positive NSCLC
patients.
TABLE 1 ALK tyrosine kinase inhibitors, target and cellular IC50 for inhibiting ALK.
Drug Target IC50 EML4-ALK variant 1 WT (nM)
Crizotinib c-MET, ALK, ROS1 23
Ceritinib ALK, ROS1 12.5
Ensartinib ALK, ROS, MET, NTRK, AXL 1.28
Alectinib ALK 1.377
Brigatinib ALK, ROS1, EGFR 0.959
Lorlatinib ALK, ROS1 0.267
Based on Horn L, Whisenant JG, Wakelee H et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients
with ALK+ lung cancer. J Thorac Oncol 2019;14(11):1901–11.
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ALK TKI in first line setting
Crizotinib
Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases
c-MET, ALK andROS1.Although initially developed as a potent small molecule inhibitor of c-
MET, in ALK-translocated cell lines, crizotinib inhibited downstream effector functions and
induced apoptosis [14–16], supporting its activity as a potent inhibitor of ALK. The mean ap-
parent plasma terminal elimination half-life of crizotinib in patients with ALK-positive
NSCLC was 42h following a single dose of crizotinib 250mg [17]. A phase I clinical trial
was designed to include a dose-escalation phase, followed by a dose-expansion phase
at the maximum tolerated dose (MTD) in patients with MET-amplification or ALK-
rearrangement. Of note, this trial was already enrolling patients in the dose-escalation phase
when ALK-rearrangement in NSCLC was first reported in August 2007. Two patients with
NSCLC harboring ALK-rearrangement were treated with crizotinib during dose escalation
and showed dramatic improvement in their symptoms. This observation led to large-scale
TABLE 2 Efficacy of ALK tyrosine kinase inhibitors in first-line setting in ALK-positive non-small cell lung
cancer patients.
Trial Treatment N RR (%) PFS (months) OS (months)
PROFILE 1014
[4,5]
Crizotinib vs.
Chemotherapy
343 74 vs. 45
(P < .001)
10.9 vs. 7.0a
(HR 0.45; P < .001)
NR vs. 47.5
(HR 0.76;
P ¼ .098)
PROFILE 1029 [6] Crizotinib vs.
Chemotherapy
207 87.5 vs. 45.6
(P < .001)
11.1 vs. 6.2a
(HR 0,402;
P < .001)
28.7 vs. 27.7
(HR 0.897;
P ¼ .33)
ASCEND-4 [46] Ceritinib vs. Chemotherapy 376 73.0 vs. 26.3 16.6 vs. 8.1a
(HR 0.55;
P < .00001)
NR vs. 26.2
(HR 0.73;
P ¼ .056)
ALEX [7,8] Alectinib600 vs. Crizotinib 303 83% vs. 76
(P ¼ .09)
34.8 vs. 10.9
(HR 0.43; P < .001)
Not estimable
(HR 0.69;
0.47–1.02)
J-ALEX [9,10] Alectinib300 vs. Crizotinib 207 92% vs.
79%
34.1 vs. 10.2a
(HR 0.37;
0.26–0.52)
NR vs. 43.7
(HR 0.80;
P ¼ .386)
ALESSIA [11] Alectinib600 vs. Crizotinib 187 92% vs.
79%
(P ¼ .0095)
NR vs. 11.1a
(HR 0.22;
P < .0001)
Not estimable
(HR 0.28;
P ¼ .0027)
ALTA-1L [12,13] Brigatinib vs. Crizotinib 275 74% vs.
63%
(P ¼ .0342)
24.0 vs. 11.0a
(HR 0.49; P < .001)
Not estimable
(HR 0.92;
0.57–1.47)
CROWN Lorlatinib vs. Crizotinib 280 Pending Pending Pending
EXALT-3 Ensartinib vs. Crizotinib 290 Pending Pending Pending
a PFS assessed by independent review. NR, not reached.
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prospective screening of NSCLC patients and recruitment of ALK-positive NSCLC patients
into an expanded molecular cohort at the MTD of 250mg twice daily. The trial reported a
meaningful clinical activity, with a response rate (RR) of 61% and median progression free
survival (PFS) of 9.7months [18,19], launching the phase II PROFILE 1005 trial [20] and
the phase III PROFILE 1007 registration trial [21] in previously treated advancedALK-positive
NSCLC patients. In the PROFILE 1007 trial, crizotinib was associated with a longer PFS
(7.7months versus 3.0months, hazard ratio [HR], 0.49, 95% confidence interval [CI],
0.37–0.64, P < .001), higher RR (65% versus 20% for chemotherapy; P < .001), and significantly
greater improvement in patient-reported symptoms, global quality of life (QOL), and delayed
time to deterioration (TTD) of prespecified lung cancer symptoms compared with standard
second-line chemotherapy [21,22].
Based on these results, crizotinib was approved by FDA in 2011 and EMA in 2012 as stan-
dard treatment for lung cancers harboring ALK fusions, identified through a companion di-
agnostic assay. The efficacy of crizotinib in first-line setting in advancedALK-positive NSCLC
patients has been assessed in two randomized phase III clinical trials, the PROFILE 1014 [4,5]
and the PROFILE 1029 [6] only performed in Asian patients.
The phase III PROFILE 1014 trial randomized 343 treatment-naı̈ve ALK-positive NSCLC
patients to crizotinib or platinum-pemetrexed chemotherapy up to six cycles. Crossover to
crizotinib treatment after disease progression was permitted for patients receiving chemo-
therapy. Crizotinib achieved the PFS primary endpoint assessed by independent radiologic
review (10.9months with crizotinib versus 7.0months with chemotherapy, HR 0.40; 95% CI:
0.35–0.60, P < .001). The HR for PFS favored crizotinib across most subgroups defined
according to stratification factors (ECOG performance status, race, presence or absence of
brain metastases) and other baseline characteristics such as age or gender. Likewise,
crizotinib reported higher RR compared with chemotherapy (74% versus 45%, P < .001).
Themost common adverse events (AEs) with crizotinib were vision disorders (71%), diarrhea
(61%), and edema (49%), however, most AEs in the two treatment groups were grade 1 or 2 in
severity. Grade 3 or 4 elevations of aminotransferase levels occurred in 24 patients in the
crizotinib group (14%), but these elevations were managed primarily with dose interruptions
or dose reductions. Permanent discontinuation due to AEs occurred in 14% and 12% of pa-
tients in the crizotinib and chemotherapy arm, respectively. As compared with chemother-
apy, crizotinib was associated with greater reduction in lung cancer symptoms and greater
improvement in quality of life [4]. These data led to crizotinib being the first ALK TKI to
achieve worldwide approval for ALK-positive NSCLC patients in first-line setting.
Overall survival (OS) data were not mature at the time of the PFS analysis for the PROFILE
1014 trial with only 26% of deaths reported and amedian follow-up duration of 17months. At
that time OS did not differ significantly between the two arms (HR 0.83; 95% CI: 0.54–1.26,
P ¼ .36) [4]. Likewise, after a median follow-up of 46months in both arms, median OS was
not reached (NR) in crizotinib arm compared with 47.5months with chemotherapy (HR
0.760; 95%CI: 0.548–1.053; P ¼ .0978). Survival probability at 4yearswas 56.6%with crizotinib
and 49.1% with chemotherapy [5].
The absence of OS benefit with crizotinib in the PROFILE 1014 trial could be explained as
84.2% of patients in the chemotherapy arm received crizotinib at the time of progression.
When OS was adjusted for crossover, HR favored crizotinib with a median OS of 59.8months
compared with 19.2months with chemotherapy (HR 0.346; 95% CI: 0.081 to 0.718) [5].
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Likewise, in the crizotinib arm, 24% received a subsequent ALK TKI and 32.0% of patients
received treatment other than anALK TKI (60% platinum-based chemotherapy) as a first sub-
sequent treatment. An exploratory analyses according to the subsequent treatment arm
reported that the longest OS was observed in crizotinib-treated patients who received a sub-
sequent ALK TKI (N ¼57, median OS not reached), whereas patients in the crizotinib arm
who received treatment that did not include an ALK TKI in any line of subsequent treatment
(N ¼37) had a median OS of 20.8months. In the chemotherapy arm, patients who received at
least one ALK TKI in any line of subsequent treatment (N ¼145) had a median OS of
49.5months. Lastly, the small subset (N ¼3) of patients who received treatment that did
not include an ALK TKI in any line of subsequent treatment had a median OS of 12.1months
[5]. These data suggests that treatment with ALK TKI such as crizotinib may have a positive
impact in the patients’ outcome. There is further indirect evidence that crizotinib prolongs OS
in patients harboring an ALK-rearrangement. In a retrospective comparison of 82 patients
with ALK-rearrangement receiving crizotinib, 36 patients with ALK-rearrangement not re-
ceiving crizotinib, 67 patients with an activating EGFR-mutation and 253 patients with
wild-type EGFR and ALK survival were compared. ALK-positive patients treated with
second- or third-line with crizotinib had a 1-year survival of 70% compared with 1-year sur-
vival of 44% for those ALK-positive patients treated with any other second- or third-line ther-
apy (HR 0.36; 95% CI 0.17–0.75; P ¼ .004) [23].
One subgroup of patients with special interest in oncogenic addicted tumors is those with
brain metastasis (BM). In more recent series with central nervous system (CNS) screening,
baseline incidence of BM in ALK-positive NSCLC patients ranges from 14% to 42%
[7,9,11,12]. However, although in the PROFILE 1014 trial baseline CNS screening was not
mandatory 79 out of 343 (23%) patients in had stable and treated BM (tBM) at baseline [4].
Intracranial disease control rate at 12-weeks (85% versus 45%, P < .001) and at 24-weeks
(56% versus 25%, P ¼ .006, respectively) was higher with crizotinib than with chemotherapy,
respectively. Indeed, PFS was significantly longer with crizotinib versus chemotherapy in
tBM present (9.0months versus 3.0months, HR 0.40, P < .001) and BM absent (11.1months
versus 7.2months, HR 0.51, P < .001). However, percentages of patients with brain as the sole
site of progression were higher with crizotinib than with chemotherapy in the intention to
treat population (24% versus 10%), in tBM present (38% versus 23%) and in BM absent sub-
group (19% versus 6%) [24]. Likewise, the OS with crizotinib only favored patients without
BM at baseline (HR 0.672; 95%CI: 0.457–0.987; P ¼ .0413) but for the subgroup of patients with
tBM at baseline, the difference in OS did not reach statistical significance (HR 1.285; 95% CI:
0.716 to 2.306; P ¼ .3991) [5].
The PROFILE 1014 study strongly suggested that with optimal ALK TKI sequencing re-
markable and clinically meaningful prolonged survival can be obtained [5], and these data
were also confirmed by the French retrospective CLINALK study [25] and other cohorts
[26] with a median OS up to 7.5years from metastatic disease diagnosis for those patients
who received different ALK TKI in the therapeutic strategy after upfront crizotinib. There-
fore, it suggests that there is a subgroup of ALK-positive tumors with continued ALK-
dependency at the time of crizotinib-acquired resistance (AR). Intra-tyrosine kinase
ALK-mutations are the main mechanism AR to ALK TKI [27]. Approximately one quarter
of crizotinib-refractory patients haveALK-mutations detected by plasma or tissue genotyping
[28]. However, the efficacy of next generation ALK TKI in crizotinib-refractory setting is
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independent of the occurrence of acquired ALK-mutations [28–31], and the efficacy was com-
parable among patients with and without ALKmutations [28,29]. In crizotinib-refractory pa-
tients the lack of AR ALK-mutations could be explained due to the inability of crizotinib for
blocking the ALK-rearranged tumors that may be overcome with a more potent and selective
next generation ALK TKI. Similarly in crizotinib-refractory patients with AR ALK-mutations,
the efficacy of next-generation ALK TKI could be explained by the fact that majority of these
mutations impart sensitivity to most of next-generation ALK TKI [27]. Therefore, majority of
crizotinib-resistant tumors are still driven by ALK [28], and that effective post-crizotinib se-
quential strategies with next generation ALK TKI could be proposed also without knowing
the specific mechanism of AR [32].
Finally, treatment beyond progression is a daily clinical strategy that aims to extend the
benefit of personalized treatment before switching to other therapeutic strategy. In the PRO-
FILE 1014, among patients randomly assigned to crizotinib, 65 out of 89 patientswith progres-
sive disease (73%) continued to receive crizotinib beyond disease progression for a median of
3.1months [4]. This potential clinical benefit of crizotinib beyond progression was also
reported in a cohort of 120ALK-positive NSCLC patients (51%with brain progression). Treat-
ment beyond progression with crizotinib was correlated with longer median OS compared
with those patients who received other chemotherapy (16.4 vs. 5.4months) [33], although this
benefit could also be related to local therapies andmore indolent disease in the crizotinib arm.
For patients with oligoprogressive disease, even with isolated CNS progression, treatment
with local therapies, either surgery or radiotherapy, while continuing crizotinib could be
viewed as an acceptable option [34]. In the PROFILE 1014 study, among 25 patients with in-
tracranial progression on crizotinib, 19 received radiotherapy for their BM while continued
crizotinib. Median treatment time beyond intracranial progression in these 22 patients was
20.4weeks, which was numerically longer than the 11.7weeks median treatment time beyond
extracranial progression [24]. Similarly, in a retrospective single-institution study, local ther-
apy (either surgery or radiotherapy) for BM in EGFR-mutant (17 treated with erlotinib) or
ALK-rearranged (38 treated with crizotinib) NSCLC patients and CNS progression allowed
continuation of therapy for an additional 7.1months [35]. These data reinforce local therapies
as potential strategies in oncogenic addicted NSCLC patients, including ALK-positive
tumors.
Although the PROFILE 1014 reported the significant superiority of crizotinib in untreated
ALK-positive NSCLC patients in the first-line setting [4,5], this benefit was only consistent in
smaller subset of East Asian patients. The randomized phase III PROFILE 1029 trial, prospec-
tively evaluated crizotinib versus platinum-pemetrexed chemotherapy in 207 ALK-positive
East Asian NSCLC patients. Crizotinib achieved the PFS primary endpoint assessed by inde-
pendent review, (11.1months versus 6.2months, HR 0,402; 95% CI: 0.286–0.565; P < .001), and
also improved the RR (87.5% versus 45.6%, p<0.001) comparedwith chemotherapy. Therewere
no differences in the OS (28.7months versus 27.7months, HR 0.897; 95% CI: 0.556–1.445,
P ¼ .33), most likely because of the low percentage of deaths across both treatment arms
(35.1%) and the high rate of patients in the chemotherapy arm who subsequently received
crizotinib treatment (81%). Safety profile in PROFILE 1029 [6] were consistent with the
PROFILE 1014 [4], and crizotinib did also improve QoL compared with chemotherapy
[6]. Of note, neither PROFILE 1014 [4,5] nor PROFILE 1029 [6] included maintenance
treatment with pemetrexed because both studies were designed and initiated before
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maintenance pemetrexed was established as a standard of care. However, the pemetrexed
maintenance would probably have a minor impact on the PFS endpoint of both trials.
According to current data, crizotinib is a potential therapeutic strategy in first-line setting
for advanced ALK-positive NSCLC patients even for those patients with asymptomatic and
treated baseline BM. However, most patients develop drug resistance after approximately
11months of crizotinib treatment and a frequent site of treatment failure is the CNS. The lim-
ited intracranial activity with crizotinib is due to the fact that crizotinib concentration in ce-
rebrospinal fluid is much lower than in blood plasma (cerebrospinal fluid to plasma ratio
0.0026 [36]), and this could be explained as crizotinib is a substrate to the p-glycoprotein trans-
porter (ABCB1), a transmembrane protein delivering the drug to the extracellular space, ham-
pering the brain accumulation of the drug [37]. Indeed, nearly half of patients have at least
four BM at the time of intracranial progression with crizotinib [38]. Although patients with
BM may achieve a prolonged OS (median OS after development of brain metastases of
49.5months) [26,38], BM is the main cause of poor QoL among NSCLC patients [39]. There-
fore, newer and more potent selective ALK TKI with higher intracranial activity have been
developed with the aim to increase the disease control in the CNS and to improve patients’
outcomes.
Ceritinib
Ceritinib is an oral ATP-competitive ALK and ROS1 TKI, but contrary to crizotinib does
not have MET TKI activity, nevertheless may inhibit other receptors to a lesser extent such
as the insulin-like growth factor 1 receptor (IGF-1) [40]. In vitro, ceritinib inhibits ALK with
a 20-fold greater potency than crizotinib, crosses the blood-brain barrier (BBB) in vivo and
shows nanomolar potency against patient-derived crizotinib-resistant tumor cell lines
[29,41]. Ceritinib has a half-life of 40h, and steady state is achieved after 15days [29] with in-
creased absorption with food, especially when including high fat content. Ceritinib is primar-
ily metabolized by CYP3A4, therefore, the concomitant use either inhibitors or inducers of
3A4 substrates is not recommended [40].
The clinical development of ceritinib has been carried through several clinical trials
(ASCEND-1 to ASCEND-8). In the phase I ASCEND-1 trial among 246 patients with ALK-
rearrangedNSCLC, including bothALKTKI-naı̈ve (N ¼83) andALKTKI-pretreated patients
(N ¼163), ceritinib at the recommended dose (RD) of 750mg/day reported a very promising
RR (72.3% and 56.3%) and median PFS (18.4months and 6.9months, naı̈ve an pre-treated, re-
spectively), even among 94 patients with baseline BM with an intracranial RR (icRR) of 79%
and 65%, respectively [29,42]. Of note, ceritinib activity was observed in patients with orwith-
out crizotinib resistancemutations [29]. Based on these data, ceritinib obtained an accelerated
FDA approval for crizotinib-refractory patients in 2014 and by EMA in 2015. Later, both phase
II trials, the ASCEND-2 [43] trial and the ASCEND 3 trial [44], confirmed the clinical benefit of
ceritinib in previously treated and TKI-naı̈ve population, respectively. Finally, the phase III
ASCEND-5 trial confirmed the efficacy of ceritinib over standard second-line chemotherapy
in crizotinib and platinum-based chemotherapy-refractory ALK-positive NSCLC patient [45].
Of note, the ASCEND-3 trial reported a median OS of 51.3months, which confirms the
prolonged and clinical meaningful survival benefit of ALK-positive TKI-naı̈ve patients
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treated with personalized treatment [44], endorsing the survival data from previous studies
or cohorts with upfront crizotinib [5,25,26].
The phase III ASCEND-4 trial [46] confirmed the efficacy of ceritinib in the first-line setting.
In the trial, 376ALK-positive (assessed by immunohistochemistry) and TKI-naı̈ve NSCLC pa-
tients were randomly assigned to ceritinib (n ¼189) or platinum-pemetrexed chemotherapy
with pemetrexed maintenance (n ¼187). In the chemotherapy arm, crossover to ceritinib in
case of progression was allowed. Ceritinib achieved the primary endpoint, reporting a signif-
icant longer PFS by independent review compared with chemotherapy (16.6months versus
8.1months, HR 0.55, 95% CI: 0.42–0.73]; P < .00001), which reached 26.3months compared
with 6.8months (HR 0.48; 95% CI: 0.33–0.69) for those patients without baseline BM. How-
ever, ceritinib did not improve PFS among 121 patients with baseline asymptomatic and sta-
ble BM with or without previous radiotherapy (10.7months versus 6.7months, HR 0.70; 95%
CI: 0.44–1.12). Ceritinib also improved the RR (73% versus 27%). The median OS was not
reached in the ceritinib arm and was 26.2months in the chemotherapy arm (HR 0 73,
95%: CI 0.50–1.08; P ¼ .056), with 2-year OS of 71% versus 58.2% respectively. Lack of survival
benefit could be explained as 105 out of 145 (72%) patients received an ALK TKI after discon-
tinuation of chemotherapy. Treatment beyond progression with ceritinib achieved an addi-
tional exposure of 9.6weeks. Among 44 patients with measurable BM at baseline, the icRR
with ceritinib was 73% compared with 27.3% with chemotherapy. The median duration of
intracranial responsewith ceritinibwas of 16.6months. Themost commonAEs in the ceritinib
arm were diarrhea (85%), nausea (69%), vomiting (66%), and an increase in alanine amino-
transferase (60%), whereas in the chemotherapy arm were nausea (55%), vomiting (36%)
and anemia (35%); with a grade 3–4 AEs in 65% and 40% of cases, respectively. Up to 80%
of patients in ceritinib arm required dose adjustment or interruptions due to toxicity, mainly
gastrointestinal toxicity (28%). However, only 5% of patients discontinued ceritinib due to
AEs, and ceritinib significantly improved lung-cancer specific symptoms and prolonged
TTD [46]. Based on these results, the FDA approved ceritinib as first-line treatment in
ALK-positive NSCLC patients in May 2017.
Ceritinib at the dose of 750mg/day fasted might be associated with a high frequency of
gastrointestinal toxicity and raised liver enzymes, which may compromise the treatment
compliance. In the phase I ASCEND-8 trial, 306 patients were randomized to ceritinib
450-mg fed (N ¼108) or 600-mg fed (N ¼87) or 750-mg fasted (N ¼111), of which 304 patients
were included in safety analysis and 198 treatment-naive ALK-positive NSCLC patients were
included in the efficacy analysis (450-mg fed [N ¼73], 600-mg fed [N ¼51], and 750-mg fasted
[N ¼74]). Brain metastases at baseline were present in 32.9%, 29.4%, and 28.4% of patients in
the 450-mg fed, 600-mg fed, and 750-mg fasted arms, respectively [47]. The RR by indepen-
dent review was 78.1%, 72.5% and 75.7%, respectively, whereas the median duration of re-
sponse was not estimable, 20.7months and 15.7months, respectively. Likewise, the median
PFS was not estimable, 17.0months and 12.2months, respectively. The safety analysis in
the whole population reported that the arm at 450-mg fed showed the highest median relative
dose intensity (100% versus 78.5% versus 83.7%), lowest proportion of patients with dose re-
ductions (24.0% versus 65.1% versus 60.9%) as well as dose interruptions (50.9% versus 74.4%
versus 72.7%), and lowest proportion of patients with gastrointestinal toxicities (75.9% versus
82.6% versus 91.8%). From a pharmacokinetic perspective, the two doses (450mg with food
and 750mg fasted) give nearly the same systemic exposure (area under the curve [0 to 24h],
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geometric mean ratio = 1.04; maximum serum concentration, geometric mean ratio = 1.03);
therefore, the penetration into the brain and intracranial antitumor activity are expected to
be equivalent. The reason for similar systemic exposure with the lower dose is the higher ab-
sorption of ceritinib when administered with food [47]. ASCEND-8 study confirms previous
results fromASCEND-1 trial, which reported that ceritinib at a dose of at least 400mg ormore
daily was similarly effective than 750mg daily in crizotinib-refractory setting (RR 56% versus
56%, respectively), as well as in crizotinib-naı̈ve patients, as RR with at least 400mg of
ceritinib daily in this population was of 62% [29]. Therefore, ceritinib at a dose of 450mg with
food compared to 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity
and should be the preferred dose regimen in daily clinical practice in ALK-positive NSCLC
patients even among those with brain metastases.
Based on the onset of BM in ALK-positive NSCLC patients and the intracranial activity of
ceritinib [41,42], the phase II ASCEND-7 trial was designed to prospective evaluate the activ-
ity of ceritinib (750mg daily fasted) in ALK-positive NSCLC patients with active BM either
newly diagnosed or progressive, and at least one extracranial measurable lesion by RECIST
v1.1 criteria. Patients may have been pretreated with chemotherapy and/or crizotinib, and
were assigned to four different arms depending on prior treatment: arm 1 (N ¼42) previously
treated with brain radiotherapy and an ALK TKI; arm 2 (N ¼40) no previous radiotherapy
but previously treated with an ALK TKI; arm 3 (N ¼12) previously treated with brain radio-
therapy and ALK TKI, arm 4 (N ¼44) treatment naı̈ve without previous radiotherapy. The
RR, DoR and PFS in the whole population was 36%, 10.8months and 7.2months in arm 1,
30%, 12.8months and 5.6months in arm 2, 50%, not estimable and not estimable in arm 3,
and 59%, 9.2months, and 7.9months in arm 4, respectively. The icRR in patients with mea-
surable BM was 39.3%, 27.6%, 28.6%, and 51.5% in arms 1 to 4 respectively. The ASCEND-7
mirrors the icRR reported in ALK-positive NSCLC patients with active BM and crizotinib re-
fractory in the ASCEND-5 trial (35%) [45], as well as partially in TKI-naı̈ve patients in the
ASCEND-4 trial (73%) [46]. The ASCEND-7 trial had a fifth arm that enrolled 18 patients
with leptomeningeal carcinomatosis with or without active metastases [48]. Out of 18 pa-
tients, 78% also had brain metastases and 89% had received prior crizotinib. The RR was
17%with an icRR of 13%. Themedian DoR and PFS was 5.5 and 5.2months, respectively with
a median OS of 7.2months. These results suggest a meaningful clinically significant benefit
with ceritinib in poor prognosis ALK-positive population.
Alectinib
Alectinib is a highly selective and potent TKI targeting ALK (IC50: 1.9nM) and RET (IC50:
4.8nM) [49,50]. Alectinib has shown systemic and intracranial efficacy in ALK-positive lung
cancer tumors [50,51], and alectinib has reported a high brain-to-plasma ratios (0.63–0.94) on
animal models. Unlike crizotinib and ceritinib, preclinical studies suggest that alectinib is not
a substrate of glycoprotein-P, a key drug efflux pump typically expressed in the BBB, and that
it has greater CNS activity than other ALK TKIs [52]. Indeed, alectinib achieved significant
reduction in the size of tumors remaining after treatment with crizotinib in xenograft models,
as well as tumors harboring secondarily acquired ALK resistance mutations [53]. According
to the results of phase I/II studies, the dose of alectinib is 600mg twice daily under fed
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conditions in non-Japanese patients [54], whereas the dose is 300mg twice daily in Japanese
ALK-positive NSCLC patients [55,56].
The efficacy of alectinib (600mg twice daily) in crizotinib-refractory ALK-positive NSCLC
patients was evaluated in two pivotal, single-arm, open-label phase II trials: NP28673 [57] and
NP28761 [58]. Pooled analyses of both studies reported a RR of 51%,median PFS of 8.3months
[59], and median OS of 29.1months [60], with an icRR of 64% [61]. The efficacy of alectinib in
the crizotinib-refractory setting was later confirmed in the phase III ALUR study [62]. Results
of both phase II trials launched alectinib approval in crizotinib-refractory population by FDA
on December 2015. Two years later, results from ALEX trial [7] led alectinib approval in first-
line setting by both, the EMA and FDA in 12th October 2017 and in 6th November 2017,
respectively.
The phase III ALEX study randomized treatment-naı̈ve ALK-positive NSCLC to receive
either alectinib (600mg twice daily, N ¼152) or crizotinib (250mg twice daily, N ¼151). Pa-
tients with asymptomatic BM or leptomeningeal carcinomatosis were eligible, and baseline as
well as subsequent brain imaging was performed every 8weeks until disease progression.
The primary endpoint was investigator-assessed PFS and crossover was not allowed per pro-
tocol. Alectinib significantly improved the PFS compared with crizotinib [7], with a final me-
dian PFS of 34.8months versus 10.9months, respectively (HR 0.43; 95% CI: 0.32–0.58;
P < .0001), and this benefit occurred in patients with baseline BM (N ¼122, 25.4months ver-
sus 7.4months, respectively, HR 0.37, 95% CI: 0.23–0.58) and in those without BM (N ¼181,
38.6months versus 14.8months, respectively, HR 0.46, 95% CI: 0.31–0.68) [8]. The efficacy of
alectinib was demonstrated in practically all patients’ subgroups, regardless of the type of
EML4-ALK fusion variant and themethod used for its determination [63]. Although crossover
in ALEX trial was not allowed, no differences in OS have been reported between alectinib
versus crizotinib (HR0.69, 95%CI: 0.47–1.02,with a similarHR inpatientswith BMat baseline,
HR 0.60, 95%CI: 0.34–1.05 and in patients without BM at baseline, HR 0.77; 95%CI: 0.45–1.32).
However, recently it has been reported that the 5-year OS rate with alectinib was 62.5%
versus 45.5% with crizotinib; the OS data remain immature with 37% of events recorded
(stratified HR, 0.67; 95% CI: 0.46–0.98), supporting alectinib as stronger first-line treatment
option in ALK-positive NSCLC patients. Likewise, in the ALEX trial, alectinib compared
with crizotinib improved the RR but the difference was not statistically significant (83%
versus 76%, P ¼ .09) [7,63], although the DoR was meaningful longer in alectinib arm
(33.1months versus 11.1months, respectively). Despite the longer median treatment dura-
tions for alectinib compared with crizotinib (27.0months versus 10.8months), fewer pa-
tients had grade 3–5 AEs (48.7% versus 55%, respectively) [8], and the percentage of
treatment discontinuations (13.2% versus 13.2%), dose reductions (16.4% versus 20.5%)
and dose interruptions (22.4% and 25.4%) were slightly lower with alectinib than with
crizotinib [63], and AEs of any grade favored alectinib compared with crizotinib, except
for myalgia and anemia [7]. Patients treated with alectinib reported clinically meaningful
improvement in QoL and multiple lung cancer symptoms for a longer duration than those
treated with crizotinib, but these differences were not statistically significant [64].
As extracranial efficacy of alectinib is similar to crizotinib, the longer PFS benefit with
alectinib seems mainly driven by the higher intracranial activity of alectinib. Out of 122 pa-
tients with baseline BM, 43 had measurable lesions (alectinib,N ¼21; crizotinib, N ¼22). The
icRR was 85.7% with alectinib versus 71.4% with crizotinib in patients who received prior
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radiotherapy and 78.6% versus 40.0%, respectively, in those who had not. Indeed, the
12-months cumulative incidence rate of CNS progression was higher in crizotinib arm than
in alectinib arm in both, patientswith BMat baseline (59% versus 16%) and among thosewith-
out BM at baseline (32% versus 4.6%, respectively). Time to CNS progression was signifi-
cantly longer with alectinib versus crizotinib and comparable between patients with and
without baseline BM (P < .0001) [65]. CNS results from ALEX study confirmed alectinib as
a new SoC for untreated ALK-positive NSCLC patients regardless of presence or not of
baseline BM.
The efficacy of alectinib compared with crizotinib in Asian population has been tested in
two randomized phase III clinical trials, the J-ALEXwith alectinib at 300mg twice daily [9,10],
and ALESSIA trial with alectinib at 600mg twice daily [11]. These studies allowed the ap-
proval of alectinib in first-line setting of ALK-positive NSCLC patients in China on August
2018 and in May 2018 in Japan.
In the J-ALEX study, 207 Japanese ALK-positive treatment naı̈ve NSCLC patients were en-
rolled. Although baseline characteristics were generally balanced, there was a greater propor-
tion of patients with baseline BM in the crizotinib arm (29/104 patients [27.9%]) than in the
alectinib arm (14/103 patients [13.6%]). The primary endpoint was PFS assessed by indepen-
dent review, and a sustained improvement in PFS with alectinib relative to crizotinib was
shown (34.1months vs. 10.2months; HR 0.37; 95%CI: 0.26–0.52) and the imbalance in baseline
BM did not impact on the primary-endpoint results [9,10]. The independent review-assessed
cumulative incidence rates of CNS and non-CNS progression were lower with alectinib than
with crizotinib at all time points in patients both with and without baseline CNS metastases
[66]. After a median follow-up of 42months, median OS was not reached with alectinib and it
was 43.7months with crizotinib (HR 0.80; 99.87% CI: 0.35–1.82; P ¼ .3860). Treatment cross-
over after study withdrawal was allowed and 41% of patients in the alectinib arm and 89% of
patients in the crizotinib arm received at least one post-progression therapy, mainly an ALK
TKI, and in the crizotinib arm, 84% received alectinib as a post-progression treatment. Com-
pared with alectinib, crizotinib-treated patients had a higher incidence of related serious AEs
(25.0% vs. 13.6%, respectively) and grade3 AEs (60.6% vs. 36.9%, respectively [9,10].
ALESIA was a randomized, open-label, phase III trial performed in 21 investigational sites
in China, South Korea, and Thailand, and enrolled 187 patients whowere randomized (2:1) to
receive either alectinib (N ¼125) or crizotinib (N ¼62). The study reached its primary end-
point of PFS assessed by independent review and was statistically significantly longer with
alectinib than crizotinib (NR versus 11.1month, HR 0.22, 95% CI 0.13–0.38; P < .0001). The RR
also favored alectinib compared with crizotinib (91% versus 77%, P ¼ .0095), as well as the
duration of response (HR 0.22, 95% CI 0.12–0.40; P < .0001). The time to CNS progression
(CNS-HR 0.14) and icRR were also better with alectinib than crizotinib (73% versus. 22%, re-
spectively). Again, OS data were immature at the primary analysis (HR 0.28; 95%CI:
0.12–0.68; P ¼ .0027; median OS not estimable in both arms), with an event rate of 6.4% in
the alectinib arm and 21.0% in the crizotinib arm. In ALESIA trial, crossover was not allowed
and only 24% of patients in the control arm received a next-generation ALK TKI at crizotinib-
progression. Toxicity was as expected and similar to other studies [11].
Based on the results of these phase III clinical trials, alectinib appears as a new potential
standard treatment in first-line setting based on prolonged PFS compared with crizotinib,
and the capability to avert the CNS progression in ALK-positive NSCLC patients with or
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without BM at baseline. The mature OS with alectinib remains unknown, and currant data
does not show survival differences compared with crizotinib. Of note, crossover is always
desirable in settings where a drug has already proven of benefit in a subsequent line of ther-
apy and exists an attempt to be advanced to an earlier line [22]. Therefore, under current stan-
dards, the control arm from ALEX and ALESIA trials should be considered suboptimal and
under-treated as crossover was not allowed. Finally, indirect cross-trial comparisons suggest
that efficacy of alectinib regarding to RR and PFS is similar regardless of the dose, and
whether higher doses would lead to longer PFS or higher tumor penetration has been raised.
Brigatinib
Brigatinib (AP26113) is another next-generation ALK TKI (also active againstROS1, EGFR-
T790M, IGFR and FLT3 mutations). Brigatinib potently inhibits ALK and ROS1, with a
high degree of selectivity over more than 250 kinases. Across a panel of ALK-positive cell
lines, brigatinib inhibited native ALK (IC50, 10nmol/L) with 12-fold greater potency than
crizotinib [67], and also reported a broader spectrum of preclinical activity than ceritinib
and alectinib against known crizotinib-resistant ALK-mutants [68,69]. Superior efficacy of
brigatinib was also observed in mice with ALK-positive tumors implanted subcutaneously
or intracranial [67].
In the phase I/II trial, brigatinib was assessed at doses of 30–300mg in different patient
cohorts. In ALK-rearranged NSCLC patients cohort, brigatinib showed promising clinical ac-
tivity and an acceptable safety profile in crizotinib-treated (N¼71, RR 63% and median PFS
and OS of 13.2months and 30.1months, respectively) and crizotinib-naive patients (N¼8, RR
100%, and median PFS and OS of 34.2months and not reached, respectively) [70,71].
According to the efficacy, the dose of 180mg once daily was the recommended phase II dose.
However, in light of accumulating early pulmonary events with this dose, which occurred
within 7days of treatment initiation, two alternative regimens were investigated in the phase
II trial [70]. Based on the results of this phase I/II trial, brigatinib was granted break-through
therapy designation by the FDA in October 2014.
In the ALTA phase II trial, 222 crizotinib-refractory ALK-positive patients were random-
ized to either oral brigatinib 90mg once daily (arm A) or 180mg once daily with a 7-day
lead-in at 90mg (arm B). Patients were stratified by CNS metastases and best response to
crizotinib. At baseline, 71% and 67% had BM in arm A and arm B, respectively. The RR
and median PFS were 46% and 9.2months in arm A and 56% and 16.7months in arm B, with
a median OS of 29.5months and 34.1months, respectively. Brigatinib showed a high icRR
reaching 50% and 67% respectively; and icPFS was 12.8 versus 18.4months [72]. For instance,
brigatinib is the ALK TKI with the longest PFS and icPFS in the post-crizotinib setting. Glob-
ally, these promising results launched to assess the efficacy of brigatinib in treatment-naı̈ve
population.
The ALTA-1L phase III trial randomized 235 ALK-positive TKI-naı̈ve NSCLC patients to
receive brigatinib at a dose of 180mg once daily (with a 7-day lead-in period at 90mg) or
crizotinib at a dose of 250mg twice daily. Unlike previous phase III clinical trials previous
chemotherapy was allowed and 26% of patients had previously received chemotherapy in
advanced disease. Likewise, one-third of patients had baseline asymptomatic BM. Brigatinib
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achieved the PFS primary endpoint assessed by independent review, and the most recent
updated data in PFS reported a median PFS of 24.0months compared with 11.0months with
crizotinib (HR 0.49, 95% CI 0.35–0.68, P < .001), and this benefice occurred regardless of pre-
vious chemotherapy (HR 0.44, 95%CI 0.23–0.83 for 73 patients previously treated with
chemotherapy; and HR 0.52, 95% CI: 0.35–0.70 for 202 patients without previous chemother-
apy) or the occurrence of baseline BM (HR 0.25, 95% CI: 0.14–0.46, P < .0001 for 81 patients
with BM; and HR 0.65, 95% CI: 0.44–0.97, P ¼ .0298 among 194 patients without BM at base-
line). Confirmed RR was of 74% and 62% for brigatinib and crizotinib (P ¼ .0342), respec-
tively, and median DoR was not reached for brigatinib and was of 13.8months with
crizotinib. OS data is still immature (HR 0.92; 95% 0.57–1.47, P ¼ .771), but crossover was
allowed in ALTA-1L trial and 44% of patients in crizotinib arm crossed over to brigatinib.
For these crossing patients, the RR and median PFS with second-line brigatinib were
54.1% and 15.6months respectively [12,13]. In the ALTA-1L trial, brigatinib compared with
crizotinib improved the icRR (in the group of patients with any BM at baseline [N ¼96]: 66%
versus 16%, P ¼ .0001, respectively; as well as in the measurable BM group [N ¼41]: 78% and
26%, P < .0001, respectively) and icPFS (24months versus 5.6months, HR 0.31, 95% CI:
0.17–0.56, P < .0001) [12]. The most common AEs with brigatinib were an increased creatine
kinase level (39%), cough (25%), hypertension (23%) and an increased lipase level (19%).
Grade3 AEs were reported in 61% of patients in the brigatinib and 55% of patients in the
crizotinib arm [13]. Early onset (within 14days after treatment initiation) of interstitial lung
disease or pneumonitis occurred in 5% and 2%, respectively. Finally, the dose reductions rate
was of 38% and 25% in brigatinib arm and crizotinib arm respectively, whereas discontinu-
ation rate due to AEs was of 13% and 9%, respectively [12]. Despite these differences,
brigatinib was associated with improved health related QoL compared with crizotinib
[12,73]. Based on these results, on May 22, 2020, U.S. FDA has approved brigatinib as first-
line treatment in ALK-positive advanced NSCLC patients. Simultaneously, the EMA Com-
mittee for Medicinal Products for Human Use (CHMP) adopted a positive opinion
recommending the approval of brigatinib as upfront treatment in the same population.
Ensartinib
Ensartinib (X-396) is a novel, aminopyridazine-based small molecule that potently inhibits
ALK. Ensartinib is 10-fold more potent than crizotinib for inhibiting the growth of ALK-
positive lung cancer cell lines, and reported activity in a broad spectrum of ALK-mutations.
Additionally, ensartinib have reported some degree of activity against ROS1, cMET,AXL and
TRKA, B, C [74]. Ensartinib has been tested in both, crizotinib refractory [75,76] andALKTKI-
naı̈ve patients [75].
In the phase I/II eXalt-2 trial, 37 patients were enrolled in dose escalation, and 60 patients
were enrolled in dose expansion. The most common treatment-related AEs were rash (56%),
nausea (36%), pruritus (28%), vomiting (26%), and fatigue (22%); and 23% of patients expe-
rienced a grade 3–4 AEs, mainly rash and pruritus. The maximum tolerated dose was not
reached, but the recommended phase 2 dose (RP2D) chosen was 225mg daily. Among the
ALK-positive efficacy evaluable patients treated at 200mg, the RR was 60% and median
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PFS was 9.2months. Of note, in ALK TKI-naı̈ve patients the RR was 80% and the median PFS
was 26.2months. Ensartinib also reported intracranial activity with an icRR of 64% [75].
Plasma from 76 patients (17 TKI-naı̈ve) enrolled in the phase I/II eXalt-2 trial was collected
for circulating tumor DNA (ctDNA) analyses. Disease-associated genetic alterations were
detected in 74% (56 of 76) of patients, the most common being EML4-ALK. Of note, the con-
cordance rate of ALK fusion between plasma and tissue was 91% (20 of 22 blood and tissue
samples). The efficacy of ensartinib was evaluated according to different EML4-ALK variants
detected in the ctDNA analyses. Those patients with a detectable EML4-ALK variant 1 (V1)
fusion compared with variant 3 (V3) had improved RR (53% and 14%) and longer PFS
(8.2months and 1.9months) to ensartinib [77]. Although, the study did not report the efficacy
in TKI-naı̈ve patients according to the EML4-ALK V1 and V3, the data reported suggests that
ALK-positive lung cancer is a more complex and heterogeneous disease and other factors
should bear in mind for making treatment decisions in the first-line setting and beyond.
These promising results in the phase I/II trial launched the ongoing phase III eXalt-3 clin-
ical trial (NCT02767804, Fig. 1) assessing the PFS benefit of ensartinib compared with
crizotinib in ALK TKI-naı̈ve NSCLC patients in first-line setting. Of note, patients with
asymptomatic BM and previous chemotherapy are allowed.
Lorlatinib
Lorlatinib is an oral and selective third-generation ALK and ROS1 TKI specifically devel-
oped to penetrate the BBB through reduction of P-glycoprotein-1 mediated efflux with broad
ALK mutational coverage [78]. Lorlatinib has also shown antitumor activity in ALK-positive
intracranial tumor models [79], and in the clinic lorlatinib has reported a mean ratio of cere-
brospinal fluid (CSF)/plasma (unbound) of 0.75, and a half-life ranging from 19 to 28h [80].
In a phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activ-
ity in 54 patients with advanced ALK- or ROS1-positive NSCLC, most of whom had CNSme-
tastases and had previously had two or more TKI treatments fail. Among 41 ALK-positive
FIG. 1 Ongoing phase III clinical trials with second- and third-generation ALK TKI compared with crizotinib
in first-line setting in ALK-positive NSCLC patients.
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NSCLCpatients, the RRwas 46%with amedianDoR of 12.4months and in patients withmea-
surable BM, the icRRwas 46%. The estimatedmedian PFS was 9.6months. Themost common
AEs in the safety population were hypercholesterolaemia (72%), hypertriglyceridaemia
(39%), peripheral neuropathy (39%), and peripheral edema (39%). Cognitive, speech, and
mood effects (39%) were generally transient and reversible. Almost one-third of patients
temporarily discontinued lorlatinib at any point and 24% of patients required at least one
dose reduction because of treatment-related AEs. The RP2D selected was 100mg once daily
[80]. As some of these AEs are very drug-specific, a clinical guideline for the management of
AEs associated with lorlatinib has been recently published [81].
Based on these data, the FDA granted lorlatinib accelerated approval status in November
2018 for ALK-positive NSCLC patients who had progressed on crizotinib and at least one ad-
ditional ALK TKI or who had disease progression on alectinib or ceritinib as the first ALK TKI
received. In May 2019, the EMA also approved lorlatinib for use in these patient populations.
In the phase II trial, 276 ALK/ROS1-positive NSCLC patients were enrolled into six differ-
ent expansion cohorts (EXP1–6) on the basis of ALK and ROS1 status and previous therapy
[82,83]. In the cohort EXP1 of TKI-naı̈ve ALK-positive NSCLC patients (N ¼30), lorlatinib
reported a RR and icRR of 90% and 67%, respectively, with a median PFS and icDoR not
reached [82], supporting its efficacy as a potential strategy in first-line setting. The ongoing
phase III CROWN trial (NCT03052608, Fig. 1) assesses the efficacy in terms of PFS of lorlatinib
compared with crizotinib in first-line setting in TKI-naı̈ve ALK-positive NSCLC patients
(Fig. 1). Patients with asymptomatic BM are also allowed. The trial has completed the recruit-
ment and results are awaited, although data coming from the phase II trial with lorlatinib in
this population preclude that lorlatinib will achieve the primary endpoint.
Others ALK TKI
ASP3026, is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has po-
tent in vitro activity against crizotinib-resistant ALK-positive tumors [84].
Repotrectinib (TPX-0005) is a next-generation ROS1, pan-TRK, and ALK TKI, overcomes
resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.
Repotrectinib may represent an effective therapeutic option for patients with ROS1-,
NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs
[85]. However, major development of this drug is among ROS1 and NTRK-positive tumors.
WX0593 is a potent ALK and ROS TKI, which has been tested in a phase I trial enrolling 46
ALK- and 10 ROS1-positive NSCLC patients (39% previously treated with crizotinib). InALK-
positive populationWX0593 reported a RR of 66% (81% in 21 crizotinib-naı̈ve patients; 44% in
18 crizotinib-refractory patients; and 80% among 5 patients previously treated with crizotinib
and a other ALK TKI), whereas the RR reached 30% in the whole ROS1-positive NSCLC pa-
tients. The most common AEs were hypercholesterolemia, nausea, hypertension, and in-
creased liver enzymes. A phase II is ongoing and evaluates the RR at 120 and 180mg,
respectively [86].
TSR-011 (Belizatinib) is a dual ALK and TRK inhibitor, active against ALK inhibitor resis-
tant tumors in preclinical studies. In a phase I clinical trial reported a partial response of 43%
(6/14) among TKI-naive ALK-positive NSCLC patients. Based on the limited clinical activity
45ALK TKI in first line setting
was observed and the competitive ALK inhibitor landscape and benefit/risk considerations,
further TSR-011 development was discontinued [87].
Future challenges in first-line setting
Optimal ALK TKI in first-line setting
ALK-positive NSCLC patients may have a prolonged OS, with a 4-year OS ranging from
52% to 65% [8]. Although the prolonged survival inALK-positive NSCLC seemsmore related
to the sequencing strategies at progression rather than the ALK TKI subtype in first line set-
ting [5], data coming from ALEX trial and ALTA-1L support second-generation ALK TKIs as
the new SoC in first line setting based on prolonged PFS and higher intracranial activity com-
paredwith crizotinib. Whether one second-generation ALK TKI is more suitable than other in
first-line setting remains unknown, as there is no head-to-head clinical trial. Taking into ac-
count all the limitations and bias, cross trial comparison between brigatinib and alectinib has
reported similar outcomes in terms of RR (74% versus 72%), PFS by investigator (29.4months
and HR 0.43 versus 34.8months and HR 0.43), and icRR in measurable BM (78% versus 81%)
[8,12,65]. Unlike to alectinib, brigatinib improved the health-related QoL [12,64], and
brigatinib has also shown the longest median icPFS (24months and 2-year icPFS rate of
48% [12]) reported with ALK TKI in the first-line setting. Therefore, it is possible that soon,
not alectinib, but brigatinib will be the preferred ALK TKI to be used for the first-line therapy
ofALK-positive NSCLC patients. Similarly, in the coming future, results of the ongoing phase
III CROWN and EXALT trial (Fig. 1) may shift the treatment paradigm once again, towards
upfront lorlatinib, the third generationALK TKI. However, this new treatment approachwith
upfront next-generation ALK TKI has also challenged the current sequential strategy with
ALK TKI at the time of progression.
Therefore, the resistance mechanisms to these next generation ALK TKIs need to be elu-
cidated, especially if third-generation ALK TKI become the new standard of care (SoC), in
order to establish subsequent personalized treatment strategies, when appropriate. Sequen-
tial personalized treatment strategies affect the management of patients with oncogene-
addicted tumors, and although sequential strategy of second- followed by third-generation
ALK TKI is optimal, there is no clinical data about themost suitable sequential approach after
upfront third-generation ALK TKI [32].
In this new treatment paradigm, further improving treatment efficacy in the first-line set-
ting is an additional challenge. ALK is an heterogeneous disease with several fusion-partners
specially after the widespread use of next generation sequencing (NGS) [88], and ALK-
rearranged NSCLC harbors a spectrum of concurrent genomic alterations at baseline, such
as TP53-mutation, that may have prognostic and predictive significance [77,89,90]. It remains
unknown whether the efficacy of ALK TKIs may vary according to the fusion partner or
whetherALK-positive tumors with co-mutationsmay obtain higher benefit with combination
strategies or with upfront third-generation ALK TKIs. Although not universal, different stud-
ies have shown differences in sensitivity to ALK TKIs according to the EML4-ALK fusion type
[63,77,91–93]. Therefore, defining the phenotypes withinALK-rearranged tumors, either with
tissue or liquid biopsies, which are associatedwith the greatest benefit from the different ALK
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TKIs or associated with increased risk to onset specific ALKmutations such as G1202R [93] is
also a challenge, with the aim to better personalize the first-line treatment approach and be-
yond. Highlighting the importance of potential combination strategies in first-line setting in
ALK-positive NSCLC patients with either angiogenic agents (NCT03779191, NCT02521051)
or chemotherapy (instead of ALK TKI monotherapy) in specific subgroups of patients is an-
other real challenge.
Finally, at current fixed dose of ALK TKI, interpatient variability in exposure may reach
40%, and drug exposure is the main mechanism of primary acquired resistance with TKIs
[94]. Although the degree of BBB penetration and CNS retention of specific TKIs depend
on its molecular structure, both, extracranial and intracranial activities may also be related
to drug exposure. Recently, a retrospective pharmacokinetic study enrolling 100ALK-positive
NSCLC patients (48 treated with crizotinib and 52 treated with alectinib), reported that 48%
and 37% of patients treatedwith crizotinib and alectinib had plasma concentrations below the
minimum threshold, and PFS on crizotinib or alectinib was shorter for those patients with not
enough drug exposure (crizotinib: 5.7months versus 17.4months, P ¼ .08; alectinib:
12.8months versus not-reached, P ¼ .04) [95]. Therefore, based on these results and the fact
that almost 20% of patients enrolled in phase III clinical trials reported dose-reductions, in-
terruptions or dose discontinuations, another future challenge is the therapeutic drug mon-
itoring with the aim to individualize treatment and improve treatment outcomes.
Role of liquid biopsies in first-line setting
In the coming future baseline genomic profile according to liquid biopsy results may be-
come a new standard as almost one-third of advanced NSCLC patients do not have adequate
tumor tissue for genomic profiling [96]. Liquid biopsy can be used for knowing the broad ge-
nomic profile at baseline or at the time of progression in ALK-positive NSCLC [28,77,97]. Pro-
spective validation of the efficacy of TKI in druggable oncogenic NSCLC population based on
liquid biopsy results is also a challenge. The ongoing multicohort phase II/III BFAST trial
assessed efficacy (RR) of targeted therapies or immune checkpoint inhibitors according to
the results of liquid biopsy assessed by NGS. Out of 2188 patients with blood-based NGS re-
sults, 119 patients (5.4%) had ALK-positive disease and 87 patients received alectinib (43%
TP53 co-mutation). The RR and 12-months PFS assessed by investigator were 87.4% and
78.4% [98], which were very similar to data reported in ALEX trial [7]. Data from BFAST trial
validates the clinical utility of blood-based NGS as an additional method for making clinical
decision in ALK-positive NSCLC patients.
Brain metastases, upfront ALK TKI or radiotherapy
The optimal treatment management of patients with BM and the optimal place of radio-
therapy is also a challenge. Almost one-third ofALK-positive NSCLC patientsmay have brain
metastases at baseline, which may be associated with reduced quality of life. In oncogenic
addicted NSCLC patients with BM, a multidisciplinary approach is the optimal strategy.
However, based on the available clinical data and longOS in patients with asymptomatic syn-
chronous BM at diagnosis and the high intracranial efficacy of next-generation ALK TKI,
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treatment with next-generation ALK TKIs alone should be considered as the initial treatment
even in some patients with symptomatic BM. However, close CNS surveillance is strongly
recommended for early intervention in patients with an inadequate CNS response. This strat-
egy may defer CNS radiotherapy and avoid long-term neurologic side effects associated with
local therapies, mainly radionecrosis. In other cases, sequential treatment initiated with local
therapy followed by a TKI is appropriate. For patients who experience CNS progression with
controlled extracranial disease while on TKI treatment, local therapy (preferably stereotactic
radiosurgery, SRS) followed by the same TKI is an option in patients with a limited number of
lesions or who are asymptomatic. In cases of multiple CNS progression, a switch to another
ALK TKI with higher CNS-penetration activity may be appropriate [99]. However, prospec-
tive evidence of these strategies is required.
Conclusion
Nowadays, based on the improved PFS and better intracranial activity, alectinib and
brigatinib are the most suitable first-line treatment options in ALK-positive patients. Indeed,
alectinib has reported to improve the 5-year OS compared with crizotinib, endorsing the role
of upfront second-generation ALK TKIs. In the future, new ALK TKIs may change the treat-
ment sequential strategy and it is relevant to definemechanisms of resistance to establish per-
sonalized treatments at progression and improving the survival of ALK positive patients.
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Abstract
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) resistance constitutes a relevant issue in
ALK-positive non-small cell lung cancer (NSCLC). BeyondALK-TKIs, other treatment strategies are envisaged
during the course of disease, especially once ALK-TKI options are exhausted. Chemotherapy represents a
valuable therapeutic weapon in this subgroup of patients, who are particularly sensitive to pemetrexed-based
regimens. In addition, immune checkpoint inhibitors and antiangiogenics are being intensively investigated
for the treatment ofALK-positiveNSCLC. From the perspective of combination approaches, atezolizumabplus
bevacizumab and carboplatin-paclitaxel demonstrated a promising activity and received Food and Drug Ad-
ministration approval after failure of previous targeted therapy in ALK-driven NSCLC. The aim of the present
chapter is to review the current knowledge about systemic treatments other thanALK-TKIs, ranging from pre-
clinical evidences to clinical implications. Moreover, ongoing research focused on novel therapeutic strategies
will be discussed.
Abbreviations
ALK anaplastic lymphoma kinase
NSCLC non-small cell lung cancer
PD-1 programmed cell death protein 1
PD-L1 programmed cell death ligand 1
TS thymidylate synthase
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
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Introduction
The development of targeted therapies with anaplastic lymphoma kinase (ALK) tyrosine
kinase inhibitors (TKIs) dramatically changed the management and prognosis of ALK-
positive non-small cell lung cancer (NSCLC) patients. ALK-TKIs, ranging from the first-in-
class crizotinib to the last FDA-approved lorlatinib, significantly improved progression-free
survival (PFS), overall response rate (ORR) and quality of life in this peculiar subgroup of
patients. To date, alectinib—which is a second generation ALK-TKI—is the current preferred
first-line therapy in advancedALK-positive NSCLC,with amedian PFS reaching 34.8months,
based on the updated analysis of the phase III ALEX trial [1]. Despite the remarkable activity
of ALK-TKIs, both in terms of extracranial and intracranial responses, acquired ALK-TKIs
resistance constitutes a major challenge, and the optimal next-line therapy still remains to
be assessed. In this regard, the landscape of resistance mechanisms driven by eitherALKmu-
tations or activation of alternative signaling pathways has become increasingly complex and
patients could inexorably experience the failure of ALK inhibition. As a consequence, differ-
ent treatment strategies beyond ALK-TKIs are envisaged, especially in the absence of action-
able ALK resistance mutations.
The aimof this chapter is to review the current evidence about systemic treatments other than
ALK-TKIs in advanced ALK-positive NSCLC, with a focus on chemotherapy, immune check-
point inhibitors (ICIs) and antiangiogenic agents, whose rationale is summarized in Fig. 1.
FIG. 1 Chemotherapy, immunother-
apy, and antiangiogenic agents in ALK-
driven NSCLC. ALK, anaplastic lym-
phoma kinase; NSCLC, non-small cell
lung cancer; PD-1, programmed cell
death protein 1; PD-L1, programmed
cell death ligand 1; TS, thymidylate
synthase; VEGF, vascular endothelial
growth factor; VEGFR, vascular endo-
thelial growth factor receptor.
56 3. Systemic treatments other than TKI
The role of chemotherapy in ALK-positive NSCLC
Most advanced ALK-positive NSCLC patients will receive chemotherapy at some point in
the course of the disease, mainly after failure of previous ALK-TKIs. Thus, it is important to
enlighten the efficacy of chemotherapeutic agents in this molecularly distinct subgroup of
patients.
When comparing ALK-TKIs to standard chemotherapy regimens for the treatment of
metastatic ALK-positive NSCLC, both in first-line and in second-line, chemotherapy dem-
onstrated inferior outcomes [2–7]. In this regard, available evidence comes from random-
ized phase III trials which are summarized in Table 1. In the second-line studies,
chemotherapy consisted of pemetrexed 500mg/m2 or docetaxel 75mg/m2 every 3weeks
[2–4]. When ALK-TKIs’ efficacy was assessed in first-line, chemotherapy comparator arms
were based on pemetrexed 500mg/m2 with either cisplatin 75mg/m2 or carboplatin AUC
5–6, IV every 3weeks for 6cycles, or for 4cycles followed by maintenance pemetrexed
[5–7]. In these studies, chemotherapy granted a median PFS of 1.6–3.0months and
6.8–8.1months in second- and first-line, respectively [2–7]. ORR achieved by chemotherapy
agents did not exceed 46% front-line, with worse results after failure of a previous treatment
[2–7]. Furthermore, from the available data, chemotherapy demonstrated a limited efficacy
in reducing existing brainmetastases, as well as preventing the onset of new central nervous
system (CNS) lesions [2–7]. However, it should be noted that none of the above-mentioned
phase III trials identified statistically significant differences in OS between the ALK-TKI
arm and chemotherapy arm, probably due to a cross-over in their relative chemotherapy
arm and the immaturity of results [3,4,6,7,9–11]. Moreover, it is important to emphasize that
TABLE 1 Efficacy of chemotherapy in ALK-positive NSCLC: evidence from phase III randomized trials.
Study
Patients
in CT arm
No of
BM (%)
Experimental
arm CT arm
mPFS
(months) ORR IRR Reference
First line
PROFILE
1014
171 47 (27) Crizotinib
250mg
PO BID
Pemetrexed
500mg/m2
with either
cisplatin
75mg/m2 or
carboplatin
AUC 5–6, IV
q3w for
6cycles
7.0 45% Intracranial
progression/
new lesions:
15%
[5]
Lu et al. 103
(Asian)
32 (31%) Crizotinib
250mg
PO BID
Pemetrexed
500mg/m2
with either
cisplatin
75mg/m2 or
carboplatin
AUC 5–6, IV
q3w for
6cycles
6.8 46% NA [8]
Continued
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the treatment outcomes, including ORR and PFS, following platinum-based combination
chemotherapies in ALK-positive patients are similar to those of the historical controls in un-
selected NSCLC [12–14].
In a more recent multicenter retrospective analysis, Lin et al. explored the efficacy of plat-
inum/pemetrexed chemotherapy in patients with advanced ALK-positive NSCLC refractory
to at least one second-generation ALK-TKI. Among 58 patients enrolled, almost one third
of patients achieved an objective response and median PFS was 4.3months [15]. Although
ORR was similar to what reported in prior phase III trials of treatment-naive ALK-positive
patients [5–7], the relatively short median PFS suggested that ALK-positive tumors may be
less sensitive to chemotherapy once they have become resistant to ALK-TKI [15]. In this
clinical setting, lorlatinib may be preferable to chemotherapy based on the demonstrated
efficacy after failure of second-generation ALK-TKI, especially on CNS, even if a direct
comparison between lorlatinib and chemotherapy is lacking [16,17].
TABLE 1 Efficacy of chemotherapy in ALK-positive NSCLC: evidence from phase III
randomized trials—cont’d
Study
Patients
in CT arm
No of
BM (%)
Experimental
arm CT arm
mPFS
(months) ORR IRR Reference
ASCEND-4 187 62 (33%) Ceritinib
750mg PO
QD q3w
Pemetrexed
500mg/m2
with either
cisplatin
75mg/m2 or
carboplatin
AUC 5–6 for
4cycles
followed by
maintenance
pemetrexed
8.1 20% 21.2% [7]
Second line
PROFILE
1007
174 60 (34%) Crizotinib
250mg
PO BID
Pemetrexed
500mg/m2 or
docetaxel
75mg/m2 q3w
3.0 20% NA [2]
ASCEND-5 116 69 (59%) Ceritinib
750mg PO
QD q3w
Pemetrexed
500mg/m2 or
docetaxel
75mg/m2 q3w
1.6 7% NA [3]
ALUR 35 26 (74%) Alectinib
600mg
PO BID
Pemetrexed
500mg/m2 or
docetaxel
75mg/m2 q3w
1.6 3% 0% [4]
BID, bis in die; BM, brain metastases; CT, chemotherapy; IRR, intracranial response rate; mPFS, median progression-free survival;
NA, not available; No, number; ORR, overall response rate; PO, per os; QD, quoque die.
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Regarding chemosensitivity of ALK-positive NSCLC, previous research showed that ALK-
positive patients are sensitive to platinum-based chemotherapy in the same manner than
ALK-negative ones. In a retrospective study by Shaw and collaborators including advanced
NSCLC patients, median time to progression (TTP) for patients who received platinum-based
chemotherapy was in the same range of 8 to 10months, regardless of ALK status [18]. Simi-
larly,when Lee and colleagues retrospectively investigated the efficacy of chemotherapy in 21
ALK-selected NSCLC patients, the PFS was similar with that of a matched cohort of ALK-
negative patients [19]. In both studies, ORR of chemotherapy ranged from 25% to 35%,
overlapping with unselected NSCLC populations [18,19]. Consistent with these findings,
Takeda and collaborators documented a similar sensitivity to platinumdoublet, both in terms
of ORR and PFS, among 200 patients with advanced nonsquamous NSCLC who were
grouped according to ALK and EGFR status [20].
Interestingly, different studies have suggested that ALK-positive patients could be parti-
cularly responsive to pemetrexed. In an ALK enriched population of 89 NSCLC patients,
across different lines of therapy, ALK positivity predicted a favorable PFS to pemetrexed
(monotherapy or platinum-based combination), and this finding was confirmed on a multi-
variate analysis adjusting for line of therapy, mono- versus platinum and non-platinum com-
bination therapy, age, sex, histology, and smoking status. In this report, the median PFS was
9months with pemetrexed regimens in 19 ALK-positive patients, exceeding that of 37 ALK/
EGFR/KRAS-negative patients by 5months [21]. Consistently, in a retrospective analysis,
15 ALK-positive patients who received second-line pemetrexed and beyond showed longer
TTP than EGFR-mutated or ALK-negative patients (9.2 versus 1.4 versus 2.9months,
P ¼ .001). The same positive trend was observed for ORR (47% versus 5% versus 16%,
P ¼ .001) [22]. Further larger cohort studies validated the notion that pemetrexed is an effec-
tive treatment strategy in ALK-positive NSCLC, both as a monotherapy and in combination
with platinum [23–25].
Although it is unclearwhyALK-positive patients derive a greater benefit frompemetrexed,
a biological rational could be taken into account. Indeed, ALK-positive NSCLC expresses low
levels of thymidylate synthase (TS), whose high expression is a well-known mechanism of
resistance to pemetrexed [26,27]. In vitro data showed that ALK-positive cells had signifi-
cantly lower TS mRNA levels with regard to control cells [22]. When assessing TS expression
on tissue specimens from 257 NSCLC patients, a low expression level of TS mRNA was ob-
served more frequently in ALK-positive specimens than ALK-negative controls (P < .05) [28].
Concerning this relevant association, the molecular mechanism underlying the link between
ALK and TS remains to be explained.
The role of immunotherapy in ALK-positive NSCLC
The clinical implementation of ICIs targeting the PD-1/PD-L1 axis has certainly revolu-
tionized the current treatment strategies for advanced NSCLC. However, ICIs’ efficacy varies
greatly according to different immune andmolecular profiles of these tumors. In particular, in
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the case of NSCLC patients harboring actionable driver mutations (i.e., EGFR, ALK, ROS1),
the role of ICIs is controversial. Large scale efficacy data in these molecular subgroups are
not available, since oncogene-addicted NSCLC patients have been usually excluded from
phase III immunotherapy trials. Overall, current evidence suggests that ICIs have rather a
weak activity in oncogene-driven NSCLC, and this could be due to the low tumor mutational
burden and low immunogenicity which is typical of these tumors [29,30]. As a consequence,
to date, immunotherapy single agents should be usually proposed only after exhaustion of
more validated treatments such as TKIs and chemotherapy [31].
Focusing on ALK-positive NSCLC, few studies with ICIs included these patients, thus
precluding definitive conclusions (Table 2). From the molecular point of view, it has been
demonstrated that ALK rearrangement upregulates PD-L1 expression in vitro. On the other
hand, the inhibition of ALK by alectinib or by siRNA-mediated ALK knockdown decreased
PD-L1 levels [44]. A positive correlation between ALK and PD-L1 expression has been also
described in clinicopathological studies [44–47], but this observation has not been confirmed
in further meta-analyses [48,49].
The large randomized phase III trials CheckMate 057, KEYNOTE 010 and OAK allowed
ALK-positive patients to be enrolled [32,33,50]. In these studies, single-agent nivolumab
TABLE 2 ALK positive NSCLC patients enrolled in clinical trials with ICIs.
Study Phase
ALK+ patients
(% of the total)
Clinical
setting Trial design Reference
ICI monotherapy
CheckMate 057 III 21 (4%) 2nd line Nivolumab vs docetaxel [32]
KEYNOTE 010 II/III 8 (<1%) 2nd line Pembrolizumab vs docetaxel [33]
OAK III 2 (<1%) 2nd line Atezolizumab vs docetaxel [34]
ATLANTIC II 15 (Cohort 1, 14%) 3rd line Durvalumab [35]
ICI combinations
Antonia et al. Ib 1 (1%) 1st line Durvalumab+tremelimumab [36]
CheckMate 370
(Cohort E)
I/II 13 1st line Nivolumab+crizotinib [37]
JAVELIN Lung 101 Ib 28 2nd line Avelumab+lorlatinib [38]
Felip et al. Ib 36 1st line Nivolumab+ceritinib [39]
Kim et al. Ib 21 1st line Atezolizumab+alectinib [40]
Chalmers et al. I 3 1st line Ipilimumab+crizotinib [41]
IMpower150 III 35 (<1%) 1st line Atezolizumab+CP vs
bevacizumab+CP vs
atezolizumab+bevacizumab+CP
[42]
IMpower130 III 47 (<1%)a 1st line Atezolizumab+CnP vs CnP [43]
a This number includes patients with EGFR mutations.
CnP, carboplatin+nab-paclitaxel; CP, carboplatin+paclitaxel; CT, chemotherapy.
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(anti-PD-1), pembrolizumab (anti-PD-1) and atezolizumab (anti-PD-L1) were compared to
docetaxel in second-line, respectively. However, the number of ALK-positive patients who
were included was too low to speculate on the efficacy of ICI monotherapy in this subgroup
of patients. Next, ATLANTIC trial assessed the effect of durvalumab (anti-PD-L1) treatment
in three cohorts of patients with NSCLC, defined by EGFR/ALK status, who had been treated
with at least two previous systemic regimens [35]. In particular, EGFR+/ALK+ subjects
(cohort 1) achieved worse outcomes than EGFR-/ALK patients (cohort 2 and 3), and all ob-
jective responses in cohort 1 occurred in EGFR+ patients, where high PD-L1 expression
enriched for responses [35].
Moving to combination strategies, ICIs in addition to ALK-TKIs have been recently tested
in early phase studies. Crizotinib plus nivolumab resulted in severe hepatic toxicities (38%)
leading to treatment discontinuation and interruption of further enrollment [37]. The combi-
nation of crizotinib plus ipilimumab (anti-CTLA4), given at the dose of 3mg/kg for 4cycles
concurrent with the ALK-TKI, induced hypophysitis and another grade 2 pneumonitis in two
out of three patients. Against substantial toxicities, the study showed promising PFS and OS
on a very small scale [41]. Crizotinib has also been investigated in combination with
pembrolizumab, but the trial has been prematurely terminated due to low enrollment [51].
Other second-generation ALK-TKIs are being explored in combination with immunother-
apy, showing the same concerns about tolerability. A not negligible incidence of grade 3–4
hepatic toxicities, as well as rash and lipase level increase, was documented when ceritinib
was combined with nivolumab in both pretreated and treatment-naı̈ve ALK-positive patients
[39]. Again, despite relevant adverse events (AEs), the latter combination resulted in prom-
ising activity, particularly in patients with high PD-L1 expression [39]. Beyond ceritinib, Kim
et al. recently published the data from a phase Ib trial of alectinib plus atezolizumab, in which
alectinib was given for 7days before combining with atezolizumab [40]. 21 previously-
untreated ALK-positive patients, including those with asymptomatic brain metastases, were
enrolled in this study. Taking into account the small number of patients, ORR achieved by
alectinib plus atezolizumab was 81% and the median PFS and duration of response were
21.7months (95% CI: 10.3–21.7) and 20.3months (95% CI: 11.5–20.3), respectively. The inci-
dence of grade 3 AEs with the combination therapy was 52.4%, with no new safety findings
and grade 4–5 AEs reported [40].
Lorlatinib, a third-generation ALK-TKI, has been explored in combination with avelumab
(anti-PD-L1) in the phase Ib JAVELIN Lung 101 study [38]. Among 28 heavily pretreated
subjects with ALK-positive NSCLC, ORR was 46.7% [38], which was consistent with a prior
study of lorlatinib alone [52]. In accordance with other ALK-TKIs-ICI combination studies,
grade3 AEs occurred in 53.6% of patients and they concerned mainly hepatic function
and triglycerides levels [38].
Considering the remarkable results of chemo-immunotherapy combinations for the first-
line treatment of EGFR/ALK-negative NSCLC, this strategy has also been extended in
ALK-positive population in two large-scale randomized phase III trials [42,43].
IMpower130 study assessed the efficacy of the addition of atezolizumab to front-line
carboplatin plus nab-paclitaxel (CnP) in advanced non-squamousNSCLC, including patients
with EGFR/ALK genomic alterations after previous TKI (n ¼47) [43]. Even though the study
met its co-primary endpoints of PFS and OS in the intention-to-treat population, subgroup
analyses showed no benefit of this strategy in EGFR/ALK-positive population over standard
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chemotherapy (atezolizumab + CnP mPFS: 7.0 versus 6.0months; Hazard Ratio [HR], 0.75,
95% CI: 0.36–1.54; atezolizumab + CnP mOS: 14.4 versus 10.0months; HR, 0.98, 95% CI:
0.41–2.31) [43,53].
In the IMpower150 study, treatment-naı̈ve patients were randomized to receive
atezolizumab plus carboplatin-paclitaxel (ACP), bevacizumab plus carboplatin-paclitaxel
(BCP), or atezolizumab plus BCP (ABCP), followed by maintenance therapy with
atezolizumab, bevacizumab, or both [42]. Oncogene-addicted NSCLC patients (both EGFR-
mutated and ALK-positive) were enrolled in this study, after progression to at least one prior
TKI, although most patients (87%) did not harbor these genetic variants. To date, only results
obtained from comparison between ABCP and BCP have been published. The trial met its co-
primary endpoints comparing ABCP versus BCP, which were PFS, both in ITT wild-type
(WT) population (without EGFR mutations or ALK translocation) and among patients in
the WT population who had high expression of an effector T-cell gene signature, as well
as OS in ITT-WT population [42]. Remarkably, with the limitations of an exploratory analysis,
mPFS was also longer with ABCP than with BCP among patients with EGFR mutations or
ALK translocations (9.7 versus 6.1months; HR, 0.59, 95% CI: 0.37–0.94). In addition, ABCP
regimen prolonged mOS compared to BCP in EGFR/ALK-positive patients (Not Estimable
versus 17.5months; HR 0.54, 95% CI: 0.29–1.03) [54]. ACP arm was also superior to BCP
arm in terms of mOS in this peculiar population (21.1 versus 17.5months; HR 0.82, 95% CI
0.49–1.37),with a less extent thanABCP [54].A trend towards a superiormOS in favor ofABCP
versusBCPwas confirmed ina specifically-addressedsubgroupanalysisofEGFR-mutatedpa-
tients, but data regarding exclusively ALK-positive patients are not available yet [55]. As a re-
sult, for the first time, this trial led to the approval of ICI-CT combination strategy (ABCP) by
FoodandDrugAdministration (FDA) forEGFR-mutatedorALK-positivepatients, after failure
to previous targeted therapies. Although IMpower150 included a relatively small number of
patients, ABCP could be a promising therapeutic opportunity in pretreated ALK-positive
patients, particularly at thepoint thatALK-TKI options havebeen exhausted.Considering that
ALK-positive NSCLC is particularly sensitive to pemetrexed, other combination approaches
including pemetrexed-based chemotherapy surely deserve further investigation. A study
evaluating platinum-pemetrexed-atezolizumab triplet (+/bevacizumab) for TKI-pretreated
patients with oncogene-addicted NSCLC, including those with ALK rearrangement, is
recruiting participants [56]. In the same clinical setting, the addition of pembrolizumab to
platinum-pemetrexed doublet is currently under investigation in a phase II trial [57].
The role of antiangiogenics in ALK-positive NSCLC
Antiangiogenic drugs constitute an essential weapon in the landscape of NSCLC treat-
ment. Since angiogenesis plays a fundamental role in NSCLC development and metastatic
spread, targeted treatment against angiogenesis can lead to regression of neovessels resulting
in tumor and metastases growth inhibition. Moreover, normalizing tumor vasculature with
antiangiogenic therapy could result in increased tumor drug delivery [58]. These effects can
be obtained by acting on the vascular endothelial growth factor (VEGF) pathway by inhibiting
either its ligand or its receptor. Among antiangiogenics, the VEGF-A recombinant antibody
bevacizumab is the only agent approved for the first-line treatment of nonsquamous NSCLC
62 3. Systemic treatments other than TKI
in combination with platinum-based chemotherapy. Ramucirumab, an antibody against
VEGF receptor (VEGFR), and nintedanib, an antiangiogenic multi-TKI, are currently ap-
proved for the second-line treatment in combination with docetaxel [59].
To date, clinical trials of antiangiogenic agents specifically addressed to ALK-positive
NSCLC are lacking. However, a biological rationale supporting a putative efficacy of these
drugs in the presence of ALK alterations could be considered. In a study focused on ALK-
positive anaplastic large-cell lymphomas (ALCL), it has been demonstrated that expression
of ALK induced expression of VEGF through downregulation of miR-16 [60]. In addition,
VEGF blood levels were higher in ALK-positive ALCL patients than healthy donors [60]. Still
in ALCL, treatment with bevacizumab strongly impaired ALK-positive ALCL growth in
mouse xenografts [61]. Regarding ALK-positive NSCLC, a crosstalk between ALK and
VEGFR has been demonstrated in a preclinical model [62]. Taken together, these data support
the involvement of angiogenesis inALK-translocated malignancies, including NSCLC, which
may enhance the efficacy of antiangiogenic agents.
The largest evidence of bevacizumab-chemotherapy combination in ALK-selected patients
comes from the randomized phase III IMpower150 trial, which has been discussed above [42].
Beyond IMpower150, several clinical reports have highlighted the potential benefit of
bevacizumab in NSCLC that harbor ALK rearrangements. Habib and colleagues firstly
reported a prolonged response (>18months) to bevacizumab in addition to weekly paclitaxel
in an ALK-positive NSCLC patient who did not obtain objective responses to either of four
previous regimens [63]. In another report, an exceptional complete responsewas documented
in a 52years-old ALK-positive female patient following the combination of bevacizumab and
cisplatin-pemetrexed, including disappearance of brain lesions [64]. Liu et al. also described a
case of ALK-positive NSCLC who achieved a clinical benefit of 7months of PFS from the
combined treatment of bevacizumab plus pemetrexed, after failure of two previous ALK-
TKIs [65]. Next, bevacizumab plus pemetrexed granted long-term disease control in NSCLC
patients with ALK rearrangements compared to wild-type population in a retrospective
analysis [66].
Interestingly, previous research found that bevacizumab was also effective against
perilesional edema typically found in brain radiation necrosis subsequent to stereotactic brain
irradiation. This effect could be obtained through the inhibition of VEGF, which is typically
produced by the reactive astrocytes in response to radiation damage [67]. In this sense,
bevacizumab has been proven to reduce brain radiation necrosis in fourALK-positive NSCLC
patients with irradiated brain metastases, in concomitance with ALK-TKI, and the combina-
tion was safe and well tolerated [68].
More recently, bevacizumab plus platinum-pemetrexed combination has been demon-
strated to restore sensitivity to alectinib in a case report. Authors suggested that bevacizumab
enhanced delivery of alectinib to the tumor. Indeed, they found that cell lines derived from
the primary-resistant patient after failure of alectinib were still sensitive to the ALK-TKI
ex vivo. Thus, they hypothesized that the putative mechanism of resistance to alectinib in this
peculiar case was driven by the tumor microenvironment, which was modulated by subse-
quent bevacizumab [69]. The bigeminal inhibition of ALK and angiogenesis with alectinib
plus apatinib (VEGFR-2 inhibitor) was able to reverse alectinib resistance in cell lines [62].
Promising results were also obtained in vivo with ramucirumab combined with alectinib,
both in terms of reduced neoangiogenesis and enhanced antitumor activity [70].
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Given this background, the combination of ALK-TKIs and antiangiogenics could be an ap-
pealing strategy in order to both enhance ALK-TKI efficacy and prevent resistance. Crizotinib
plus bevacizumab is the only combination which has been prospectively investigated in
ALK-positive NSCLC patients to date. Among 16 treatment-naı̈ve subjects, this approach
granted a mPFS of 13.0months (95% CI: 9.8–6.2), with hepatic injury being the most frequent
grade3 AE reported (12.5%) [71]. Looking at the next future, novel combination approaches
with alectinib plus bevacizumab and brigatinib plus bevacizumab in ALK-selected NSCLC
populations are currently under investigation [72,73].
Conclusion
ALK-TKIs have definitely laid the foundation of the current treatment algorithm of ad-
vanced ALK-positive NSCLC. The rapidly-evolving landscape of resistance mechanisms
and development of next-generation ALK-TKIs will ensure a customized manner to treat
ALK-rearranged NSCLC by keeping the pressure on ALK. Nevertheless, since most of the
patients will experience the onset of resistance, novel treatment strategies should be consid-
ered, especially once ALK-TKIs options are exhausted. In this regard, chemotherapy still
remains a valuable opportunity, with a special mention to pemetrexed-based doublet. ICIs
and antiangiogenics surely deserve more extensive investigation, due to the limited evidence
available to date, in a view of combined approaches. Atezolizumab plus bevacizumab and
carboplatin-paclitaxel is the only combination regimen that demonstrated a compelling acti-
vity and safety in ALK-driven NSCLC on a larger scale. Novel combinations, including those
with ALK-TKIs, are being currently tested and might enrich the future weaponry to counter-
act this peculiar disease.
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[13] Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G,
Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M. Phase III randomized trial
comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–91.
https://doi.org/10.1200/JCO.2002.02.068.
[14] ArdizzoniA, Boni L, TiseoM, Fossella FV, Schiller JH, PaesmansM, Radosavljevic D, PaccagnellaA, Zatloukal P,
Mazzanti P, Bisset D, Rosell R. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of ad-
vanced non-small-cell lung cancer: an individual patient datameta-analysis. J Natl Cancer Inst 2007. https://doi.
org/10.1093/jnci/djk196.
[15] Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I,
Gainor JF, Ou SHI, Riely GJ, Shaw AT. Efficacy of platinum/pemetrexed combination chemotherapy in
ALK-positive NSCLC refractory to second-generation ALK inhibitors. J Thorac Oncol 2020;15:258–65.
https://doi.org/10.1016/j.jtho.2019.10.014.
[16] Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ,
Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ignatius Ou SH, Shaw
AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol 2018;19:1654–67. https://doi.org/10.1016/S1470-2045(18)30649-1.
[17] Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin C-C, Soo RA, Riely GJ, Ou S-HI, Clancy JS, Li S, Abbattista A,
ThurmH, SatouchiM, CamidgeDR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini J-F. ALK resistancemutations
and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin
Oncol 2019;37:1370–9. https://doi.org/10.1200/JCO.18.02236.
[18] Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical
features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol
2009;27:4247–53. https://doi.org/10.1200/JCO.2009.22.6993.
[19] Lee JK, Park HS, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS, Kim WH, Bang YJ.
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched
wild-type advanced nonsmall cell lung cancer. Cancer 2012;118:3579–86. https://doi.org/10.1002/cncr.26668.
65References
[20] TakedaM, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K. Clinical outcome for EML4-ALK-positive
patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann
Oncol 2012;23(11):2931–6. https://doi.org/10.1093/annonc/mds124.
[21] Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W,
Doebele RC.Anaplastic lymphomakinase gene rearrangements in non-small cell lung cancer are associatedwith
prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774–80. https://doi.org/10.1097/
JTO.0b013e31820cf053.
[22] Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, KimWH, Kim YT, Yang SC, Kim YW, Heo DS,
Bang YJ. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-
small cell lung cancer. J Thorac Oncol 2011;6:1474–80. https://doi.org/10.1097/JTO.0b013e3182208fc2.
[23] Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA,
Riely GJ, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced,
ALK-positive non-small cell lung cancer. Ann Oncol 2013. https://doi.org/10.1093/annonc/mds242.
[24] Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, La CY, Ahn MJ. Favorable clinical out-
comes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Can-
cer 2013;79:40–5. https://doi.org/10.1016/j.lungcan.2012.10.002.
[25] Ma D, Hao X, Wang Y, Xing P, Li J. Clinical effect of pemetrexed as the first-line treatment in Chinese patients
with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Thorac Cancer 2016;7:452–8.
https://doi.org/10.1111/1759-7714.12353.
[26] Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007;26:153–81. https://doi.org/
10.1007/s10555-007-9049-z.
[27] Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1
expression in patientswith nonsquamous non-small cell lung cancer treatedwith pemetrexed-based chemother-
apy. J Thorac Oncol 2011;6:1392–9. https://doi.org/10.1097/JTO.0b013e3182208ea8.
[28] Xu CW, Wang G, Wang WL, Bin GW, Han CJ, Gao JS, Zhang LY, Li Y, Wang L, Zhang YP, Tian YW, Qi DD.
Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell
lung cancer tissues. Exp Ther Med 2015;9:2151–4. https://doi.org/10.3892/etm.2015.2372.
[29] Spigel DR, Schrock AB, Fabrizio D, Frampton GM, Sun J, He J, Gowen K, Johnson ML, Bauer TM, Kalemkerian
GP, Raez LE, Ou S-HI, Ross JS, Stephens PJ, Miller VA, Ali SM. Total mutation burden (TMB) in lung cancer (LC)
and relationship with response to PD-1/PD-L1 targeted therapies. J Clin Oncol 2016;34:9017. https://doi.org/
10.1200/JCO.2016.34.15_suppl.9017.
[30] Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR,
Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman
JA, Mino-Kenudson M. EGFR mutations and ALK rearrangements are associated with low response rates to -
PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 2016;22:4585–93.
https://doi.org/10.1158/1078-0432.CCR-15-3101.
[31] Mhanna L, Guibert N, Milia J, Mazieres J. When to consider immune checkpoint inhibitors in oncogene-driven
non-small cell lung cancer? Curr Treat Options Oncol 2019;20:1–11. https://doi.org/10.1007/s11864-019-0652-3.
[32] BorghaeiH, Paz-Ares L, Horn L, Spigel DR, SteinsM, ReadyNE, ChowLQ, Vokes EE, Felip E, Holgado E, Barlesi
F, Kohlh€aufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM,
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Abstract
The ALK gene was first described in the 1990s in a subset of non-Hodgkin lymphoma, anaplastic large-cell
lymphoma (ALCL). Two decades later, a small proportion of non-small cell lung cancers (NSCLCs) were
found to carry an activating rearrangement of ALK. This discovery drove to the development of small-
molecule ALK inhibitors that demonstrated dramatic response rates in patients with ALK rearranged ad-
vanced NSCLC patients and increased 6 months the PFS. Therefore, ALK emerged has a relevant biomarker
and a validated therapeutic target in ALK rearrangedmalignancies even in non-NCSLC, and especially in pe-
diatric malignancies harboring ALK alterations, either as a translocation in ALCL and inflammatory
myofibroblastic tumor or as activating mutations in neuroblastoma. The results of ALK inhibition by small
molecules alone or in combination, especially in a relapse setting, are encouraging despite the emergence
of resistance toALK inhibitors. The introduction of ALK inhibitors in the therapeutic schedule of these patients
follows two main goals: first to improve response and cure rates in these high-risk patients and second to de-
crease the burden of treatment and, thus, the long-term sequelae in this pediatric population. The right use and
positioning of these molecules is still in process especially in ALCL and neuroblastoma and efforts have to be
done to better understand the resistance mechanisms to ALK inhibitors in these malignancies.
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Introduction
The anaplastic lymphoma kinase (ALK) is a tyrosine kinase encoded on chromosome 2 that
performs a physiologic role in early brain development. Its expression is restricted to devel-
oping neural tissues and absent from other normal tissues [1, 2]. The ALK gene was first de-
scribed in a subset of non-Hodgkin lymphoma and anaplastic large-cell lymphoma (ALCL). It
was identified as a gene on chromosome 2 fused to the nucleophosmin (NPM1) gene in the t
(2;5) translocation [3]. ALK activation by translocation, amplification, point mutations have
since been identified in other malignancies. Indeed, more than 2 decades later, 3–5% of non-
small cell lung cancers (NSCLCs)were found to carry an activating rearrangement of ALK [4].
This discovery drove to the development of small-molecule ALK inhibitors. The first in class,
crizotinib showed dramatic response rates in patients with EML4-ALK advanced NSCLC pa-
tients [5]. Therefore, ALK has emerged a relevant biomarker and a validated therapeutic tar-
get in ALK rearranged malignancies.
We review here the management of three, mostly pediatric, malignancies harboring acti-
vating ALK alterations: anaplastic large cell lymphoma, inflammatory myofibroblastic tumor
(IMT) and neuroblastoma, and the arising place of ALK targeting in these diseases.
Anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is a rare subtype of peripheral T-cell non-Hodgkin
lymphoma (NHL) thought to derive from cytotoxic T cells. It is mostly considered as a pedi-
atric disease as it accounts for 10–15% of all NHLs in children and 1–2% in adults. The annual
incidence of ALCL ranges from 1.2 per million in children <15 years to 2 per million in
young adults (25–34 years) [6]. Two different histological and clinical entities of ALCL have
been described: cutaneous and systemic ALCLs. Primary cutaneous ALCL is confined to the
skin and could generally be treated by surgical excision without systemic therapy with an
excellent prognosis.
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Systemic ALCL is characterized by lymph nodes involvement, peripheral, abdominal or
mediastinal frequently associated with extranodal involvement and “B symptoms” at diag-
nosis [7]. The most commonly involved extranodal sites include skin, bone, soft tissues, lung
and liver.
More than 90% of ALCL cases in children and 50–60% of ALCL in adults show an expres-
sion of the anaplastic lymphoma kinase (ALK) on tumor immunostaining indicating the pres-
ence of a translocation involving the ALK gene and different partners [8–10]. The most
common partner is nucleophosmin (NPM1); resulting from the t(2;5) translocation [11].
Fusion transcripts involving an ALK partner other than NPM1 represent about 10% of
ALK-positive ALCL and various ALK partners have been described including: tropomyosin
3 (TPM3), tropomyosin 4 (TPM4), TRK fused gene (TFG), 5¢aminoimidazole-4-carboxiamide
ribonucleotideformyltransferase/IMP cyclohydrolase (ATIC), clathrin like heavy chain 1
(CLTC), ALK lymphoma oligomerisation partner on chromosome 17 (ALO17), moesin
(MSN) and myosin heavy chain (MYH9) [12–14]. It has been demonstrated that ALK
immunostaining of a tumor depends on the ALK fusion partner, with different phenotypes
according to the transcript [15].
ALK-positive ALCL is considered as a particular histological entity. A diverse morpholog-
ical spectrum is described, with three main distinctive morphological types: common, small
cell and lymphohistiocytic, sometimes associated in the same tumor sample. Other presenta-
tions such as Hodgkin-like patterns could rarely be seen. However, all morphological vari-
ants shared the presence of large cells with a highly characteristic morphology referred to
hallmark cells. Concerning their immunophenotype, the tumor cells are positive for CD30,
and in most cases, for EMA. One or more T-cell markers are generally expressed but in some
cases the hallmark cells may have an apparent “null cell” phenotype. Cytotoxic molecules
such as TIA-1, granzyme B, or perforin are found positive on immunostaining in a large ma-
jority of cases [10].
ALK-positive ALCL is a chemosensitive disease with a complete remission (CR) rate rang-
ing from 66% to 100% whatever the drugs used but 20–40% of the patients will relapse. Event
free survival (EFS) and overall survival (OS) of pediatric ALK-positive ALCL are quite stable
over the last decades, 65–75% and 70–90%, respectively, and among different collaborative
groups using various chemotherapy backbone with different treatment duration ranging
from few months to more than a year [16].
Several factors have proven to be associated with a higher risk of treatment failure in
children/adolescents: clinical factors such as the presence of mediastinal disease, visceral
or cutaneous involvement [17], high risk histological subtype defined by the presence of a
lymphohistiocytic or small cell component [18], positive PCR for NPM-ALK in peripheral
blood and/or bone marrow at diagnosis (minimal disseminated disease, MDD) [19, 20],
low anti-ALK antibody titers at diagnosis [21], and detection of minimal residual disease
(MRD) by PCR for NPM1-ALK in the blood after the first course of chemotherapy [22]. Inter-
estingly, Damm-Welk and colleagues demonstrated that ALK-positiveALCL can be classified
in three prognostic groups: patients with no detectableminimal disseminated disease (MDD),
patients with positive MDD and no detectable minimal residual disease (MRD) 4 weeks after
the beginning of chemotherapy and patients with both positiveMDD andMRD. The outcome
in this last subgroup of patients accounting for 25–30% of all ALCLpatients is clearly badwith
3-year EFS below 20%, with some patients experiencing multiple relapses.
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There is still no gold standard for the treatment of relapse. Several retrospective studies
reported a 5-year overall survival of about 70% for patients with relapsed ALCL. In these
studies, various therapeutic approaches including a wide variety of chemotherapy regimens
were used to achieve second complete remission (CR2) and in most publications, patients
underwent consolidation regimens by high dose chemotherapy followed by either autolo-
gous or allogeneic hematopoietic stem cell transplantation (HSCT). The main factor associ-
ated with failure is less than 12 months delay from end of frontline therapy to relapse.
Impact of CD3 antibody positivity on immunostaining at diagnosis was also suggested but
is still debated [23–25]. Although it has been well demonstrated at diagnosis, little is known
about MDD and MRD status as prognostic factors at relapse.
In children, the efficacy of a risk-adapted strategy for first ALCL relapses has been
shown through a prospective trial run by the European Intergroup for Childhood non-
Hodgkin Lymphoma (EICNHL) on a cohort of 118 patients reported by Ruf and colleagues
in 2015 [26]. High-risk relapses (relapses during front line treatment or CD3 positive, 40%
of the cases) were eligible for allogeneic HSCT after reinduction of chemotherapy. This
strategy was efficient, leading to a 3-year EFS after relapse in more than 65% of patients.
On the other hand, patients with low risk relapses (CD3 negative, >12 months after diag-
nosis, 20% of the cases) were treated with weekly vinblastine and achieved a 3-year EFS for
85% of them. Following these results, allogeneic HSCT was recommended for all high-risk
relapse patients. Autologous stem cell transplant is no longer recommended in this
indication.
In adults, prognosis of relapsed ALCL seems to be poorer than in children. In a retrospec-
tive study performed by the LYSA group on relapsed/refractory ALK-positive ALCL with a
relapse treatment comprising autologous HSCT after reinduction therapy, the median pro-
gression free survival (PFS) and OSwere 5 and 12months, respectively, with a 10-year overall
survival inferior to 15% [27].
Clearly, the burden of treatment at relapse for ALK-positive ALCL could be heavy, espe-
cially for patients with multiple relapses especially considering the major place of allograft in
the relapse setting. Therefore, during the last years, other strategies were raised, first to im-
prove outcome of patients with ALCL at diagnosis and at relapse, and second to limit long-
term treatment related morbidity, with a clear need for less toxic therapeutics.
New therapeutic strategies for ALK-positive ALCL
Brentuximab vedotin
Brentuximab vedotin (BV) is an anti-CD30 antiboby conjugated to an anti-microtubule
agent, monomethyle auristatin E. In a phase 2 studywith 58 ALCL including 16 ALK-positive
ALCL, the overall response and CR rates in AKL+ ALCL were 81% and 69%, respectively,
with prolonged responses. These results led to the approval of BV by the FDA and EMA
for the treatment of relapsed ALCL in adults following failure of at least one multi-agent che-
motherapy protocol [28]. Given the neurologic toxicity of brentuximab in adults, prolonged
treatment may be difficult to manage. This drug is, thus, mostly employed as a bridge to
transplant in relapsed patients.
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ALK inhibitors
Although the ALK gene was first described in 1994 as part of a genetic rearrangement
resulting in an oncoprotein with high kinase activity in this peculiar pathology, strategy of
ALK inhibition was developed decades after in ALK-positive ALCLs only after its develop-
ment in NSCLC, mainly because of the globally favorable survival rates of these patients, but
also its orphan disease status [3]. Since then, several ALK inhibitors have been tested in this
indication.
Crizotinib, the firstALK inhibitor ever approved, is anorally availableALKandmultikinase
inhibitor that has been shown to induce high response rates in relapsed/refractory ALK+
ALCL: 6/8 ALCL patients achieved a CR in a pediatric phase 1 trial and all 9 ALCL patients
ina retrospective report inadults [29, 30].Only fewprogressionshavebeendescribed forALCL
during crizotinib treatment so far, all occurring within only 2–5 months of treatment.
Even though it induces CR in most cases, crizotinib has not yet proven curative since
abrupt relapses following crizotinib discontinuation have been described [31], and no suc-
cessful reported cases of continuous CR after discontinuation of treatment have been reported
yet. Thus, crizotinib is currently used to induce CR2 in relapsed/refractory ALK-positive
ALCL patients before allogeneic or autologous HSCT or as a life-long therapy.
As seen with NSCLC, next generation ALK inhibitors have been developed in ALK-
positive ALCL.
In thepediatric phase 1 of ceritinib, a 2ndgenerationpotentALK inhibitor, 2/2ALK-positive.
ALCLs showedCR [32]. After a dose-escalation of ceretinib, an expansion phase is ongoing
in children/adolescents. However, similarly to crizotinib, no successful discontinuation has
been reported so far and, thus, ceritinib is also mostly used to induce remission in relapsed/
refractory ALK+ ALCL patients before allogeneic HSCT. In adult, the efficacy of ceritinib
could also be shown with long lasting responses in all 3 ALK-positive ALCL patients in-
cluded in the phase I trial ASCEND-1 [33].
The next generation ALK inhibitor alectinib has also been evaluated in ALK-positive
ALCLs in pediatrics and adults in a phase 1/2 trial taking place in Japan [34]. Definitive re-
sults have not been published yet but the first report released in the 2018 ASH meeting
showed a good safety profile and an overall response rate of 80%, with 8 out of 10 patients
with rapid CR (6) or PR (2) [35]. Interestingly, the two patients who experienced progressive
disease never responded to the treatment, emphasizing the fact that resistance to ALK inhib-
itors in ALK-positive ALCLs is mainly primary resistance. Recently, an Italian study looking
into resistance to ALK inhibitors demonstrated that an excess of NPM-ALK activation and
signaling induces apoptosis via oncogenic stress responses. The conclusion of the authors
was that suspension the ALK TKI treatment could represent a therapeutic option in cells that
became resistant by NPM-ALK amplification [36]. To date, no large study is available regard-
ing the mechanism of resistance to ALK inhibitors in patients with ALK-positive ALCL.
Brigatinib is also currently under evaluation in ALK-positive ALCL in adults
(NCT03719898) with no available results yet. To date, no trial evaluates lorlatinib in ALK-
positive ALCL neither in pediatrics nor in adults.
Despite extremely good results with crizotinib in ALK-positive ALCLs, next generation
ALK inhibitors in addition to be more potent and active on some ALK resistance mutations,
present the advantage of a good central nervous system penetration, which could be valuable
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in a disease as ALCL with a particular meningeal tropism. Indeed, some isolated CNS re-
lapses have been reported while on crizotinib with dramatic responses to ceritinib, lorlatinib
and alectinib [37]. Even though all patients achieved complete remission, they may not be
cured since abrupt relapses have been reported after the discontinuation of ALK inhibitors,
even after several years of treatment. A prolonged treatment or a consolidation either with
allogeneic stem cell transplantation, brain radiotherapy or conventional chemotherapy
should be discussed in these patients. The optimal duration of treatment with ALK inhibitors
has still to be defined.
In Europe, the EICNHL group is designing a trial with an ALK inhibitor in combination
with the ALCL99 standard frontline chemotherapy backbone as frontline treatment in a phase
1 safety study. Unfortunately, no ALK inhibitor has been selected yet.
Some other combinations with chemotherapy are under evaluation. Crizotinib in combi-
nation with chemotherapy has already been tested in a phase 1 trial in children with ALK-
related malignancies (NCT01606878), and final safety data from the phase 2 trial of crizotinib
administered in combination with multi-agent chemotherapy running by the Children’s
Oncology Group (COG) (NCT01979536) will be released soon.
ALK-positive ALCL and check-point inhibitors
Accumulating evidence indicates that the immune system plays a major role in both the
pathogenesis and final control of ALK-positive ALCL. Antibodies against ALK and cytotoxic
T-cell and CD4 T-helper responses to ALK have been observed in patients with ALK-positive
ALCL both at diagnosis and at remission with a significant inverse correlation between ALK-
antibody titers and the incidence of relapses. Moreover, vaccination using truncated ALK has
been reported to induce potent and long lasting protection from local and systemic
lymphoma growth. However, it has also been shown that ALK-positive ALCL cells stron-
gly express the immunosuppressive cell-surface protein PD-L1, as determined at the
mRNA and protein levels in ALK-positive ALCL cell lines. Furthermore, results of PD-L1
immunostaining on all patient tissue samples reported so far showed a strong PD-L1 expres-
sion [38]. Analysis revealed that PD-L1 expression is induced by the chimeric NPM1/ALK
tyrosine kinase, by activating STAT3, confirming a unique function for NPM/ALK as a pro-
moter of immune evasion by inducing PD-L1. In clinics, three case-reports clearly demon-
strated that prolonged response can be achieved with anti-PD1 therapy in patients with
ALK-positive ALCL refractory to chemotherapy and/or ALK inhibitors [39–41]. These three
cases along with the unique immunogenic properties of ALCL including intrinsic PD-L1
induction and the good tolerance profile of PD1 inhibitors advocated for the development
of clinical trials evaluating the efficacy of PD-1 inhibitors in refractory/relapsed ALCL. This
hypothesis is currently under evaluation in the NIVOALCL trial testing nivolumab
monotherapy either in case of progression after targeted therapies or as consolidative immu-
notherapy in patients in CR after ALK inhibitors or brentuximab vedotin.
To summarize, ALK-positive ALCL is a rare disease with quite good outcome with front-
line standard chemotherapy and accessible to multiple targeted agents. However, some chal-
lenges remain (1) in the management of high-risk patient at diagnosis and at relapse to
increase the cure rate and decrease the global treatment burden and (2) for the investigators
in the optimal positioning of all these available novel agents.
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Inflammatory myofibroblastic tumor
Inflammatory myofibroblastic tumor is a very rare mesenchymal tumor. Historically this
disease was included in the group of “inflammatory pseudotumor” which comprises a wide
range of neoplastic and non-neoplastic (reactive) lesions [37]. Over the past decades, IMTwas
characterized as a specific entity with particular clinical, pathological andmolecular features.
IMT can occur at any age but is clearlymore frequent in the two first decades of life, especially
in children and adolescents. This tumor can be uni- or multifocal tumor. It typically arises in
the abdomen, pelvis, lung, head, or neck, but can present anywhere in the body [42–44]. Al-
though IMT can be detected as an incidental finding, i.e. on a routine chest X-ray. Patients
often present with general symptoms (fever, weight loss or fatigue) or symptoms depending
on tumor location (palpable mass, abdominal pain or gastrointestinal complaints for intra-
abdominal lesions, and cough, chest pain, or, less often, hemoptysis for pulmonary tumors).
Signs of biological inflammation are usually present in patients presenting general symptoms
[42, 45]. Histologically, IMTs are composed of a myofibroblastic spindle cell stroma with ac-
cumulation of leukocytes and plasma cells, with occasional admixed eosinophils and neutro-
phils [45]. Mitotic activity is generally low and vascular invasion infrequent [46–50].
Approximately 50% of IMT show positive ALK staining by immunohistochemistry (IHC)
[51]. ALK expression in IMT is prominent in younger patients but not limited to this popu-
lation. After the discovery of ALK rearrangement in ALCL, IMT was the first solid tumor in
whichALK translocationwas described [52]. Similarly toALCL,ALK expression in IMT signs
the presence of an ALK gene rearrangement. Several different translocation partners were
usually correlated with the specific gene fusion by immunostaining, i.e., diffuse cytoplasmic
staining with TPM3, TPM4, CARS, or ATIC, genes; nuclear membrane staining with
RANBP2, etc. This last translocation is associated with a particular subset of IMT, epithelioid
inflammatorymyofibroblastic sarcoma that seems to have amore aggressive clinical behavior
[53]. The translocation can be detected by FISH and/or RT-PCR. Of note, some ALK gene’s
fusion partners are associatedwith negative ALK expression by IHC, pleading for the system-
atic incorporation of molecular diagnostic tools for the diagnosis of IMT [54, 55]. The clinical
course of IMT is usually relatively indolent but with a trend for local recurrence and a small
risk of distant metastasis (less than 5%) [42, 43, 53]. The most commons site of metastases are
lung and brain. Treatment of IMT varies according to the location of the tumor, the size and
the extent of the disease. Complete surgical resection is the mainstay of curative treatment,
and recurrence is very infrequent in complete resection of a solitary lesion. However, local
relapse rate increase in some anatomical locations for whom obtaining complete surgical re-
section is very challenging. For patients with unresectable or metastatic disease, systemic
strategies such as steroids or other anti-inflammatory agents and cytotoxic chemotherapy
have been used with limited success.
The discovery of activating ALK rearrangements in up to half of all cases of IMT and
emergence of ALK targeting in NSCLC in the 2000s gave rise to new strategic options for
the treatment of ALK rearranged and not completely resectable IMTs [5, 46]. In 2010,
Butrynski and colleagues reported a sustained partial response to the ALK inhibitor
crizotinib in a patient with ALK-rearranged IMT, compared with the absence of activity
of crizotinib in another patient with IMT without ALK translocation. This first report con-
firmed the dependence on ALK signaling in ALK-translocated IMT [56]. More recently,
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the COG published encouraging results in 14 pediatric IMT patients treated with crizotinib.
This phase 1/2 study showed promising activity in metastatic or unresectable IMT with an
overall response rate (ORR) of 83%. Complete response was observed in 6 out of 14 patients
(36%). Lastly, a review compiled the data of 30 advanced or metastatic ALK-positive IMT
treatedwithALK inhibitors, mostly case-reports in addition to the 14 patients from the COG
trial. The overall response rate (ORR) was 80% with 40% of CR [57]. In both publications,
responders’ outcome after crizotinib discontinuation was not mentioned, and the rate of pa-
tients who could finally achieve complete resection or, on the contrary, who experienced
abrupt relapses after stopping ALK inhibitor is not known. Indeed, as in ALCL, relapse
at ALK inhibitor ceritinib discontinuation could occur even after CR achievement and
prolonged treatment as shown in a recent case-report. Nevertheless, the reintroduction
of ceritinib treatment in this patient led to CR2 [58]. This demonstrates than CR2 can be
reached by resuming ALK inhibitor and that, as in ALCL optimal treatment duration with
ALK inhibitors to avoid relapses is not known yet. Another major issue with ALK inhibitors
in ALK-positive malignancies is acquired resistance mechanisms by tumor cells. Resistance
mechanisms in IMT seem to be similar to NSCLC. Several case reports illustrated a drug-
resistance than can be overcome in most cases by the introduction of next generation ALK
inhibitors. To date, multiple next generation ALK inhibitors have been used successfully in
IMT. Notably, ALK inhibitors with good CNS penetration (brigatinib, ceritinib, alectinib
and lorlatinib) are of particular interest in the rare patients with brain metastasis [57–59].
As described above in ALCL, ALK fusion could confers a particular immunogenic status
to IMT and indeed particular immunologic status of IMT is demonstrated by the prominent
tumor-associated inflammatory infiltrate and the constitutional symptoms, including fever.
A recent pathological study, demonstrated in 35 IMT samples from 28 patients a high prev-
alence of PD-L1 expression on both tumor and infiltrating immune cells, with a 80% pos-
itivity for PD-L1 expression. Another publication showed that PD-L1 expression and
CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement in IMT.
These results suggest that immune checkpoint inhibitors may be a novel option for treating
patients with advanced IMT [60, 61].
To summarize, although IMT is considered by theWorld Health Organization to be of “in-
termediate malignancy,” curative treatment can be sometimes very difficult because of the
impossibility to perform complete surgical resection without mutilation. Moreover, in rare
cases, patients present metastatic disease at diagnosis. When standard surgical treatment
is not feasible, ALK inhibitors may play an important role in reducing tumor burden and vol-
ume. The place of immune checkpoint inhibition has to be explored in this immunogenic
disease.
Neuroblastoma
Neuroblastoma is the most common solid extracranial malignant tumor in children, ac-
counting for 8–10% of childhood cancers [62, 63]. It is an embryonal malignancy arising
from neural crest stem cells and the neuroblastic tumors present along the parasympathic
system from neck to pelvis or most commonly in the adrenal gland. The median age at diag-
nosis of neuroblastoma is around 2 years. Its presentation at diagnosis is very heterogenous.
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Indeed, the natural history of the disease could be quite benign in infants with spontaneous
resolution even in patients presenting with disseminated disease, whereas in older patients
the disease could be biologically aggressive with widespread metastases and refractory
to treatments. Considering this population, despite major progresses in neuroblastoma’s
therapeutic management during the last decades, neuroblastoma still account for 15% of
childhood cancer deaths. To improve outcome and to overcome this complexity due to het-
erogenous biological and clinical behavior, a risk-tailored approach has been developed over
the years. Prognostic factors used to stratify patients include age at diagnosis, localized or
disseminated disease, MYCN amplification, segmental chromosomal alteration, histological
type. Whereas localized mature neuroblastic tumors or neonatal tumors with numeric chro-
mosomal alteration are highly curable with a 5-year overall survival exceeding 90%, high risk
patients (>12 months with metastasis or/and MYCN amplification) accounting for almost
50% of the patients have a poorer outcome with frequent refractory disease and relapse with
a 5-year survival of 40–50% [64]. For high-risk patients the therapeutic strategy became more
complex over decades. By now, the treatment schedule comprises dose-intense induction
with cytotoxic chemotherapy, local treatment of primary tumors by surgery plus radiother-
apy, consolidation by high-dose chemotherapy followed by autologous stem cell transplan-
tation and maintenance therapy consisting in courses of retinoic acid and immunotherapy
with anti-GD2 [65, 66]. This already long and intense schedule is continuously evolving.
Questions are still rising in both the European SIOPEN and American COG groups. Single
vs tandem high dose consolidation regimens is currently under evaluation in both groups
as the role and place of 131 I-metaiodobenzylguanidine (131I-MIBG) therapy for consolida-
tion [67, 68]. The optimal timing of anti-GD2 therapy in frontline is still debated, and the use
of GD2 target in adoptive T-cell therapy programs is currently being evaluated, with various
results [69, 70]. Overall, despite better understanding in neuroblastoma biology, refinement
of risk stratification, and intensive and prolonged frontline therapy providing long-term
side effects, patients with high-risk neuroblastoma still suffer from frequent relapses [71].
Outcome of patients experiencing relapse is dismal with a 5-year OS of about 20% [72, 73].
ALK in neuroblastoma
In the last decade, the advent of next generation sequencing opened the way for better ge-
nomic characterization and identification of tumor-specific targets. Indeed, considering their
neural crest origin, ALK full length is not surprisingly expressed in neuroblastoma cells [2].
Single-base missense germline ALKmutations were found to be the genetic origin of familial
neuroblastoma and the samemutations were also detected at a somatic level in sporadic neu-
roblastomas, confirming ALK’s special place as the only mutated oncogene suitable as a ther-
apeutic target in this disease [74]. In 2014, Bresler and colleagues reported than the ALK
tyrosine kinase domain mutations occurred in 8% of neuroblastoma. Three recurrent muta-
tions R1275, F1174, and F1245, consistent with other studies, accounted for about 85% of ALK
mutations and 13 other minor site mutations were identified. They correlated significantly
with poorer survival in high- and intermediate-risk groups [75]. Some studies comparing so-
matic genome analysis of neuroblastoma samples at diagnosis and at relapses demonstrated
that ALK mutations were enriched at relapse. Deep sequencing revealed that some of these
79Neuroblastoma
mutations where already present at diagnosis at a subclonal level at a very low allele fre-
quency whereas others were acquired de novo [76–78]. These observations emphasizing
the role of ALK as a driver oncogene and given the restricted distribution in normal tissue
and frequent expression of ALK in neuroblastoma, ALK became an attractive target in this
disease.
ALK inhibition in neuroblastoma
Preclinical studies
In preclinical studies, knockdown of ALK expression in NB cells lines resulted in growth
inhibition but was foundmore effective in cells with ALK alterations than in those with wild-
type ALK. Several data suggest that not all mutations reported in neuroblastoma could be
considered as oncogenic drivers. On the other hand, some of the proven activating ALK mu-
tations lead to primary resistance to the first in class ALK inhibitor crizotinib [79]. As dem-
onstrated by Bresler and colleagues there are differential sensitivity to crizotinib based on the
type of mutation. Indeed, neublastoma with ALK R1275Q mutations were more sensitive to
crizotinib, whereas those with ALK F1174L and F1245C exhibited a relative resistance [75].
Efficacy of the next generation ALK inhibitors, such as ceritinib, alectinib, lorlatinib and
brigatinib has also been tested in neuroblastoma. Ceritinib demonstrated a 20-fold increased
in potency over crizotinib in ALK enzymatic assays and proved efficacy in both crizotinib-
naı̈ve and resistant NSCLC. However, ceritinib did not overcome crizotinib-resistant in
ALK F1174C mutant neuroblastoma [80]. Alectinib showed greater affinity than crizotinib
for the ATP-binding site and thereby improved potency against the ALK-kinase. Unlike
ceritinib, alectinib was proven to inhibit growth in ALK-wild type neuroblastoma cell-lines
as well as in ALK F1174L mutants [81]. Brigatinib is one of the most recently developed sec-
ond generation ALK inhibitors and is a highly potent and selective ALK inhibitor. In a recent
study, brigatinib maintained substantial activity against 17 secondary ALK mutants, includ-
ing F1174L, tested in cellular assays and demonstrated a superior inhibition profile compared
with crizotinib, ceritinib, and alectinib [82]. Third generation ALK inhibitor lorlatinib was
found having high potency across ALK variants and inhibited ALK more effectively than
crizotinib in vitro. It has also been able to induce complete tumor regression in crizotinib-
resistant xenograft mouse models of neuroblastoma, as well as in patient-derived xenografts
harboring the crizotinib-resistant F1174L mutation [83]. In addition to the single drug ap-
proach and the development of next generation ALK inhibitors, several combinations have
been preclinically tested to enhance crizotinib antitumor activity or to overcome resistance.
For example, chemotherapy agents and small molecules inhibitors of downstream pathways
such as mTOR have been combined with small molecules ALK inhibitors and anti-ALK an-
tibodies with some successes [79].
Clinical trials
Crizotinib was the first assessed and approved ALK inhibitor in ALK and ROS1
rearranged NSCLC with promising results. These results along with the identification of
ALK as an oncogenic driver in neuroblastoma led to the development of trials and clinical
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strategies to target ALK in neuroblastoma and in other ALK rearranged pediatric malignan-
cies, such as IMT and ALCL.
Crizotinib was first evaluated in a cohort of 79 children and young adults (<22 years) with
relapsed/refractory solid tumors, or ALCL in a phase 1–2 trial launched by the COG in 2009
[29]. Crizotinib in this population was proven safe and well tolerated and as expected,
showed similar pharmacokinetics profile as in adults [84]. Among this cohort, 34 neuroblas-
toma patients were enrolled, with 11 of them known to harbor ALK activating mutations. De-
spite an objective response rate of nearly 70% in children with other ALK rearranged tumors,
results were first discouraging in neuroblastoma patients. Indeed, only one out of 11 achieved
complete remission and three patients experienced stable disease. When looking closer at the
ALK alterations presented in these patients’ tumors, three of them harbored a mutation at the
R1275 locus, associated with a germline mutation in two. The last patient with stable disease
presented a somatic F1174Lmutation. The other seven patients with ALKmutations had pro-
gressive disease including three patients with F1174L somatic mutations. Among the other 23
patients with unknownALK alteration status, one patient achieved a CR and five had a stable
disease, prolonged for 39 cycles in one [29]. These results in neuroblastoma were clearly in-
sufficient to claim for a curative effect but they suggested an anti-tumor activity in neuroblas-
toma and confirmed the differential efficacy profile according to the locus of the ALK
mutation.
To enhance the results obtained inmonotherapy, and assessed safety and tolerability of the
addition of crizotinib to chemotherapy agents, the next trial designed by the COG associated
crizotinib with either cyclophosphamide/topotecan or vincristine/doxorubicine in patients
with refractory or relapsed ALCL or solid tumors. Limiting toxicities were dehydration, di-
arrhea and prolonged QTc and according to the authors could be due to the poor palatability
of the oral solution of crizotinib [85]. Results from this trial, especially concerning efficacy are
not yet published but seemed encouraging as crizotinib in association with standard therapy
is currently evaluated in a COG phase III trial designed for high-risk neuroblastoma with
ALK mutations (NCT03126916).
Additionally, next generation ALK inhibitors such as ceritinib, ensartinib, lorlatinib and
entrectinib are currently under clinical trial evaluation for high risk or relapsed/refractory neu-
roblastoma, alone or in combination with either chemotherapy agents or other targeted small
molecules (NCT01742286, NCT02780128, NCT02650401, NCT03213652, NCT03107988).
Ceritinib is evaluated in neuroblastoma in two pediatric trials: 1/single agent in an internation-
al pharma sponsored phase 1–2 trial with a neuroblastoma dedicated cohort (NCT01742286)
2/in combination with the small molecule CDK4/6 inhibitor ribociclib as part of a molecular
profiling program for neuroblastoma (The NEPENTHE Trial; NCT02780128). Interestingly, in
the ceritinib monotherapy trial, one patient with relapsed neuroblastoma with an ALK F1174L
mutation experienced partial response on a retroperitoneal mass but the disease concurrently
progressed in central nervous CNS, suggesting that other ALK inhibitors with better CNS pen-
etration could be used to achieve adequate concentrations in neuroblastoma sanctuary sites
such CNS [32]. It could also suggest a spatial and subclonal evolution of the disease. Ensartinib
has been chosen as the ALK and ROS1 inhibitor of the Pediatric MATCH (Molecular Analysis
for Therapy Choice) phase 2 trial, stratifying patients’ treatment according to molecular alter-
ations and including neuroblastoma among other pediatric relapsed or refractory pediatricma-
lignancies (NCT03213652). Lorlatinib is under evaluation in addition to the chemotherapy
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backbone cyclophosphamide plus topotecan in newly diagnosed high-risk neuroblastoma pa-
tient in a phase 1 trial designed by the NANT (New Approaches to Neuroblastoma Therapy)
(NCT03107988). Lastly, ALK is targeted along with other neuroblastoma alterations by the
pan- TRK, ROS1 and ALK entrectinib in the dose finding trial with a neuroblastoma specific
cohort (NCT02650401). Completion and results of these trials evaluating next generation ALK
will be crucial.
To summarize, neuroblastoma is a highly heterogenous disease in its clinical features as
well as on a biological and molecular bases, with clear unmet medical needs in the manage-
ment of high-risk patients who still suffer from dismal outcome. With promising activity in
preclinical data and encouraging signals in the first clinical trials, ALK inhibition will defi-
nitely play a role in the management of the nearly 10% of high-risk neuroblastoma patients
harboring ALK alterations. Nevertheless, the completion and results of the ongoing trials
evaluating next generation ALK inhibitors and combinations will be crucial to (1) increase
the knowledge on resistance to ALK inhibition in neuroblastoma patients and (2) ideally
position ALK inhibition in the already dense treatment schedule of high-risk patients.
Conclusion
During the past years, ALK targeting has clearly became a weapon of choice in pediatric
malignancies harboring ALK rearrangements, either translocation as in ALCL and IMT or ac-
tivating mutations as in neuroblastoma. Results of ALK inhibition by small molecules alone
or in combination, especially in a relapse setting, are encouraging despite the emergence of
resistance to ALK inhibitors. The introduction of ALK inhibitors in the therapeutic schedule
of these patients follows two main goals: first to improve response and cure rates in the high-
risk patients and second to decrease the burden of treatment and thus the long-term sequelae
in this pediatric population. The right use and positioning of these molecules are still in pro-
gress especially in ALCL and neuroblastoma and efforts have to be done to better understand
the resistance mechanisms to ALK inhibitors in these malignancies.
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Abstract
Lung cancer is a leading cause of the deaths due to cancer, and the development of effective treatments has
been an urgent issue. Over the last 15years, EGFR activating mutations and fusion genes such asALK or ROS1
have been discovered, and a number of molecular targeting drugs have been developed, that results in a re-
markable antitumor effect and great extension of the survival period for the advanced lung cancer patients. In
ALK rearranged cancer, many ALK tyrosine kinase inhibitors (ALK-TKIs) have been developed and 5 ALK-
TKIs were approved and used in clinical setting. However, the major problem is the tumor recurrence due to
the acquired resistances, and that make it difficult to achieve complete cure. The mechanism of acquired re-
sistance varies not only from case to case, but also multiple resistance mechanisms exist in each patient with
high diversity. This chapter focuses on the drug resistance mechanisms to ALK-TKIs in ALK-rearranged lung
cancer, and the potential therapeutic strategies to overcome resistance.
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Introduction
ALK (anaplastic lymphoma kinase) is expressed focally in neuronal cells and in the small
intestine. Although the precise physiological functions of ALK remain unclear, it is believed
to play a role in promoting normal development and function of the nervous system. Inter-
estingly, no apparent dysfunction was observed in the Alk gene-deleted mice [1,2], and no
universally-recognized adverse events have been associated with the administration of
ALK-specific tyrosine kinase inhibitors (TKIs). However, there are numerous reports
documenting the function of ALK in model organisms, including Drosophila and nematodes.
In Drosophila, ALK binds to its ligand, Jeb (Jelly belly) and promotes synapse formation and
gastrointestinal development [3,4].
By contrast, the function of ALK tyrosine kinase and its role in promoting malignant dis-
ease have been well studied, most notably in lung cancer associated with ALK gene
rearrangements [5]. Upon formation of fusion genes, including EML4-ALK or NPM-ALK,
the fusion protein is expressed constitutively, and ALK tyrosine kinase is activated in re-
sponse to oligomerization of the fusion partner protein; this results in constitutive activation
of cell growth signaling and the induction of tumorigenesis [5,6] (Fig. 1). To inhibit the pro-
oncogenic signaling promoted by the ALK fusion protein, ALK TKIs have been developed.
Administration of the inhibitors resulted in marked tumor shrinkage in vitro, in vivo, and
in clinical trials. To date, five ALK inhibitors have been approved and have been introdu-
ced for the treatment of non-small-cell lung cancer (NSCLC) with ALK-gene rearrangements.
The use of potent ALK inhibitors has resulted in significant improvements with respect to the
prognosis of ALK-rearranged NSCLC; survival has been prolonged remarkably. Currently,
the average survival time for patients diagnosedwithNSCLCwithALK gene rearrangements
is over 4years, even among those with advanced disease. Unfortunately, despite these initial
remarkable responses, relapse is inevitable due to acquired resistance. Drug resistance mech-
anisms can be categorized into three groups, including (1) secondary mutations that develop
in ALK (including compound mutations), (2) activation of bypass pathways, and (3) other
mechanisms including transformation to small cell lung cancer and other cancer phenotypes
[7]. This chapter provides a comprehensive insight into our current understanding of resis-
tance mechanisms to ALK-TKIs. Therapeutic strategies that have the potential to overcome
this resistance are also briefly reviewed.
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Mechanisms of resistance to ALK-TKIs
Point mutations in the ALK kinase domain mediate resistance to ALK-TKI
The first-generation ALK-TKI, crizotinib, reduced tumors in more than 60% of patients di-
agnosed with ALK-positive lung cancer, although the median progression-free survival of
patients treated with the agent was about 10months [8–10]. This result suggested that ac-
quired resistance emerged in more than half of the patients treated with crizotinib within
one year. The first reportedmechanism associatedwith crizotinib resistance involved the gen-
eration of two independent mutations in ALK; specifically, the mutations C1156Y and
L1196M were identified in cells in a pleural effusion from a patient that had relapsed while
on crizotinib treatment [11]. The ALK-L1196M mutation is at a “gatekeeper site” and is anal-
ogous to epidermal growth factor (EGFR)-T790M, the most frequently observed resistance-
associated mutation identified in first- or second-generation EGFR-TKI treated patients; it
is also analogous to the T315I mutant of ABL kinase that has been observed in relapsed
chronic myeloid leukemia in patients that had undergone treatment with the BCR-ABL
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FIG. 1 Reported ALK fusion oncogenes including the fusion genes identified in multiple cancer types.
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inhibitors, imatinib, or dasatinib. The gatekeeper residue is situated within a hydrophobic
pocket located at the hinge region at the site of ATP binding to ALK tyrosine kinase. The gate-
keeper residue plays an important role with respect to the interactions between kinases and
kinase inhibitorsandcanserve to increase the specificityof specificTKIs. For example, in the case
of ABL kinase, the gatekeeper residue, T315, interacts directly to a methyl group of the phenyl
ringof imatiniband thereby increases thepotencyandspecificityof imatinib; theT315Imutation
impairs the affinity of theABLkinase for imatinib. Likewise, in the case of the EGFR-T790M, this
mutation is believed to increase the affinity of EGFR for ATP, thereby promoting a slight
decrease in its affinity for first- or second- generation EGFR-TKIs; in other words, this results
in the relative decrease in the affinity of EGFR for the TKI, given the overall abundance of
ATPwithin the target cells. Similarly, the ALK-L1196Mmutation has been reported to promote
an increase in kinase activity along with a diminished affinity for crizotinib [12].
On the other hand, the ALK-C1156Y mutation is situated in the N-lobe of ALK and may
change the conformation of the alpha-C helix and as such it may have an impact on the con-
formation of the crizotinib binding region; however, a detailed mechanism has not yet been
clarified.
A number of additional mutations in ALK have been identified from cells isolated from
patients who underwent relapse while under treatment with crizotinib; among these are a
1151T-insertion, L1152R, I1171T, F1174L, G1202R, S1206Y, F1245V, and G1269A (Fig. 2).
The L1196M and G1269A mutations have been reported at relatively high frequency
[13,14]. The G1269 residue is located immediately adjacent to an Asp-Phe-Gly (DFG) motif
that has been recognized within the catalytic cores of protein kinases. The G1269A mutation
induces a slight structural change. However crizotinib binds at a site near to the G1269 res-
idue, and as such, this point mutation may largely affect its binding affinity. G1202R and
S1206Y mutations are “solvent front” mutations; G1202 and S1206 are situated on the outer
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FIG. 2 Major crizotinib resistant mutations. Mutated amino acid residues in ALK kinase domain were pointed in
ribbon structure of ALK (PDB-ID: 2XP2). Adapted from Katayama et al. Clin Cancer Res 2015.
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face of the ALK and are in contact with solvent. It is critical to recognize that these two mu-
tations replace relatively small amino acids (G and S) with bulky (Y) and charged (R) amino
acids, that could provide steric hindrance to crizotinib binding. Similarly, the 1151T insertion
and the L1152Rmutations are located close to C1156 in N-lobe of ALK; as such, theymay also
have a negative impact on the structure of alpha-C helix that contributes to the active protein
conformation [13]. Interestingly, ALKmutationsF1174LandF1245Vwere initially identifiedas
activatingmutations in cases of neuroblastoma [12,15]; as such, theyhave thepotential to induce
constitutive activation of full lengthALK. Specifically, themutations introduced at either F1174
or F1245 destroy the π-π interactions between their two phenyl rings that are critical in order to
maintain ALK in an inactive conformation. This conformation prohibits auto-phosphorylation
of ALK at Y1278, Y1282 and Y1283 residues found in the activation loop (A-loop).
The second-generation ALK inhibitors, alectinib and ceritinib, were reported to have the
capacity to overcome crizotinib resistance both in vitro and in vivo. Indeed, both alectinib and
ceritinib exhibited marked anti-tumor effects in patients who underwent previous treat-
ment with crizotinib as well as in those who are ALK-TKI treatment-naı̈ve. Alectinib was first
reported as a potent and selective ALK-TKI with the capacity to overcome the L1196M gate-
keeper mutation [16]. ALKs with other mutations associated with crizotinib resistance, in-
cluding C1156Y, F1174I/L, and S1206Y were also sensitive to alectinib; these results
suggest that clinical resistance to crizotinib may be overcome by alectinib. However, analysis
of specimens from patients with refractory disease together with experimental data from cell
line models has revealed that ALKmutations including I1171N/S/T, V1180L, and G1202R all
promote resistance to alectinib [17]. Similarly, albeit controversial, the L1196M gatekeeper
mutation associated with resistance to crizotinib was also identified in tumor cells from pa-
tients demonstrating resistance to alectinib [18]. However, it is important to recognize that the
IC50 of alectinib for Ba/F3 cells that express mutant EML4-ALK-L1196M is about 10-fold
higher than reported in cells expressing EML4-ALK-WT; in other words, serum concen-
trations of alectinib that can be reasonably achieved may not be high enough to inhibit the
activity of ALK-L1196M in some cases.
Ceritinib is another potent and selective ALK-TKI that has the capacity to overcome several
of the characterized mutations associated with crizotinib resistance. Indeed, cells with mul-
tiple crizotinib-resistant mutations, including L1196M and G1269A, were shown to be highly
sensitive to administration of ceritinib [19,20]. Furthermore, the I1171T and V1180L ALKmu-
tations associated with alectinib resistance could be readily overcome by treatment with
ceritinib; in fact, mutated EML4-ALK-V1180Lwas found to bemore sensitive to ceritinib than
was the wild-type EML4-ALK [17]. Ceritinib resistant mutations have also been identified,
including F1174V and G1202R [20]. Among these, the G1202R mutation confers resistance
to crizotinib, alectinib and ceritinib, while several characterized ALK mutations, including
I1171T/N/S, V1180L, and F1174V, can be overcome by any of the first or second-generation
ALK-TKIs. Interestingly, IC50 of ceritinib when used to treat cells with the EML4-ALK-
F1174Vmutations in only a few-fold higher than the wild-type; nonetheless, this “activating”
mutationwas observed frequently among ceritinib resistant patients. Themechanisms under-
lying this observation have not yet been clarified.
Brigatinib is another potent, second-generation ALK-TKI that can overcome the gate-
keeper L1196M mutation [21,22]. In addition, brigatinib was shown to be effective against
ALK with multiple single mutations including L1152R, C1156Y, V1180L, and I1171T/S/N.
In vitro findings have shown that brigatinib can effectively inhibit ALK-G1202R with an
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IC50 of approximately 100nM. However, the G1202R mutation was also observed in samples
from 3 of 7 patients who had undergone treatment with brigatinib; these results implied that
brigatinibmay have onlymarginal activity against cells harboring the ALKG1202Rmutation.
Several ALK mutations were reported in cells of patients who relapsed while on brigatinib
treatment, including the single mutations D1203N and G1202R and compound mutations in-
cluding E1210K+S1206C and E1210K+D1203N [18].
Lorlatinib is a third generation ALK-TKI with high potency and high selectivity for both
ALK and the related receptor tyrosine kinase, ROS1, in studies carried out in vitro. Lorlatinib
was shown to be effective in overcoming the impact of all single point mutations detected in
cells from crizotinib, alectinib and ceritinib-refractory patients [23]. Although the IC50 for
lorlatinib-mediated inhibition of for ALK-G1202R was much higher than that reported for
wild-type ALK, it was measured at 50–100nM. Experiments performed in vivo also clearly
showed that treatment with lorlatinib of 7.5mg/kg or higher resulted in tumor shrinkage; the
lorlatinib concentration that resulted in complete inhibition of ALK-G1202R was lower than
that detected in free plasma [23]. Lorlatinib also showed activity against NSCLC cells
expressing EML4-ALK-G1202R in vivo, and patients with tumors that harbored the
G1202R mutation responded to lorlatinib therapy in clinical trials [24,25]. Taken together,
these results suggest that lorlatinib is active against all the single ALK-TKI resistant muta-
tions. However, relapse due to acquired resistance to lorlatinib was observed in tumor cells
with compound ALK mutations, including C1156Y+L1198F, L1196M+G1202R, I1171N+
L1198F, I1171N+1203N, G1202R+G1269A, I1171S+G1269A, L1196M+D1203N, F1174L+
G1202R, and C1156Y+G1269A [26–28]. Mutagenesis screening resulted in the identification
of a number of lorlatinib-resistant compoundmutations; many of these were also identified in
specimens from lorlatinib-resistant patients. Interestingly, ALKwith the compound I1171N+
L1256F mutation was extremely resistant to lorlatinib but remained sensitive to alectinib [29]
(Fig. 3). ALK with a single L1256F mutation was also found to be tremendously resistant
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to lorlatinib, but remained quite sensitive to alectinib. Furthermore, the EML4-ALK-L1256F
single mutation was associated with reduced oncogenic activity, although ALK with an
I1171N+L1256F compound mutation maintained tyrosine kinase activity [29]. Interestingly,
Yoda et al. identified triple compound mutations (G1202R+L1204V+G1269A or E1210K+
D1203N+G1269A) in cells from lorlatinib-resistant patients [27]. Taken together, these
results suggest that while lorlatinib is active against single point mutations that confer resis-
tance to other ALK-TKIs, this drug will no longer be effective once two or more ALK muta-
tions develop simultaneously; this has been found to be the case even when the compound
mutations include single mutations that would otherwise be susceptible to lorlatinib
treatment.
Shaw et al. reported a case of a patient diagnosedwithNSCLCwith anALK rearrangement
that hadundergone sequential treatmentwith crizotinib, alectinib, ceritinib, and lorlatinib.Af-
ter completing lorlatinib treatment, the tumor eventually relapsed with an ALK C1156Y+
L1198F compound mutation. Of interest, only the C1156Y mutation had been identified after
the first roundof treatment; additionof theL1198Fmutation resulted in re-sensitizationofALK
to crizotinib [26]. Given this observation, the patient underwent a second round of treatment
with crizotinib after developing lorlatinib resistance; tumor shrinkage was confirmed for a
period of approximately half a year. Structural analysis provided an explanation for the
ALK L1198F mutation and its role in promoting resistance to lorlatinib with re-sensitization
to crizotinib. Lorlatinib has a macrocyclic structure similar to that of crizotinib and includes
a specific side chain modification. This side chain derivative was optimized to increase selec-
tivity for and inhibition of ALK, and to reduce activity against neurotrophic tropomyosin-
related kinase (NTRK) proteins. In the sequences of NTRKs, the amino acid corresponding
to L1198 residue in ALK is an F residue. To increase the selectivity of lorlatinib for ALK
alone, a nitrile group was added in a portion near the site of interaction with L1198. As such,
the ALK-L1198F mutation is resistant to lorlatinib due to a marked decrease in binding
affinity notably at or near F1198. However, the ALK L1198F mutation increased the binding
affinity of crizotinib as determined by analysis of its crystal structure [26]. Nonetheless, com-
poundALKmutations including L1196M+G1202R, F1174I+G1202R, I1171N+L1198Hare re-
sistant to all clinically-availableALK-TKIs.Okada and colleagues have shown that adaphostin
and its analogs have inhibitory activity against ALK L1196M+G1202R mutants at relatively
low concentrations [29]. Currently, sequential treatment with ALK inhibitors is a widely
accepted practice, as most of the single ALK mutations conferring resistance to TKIs can be
overcome with lorlatinib or brigatinib treatment; furthermore, as shown, earlier generation
ALK-TKIs might be able to overcome resistance to specific compound mutations. As such,
identification of resistancepatterns and their underlyingmechanisms could be very important
in order to decide optimal strategy with respect to treatment with ALK-TKIs.
Comparison of resistance-associated ALK mutations to those
of other tyrosine kinases
As noted in the previous section, many secondary mutations in ALK have been identified
that promote resistance to TKIs; the mutations in ALK that have been associated with drug
resistance are more complex and varied than those promoting TKI resistance in EGFR.
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For example, the ALK-L1196M gatekeeper mutation is in a position analogous to that of
EGFR-T790M, Abl-T315I, ROS1-L2026M, and RET-V804M. Likewise, the ALK-G1202R sol-
vent front mutation corresponds to NTRK1-G595R [30] and ROS1-G2032R [31], which is
themost common of the crizotinib-resistant mutations in cancerswith a ROS1 rearrangement.
Similarly, the ALK-G1269A mutation correspond to NTRK-G667C [30]; other parallels in-
clude ALK-L1256F to ROS1-L2086F [32], ALK-C1156Y to ROS1-L1986F, and F1174I/L/V to
ROS1-F2004V. As indicated here, most of these mutations are commonly observed among
the characterized oncogenic tyrosine kinases.
Computational simulation to predict the resistance and effective drugs
There are a number of reports that focus on in silico computational molecular dynamic
simulations of drug binding and affinity estimation.We previously performed computational
simulations focused on ALK and using MP-CAFEE and successfully quantified the binding
affinity of the ALK-TKI alectinib to several ALK-TKI resistant mutants [17,29,33]. In order to
provide a strict assessment of the prediction accuracy, we applied computational thermody-
namic simulation with MP-CAFEE to the interactions of multiple ALK-TKIs (crizotinib,
alectinib or ceritinib) and specific resistant mutants and compared the calculated binding free
energies (ΔG) with the experimental IC50 values measured in in vitro cell viability assays
targeting Ba/F3 cells expressing the EML4-ALK mutants. A clear, linear correlation was
identified when comparing the experimental IC50 values and the calculated ΔGs for all three
TKIs [29]. This result suggests that the free energy estimation using MP-CAFEE can correctly
predict the impact of each ALK-TKI resistant mutation on drug binding. Similar results were
obtained for calculated ΔGs predicted for several of the lorlatinib-resistant ALK double mu-
tations and their experimental IC50 values; however, the prediction failed for several
lorlatinib-resistant ALK compound mutations including I1171N+L1256F. This may relate
to the fact that the L1256F mutation added a phenyl ring with the potential to contribute
to an increase in π-π electric interactions; these interactions cannot be formally evaluated
by molecular dynamic simulations such as MP-CAFEE, but might be amenable to evaluation
by quantum chemistry [29]. Multiple strategies will be needed to improve current in silico
simulations so that they might be capable of providing accurate estimations of drug binding
affinities [34].
ALK-TKI resistance mechanisms other than secondary mutations
In addition to the secondarymutations within the ALK kinase domain, amplification of the
ALK fusion gene has been identified as another significant mechanism underlying crizotinib
resistance [21]. However, it is not clear that ALK gene amplification is involved in the resis-
tance observed after treatment with second or third generation ALK-TKIs. Likewise, other
mechanisms that promote growth activation, including those involving EGFR, may induce
the resistance to ALK-TKIs. This form of resistance occurs via what is known as “bypass path-
way” activation (Fig. 4). For example, specimens from patients that have developed crizotinib
resistance have included amplification of the cKIT gene and elevated stromal levels of expres-
sion of its ligand, stem cell factor [13] (Fig. 5). Likewise, EGFR and insulin-like growth factor
94 5. Resistance to ALK TKIs in patients with lung cancer
PI3KERK
(a) Gene Alteration in ALK
STAT
TKI
Crizotinib 
resistance  
L1196M, G1269A, C1156Y, 
G1202R,  I1151T ins, etc…
EGFR or IGF1R activation, 
cKIT amplification with SCF, 
Src family activation, etc…
- P-glycoprotein 
upregulation
- Microenvironment (?)
- Transformation to 
Squamous or SCLC
- Leptomeningeal 
metastasis
Alectinib 
Resistance
I1171T/N/S, G1202R, 
V1180L
cMET amplification, 
Ligand mediated activation 
(EGFR, cMET, etc…)
Ceritinib
Resistance
F1174C/V, G1202R, MEK active mutation
Resistance mechanisms in ALK rearranged cancer
Kinase
Kinase
P
(b) Bypass Pathways
PI3KERKSTAT
TKI
(c) Others
P-glycoprotein
TKI
EML4-
ALK
(WT)
EML4-
ALK
(mutant) EML4-ALK
(WT)
PP
PP
FIG. 4 ALK-TKIs (crizotinib, alectinib and ceritinib) resistance mechanisms. (A) Mutations in ALK is observed in
approximately half of the resistant patients. In other cases, (B) Bypass pathway activation, such as other receptor ty-
rosine kinase activation or growth signaling pathway activation, inducedALK-TKI resistances are observed. As other
mechanisms, (C) P-glycoprotein upregulation (to crizotinib and ceritinib), or small cell lung cancer transformation
were observed. Multiple mechanism can be found even in one patient.
ALK-TKI
ALK
EML4
cell proliferation, 
anti-apoptosis
cMET
SCF - cKIT
mediated bypass activation
HFG - cMET or cMET
amplification mediated 
bypass activation
EGFR activation mediated 
bypass activation
ALK-TKI + Imatinib
Crizotinib, or 
ALK-TKI + cMET-inhibitor
ALK-TKI + EGFR-inhibitor
HGF
Stromal cells (?)
EGFR
(ERBB3)
SCF
ALK-TKI
ALK
EML4
cell proliferation, 
anti-apoptosis
cKIT
ALK-TKI
ALK
EML4
cell proliferation, 
anti-apoptosis
Resistance
mechanisms
Potential
therapy
Bypass Pathway mediated resistance mechanisms
Stromal cells (?)
TGF-a (?)
amphiregulin
FIG. 5 Typical example of the bypass pathway-mediated resistance mechanisms and the potential combination
therapies to overcome these resistances are shown.
(IGF)1R activation, upregulation of ligands of ERBB receptor family, and KRAS- activating
mutations were all identified as mechanisms underlying acquisition of crizotinib resistance
[35–38]. Furthermore, amplification of cMET and/or upregulation its ligand, HGF, MEK ac-
tivating mutations, and activating mutations of the RAS/Src signaling pathways have been
associated with resistance to alectinib and ceritinib [36,38–40]. Of note, since crizotinib has a
potent cMET inhibiting activity (as crizotinib was originally developed and clinically evalu-
ated as a cMET inhibitor), no cases of cMET amplification have been reported in association
with resistance to crizotinib, although this aberration has been identified at significant fre-
quencies in association with resistance to alectinib or ceritinib. Experimental studies have
revealed that bypass pathway mediated resistance can be overcome by combining an inhib-
itor that suppresses the activated bypass pathway with an ALK inhibitor, such as alectinib.
However, combination therapy has not yet been established; at this time, there are no
combination therapies proven to be safe and effective in a clinical setting.
Among other resistance mechanisms, overexpression of P-glycoprotein/ ABCB1, a drug
efflux membrane transporter, was observed in association with ceritinib resistance [41]. In
this report, crizotinib and ceritinib, but not alectinib or lorlatinib, were effectively exported
by P-glycoprotein. To overcome resistance secondary to P-glycoprotein overexpression,
monotherapy with either alectinib or lorlatinib or the combination therapy with ceritinib
and a P-glycoprotein inhibitor such as MS209 has been shown to be effective. Of note, the
blood brain barrier expresses high levels of P-glycoprotein, which contributes to drug export
from cerebrospinal fluid. Lorlatinib, but not crizotinib, reached high concentration in the
CNS; as such, lorlatinib was shown to be effective for treating brain and/or leptomeningeal
metastasis in patients with lung cancer with ALK rearrangements. Recently, Arai et al.
reported that cells from metastatic leptomeningeal cancer with an ALK rearrangement se-
creted amphiregulin and activated the EGFR/ERBB3 signaling pathway [42]. Experimental
studies revealed that the combination of osimertinib (an inhibitor of amphiregulin-mediated
EGFR/ERBB3 activation) with any of the ALK inhibitors served to control leptomeningeal
metastases. Higher levels of amphiregulin were detected in the medullary cavity of patients
with ALK-TKI resistant tumors.
Results from recent studies have suggested that the ALK fusion protein is stabilized by
heat shock protein (Hsp90); stability of the ALK fusion protein was reduced in response to
treatment with an Hsp90 inhibitor, resulting in a dramatic reduction in the cellular levels
of the ALK fusion protein. Clinical trials featuring Hsp90 inhibitors for the treatment of can-
cers with ALK rearrangements revealed their significant clinical efficacy [43].
Other resistance mechanisms
In addition to the ALK-TKI resistance identified by analysis of clinical specimens, various
mechanisms underlying ALK-TKI resistance have been reported from experimental studies.
For example, the mediator complex subunit-12 (MED-12) was identified from an RNAi
screening study; knockdown ofMED-12 activated the transforming growth factor (TGF)-β re-
ceptor signaling and MEK/ERK signaling, resulting in resistance of ALK-TKIs [44]. In addi-
tion, resistance-associated with activation of yes-associated protein (YAP)1 has been
reported; treatment with an ALK-TKI together with an inhibitor of YAP1 may result in
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prolonged suppression of tumor re-growth and clinical relapse [45]. However, the detailed
molecular mechanisms underlying the crosstalk between ALK-mediated signaling and the
YAP1-associated Hippo pathway remain unclear. It has also been shown that activation of
the signaling via the Axl receptor may induce ALK-TKI resistance.
Conclusion
Summary, discoveries, and future challenges
ALK-TKIs have been under active development over the past 10years; five drugs are
currently available and several are undergoing testing in clinical trials. Various resistance
mechanisms have been identified through genetic analysis of clinical specimens from ALK-
TKI- resistant patients and via experiments carried out in cultured cell lines. Although resis-
tance due to primary ALK mutations frequently arises in response to treatment with first-line
ALK-TKIs, this can be overcome by at least one of the approved second-generation ALK-TKIs.
Further resistance emerges due to the acquisition of secondary compound mutations in ALK;
most of these are resistant to all the approved ALK-TKIs except for several compound muta-
tions, such as C1156Y+L1198F, I1171N+L1256F, and I1171N+G1269A. TKI resistance can also
emerge in response to bypass pathway activation. Experimental studies in animals have
revealed that combination therapy consisting of an inhibitor of the bypass pathway together
with an ALK-TKI typically overcomes this resistance; however, there is no clinical evidence
at this time that shows that combination therapy is safe and that it is effective at overcoming
bypass pathway-mediated resistance. In addition, there are alsomany cases inwhich themech-
anisms underlying drug resistance are unclear; elucidation of these unknown mechanisms re-
mains an important issue. Other issues include clarification of the mechanism by which the
ALK-G1202R promotes TKI resistance in EML4-ALK variant type 3 (a short variant in which
exon 6 of EML4 is fused to exon 20 of ALK) but not in EML4-ALK variant 1 (a longer variant in
which exon13 of EML4 is fused to exon20 of ALK). There is as yet no detailed whole structural
analysis that explains how the EML4-ALK fusion proteins are activated via the dimerization or
trimerization of the EML4 domains. There are several reports that suggest that next-generation
sequencing of cell-free (cf) DNA may be able to capture resistant mutations and resistance
mechanisms in advance, personalized treatment strategies might be developed to maximize
the clinical efficacy of ALK-TKIs. However, ongoing effort will be needed in order to uncover
critical problems and to improve our understanding of the inevitable emergence of resistance to
TKI therapeutics. Additional studies may provide insights into how the emergence of resis-
tance might be delayed or even counteracted as a means to improve the prognosis of NSCLC.
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Abstract
The Anaplastic Lymphoma Kinase (ALK) was identified in 1994 as the C-terminal fusion partner in the chi-
meric protein arising from the recurrent t(2;5) translocation found in the anaplastic large-cell lymphoma
(ALCL), a rare subgroup of T-cell malignancy. Since then, ALKhas been involved in several additional tumors,
both solid and hematological, through chromosomal rearrangements and activating point mutations. Follow-
ing a spectacular success of targeted therapy in another fusion gene-driven cancer (chronic myeloid leukemia)
a significant research effort has led to the development of several fairly selective ALK inhibitors. The use of
such drugs is still investigational/compassionate (i.e., off-label) in ALK-dependent tumors other than lung
cancer. Nevertheless, the activity of ALK inhibitors in ALK-positive ALCLs has been well documented,
displaying high rates of long-term disease control. Despite excellent clinical activity, however, a significant
fraction of patients still relapses after response, via both ALK-dependent (drug-resistant mutant clones)
and ALK-independent (activation of alternative pathways) mechanisms. Moreover, different ALK-positive
cancers show different responses to ALK inhibitors, likely reflecting different tumor biology, variable hetero-
geneity of the cancer cell population, aswell as different co-dependencies to additional survival pathways, that
will need to be targeted to achieve better therapeutic effects. Here, I reviewed the current literature on the in-
volvement of ALK, the clinical activity of ALK inhibitors and the mechanisms of resistance to ALK inhibition
in tumors other than non-small cell lung cancer.
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Introduction
Although ALK has attracted much attention and research effort mostly after its discovery
as a driver of lung cancer oncogenesis, the first ever description of ALK involvement in hu-
man cancer occurred in a rare T-cell lymphoma. This finding determined its official name,
that is, Anaplastic Lymphoma Kinase. Ever since, ALK has been implicated in a variety of
tumors, of different origins, all of which have in common the aberrant activation of this re-
ceptor tyrosine kinase. This chapter will describe the role of ALK alterations in cancers ex-
cluding lung carcinoma, their targeting and the associated mechanisms of drug resistance
in the context of these tumors.
Mechanisms of ALK-mediated transformation in tumors other than lung cancer
In 1994, Morris et al. identified a recurrent fusion of ALK to the nucleophosmin (NPM1)
gene in anaplastic large-cell lymphoma (ALCL) cases associated with t(2;5) chromosomal
rearrangement [1] and later described the full-length ALK as a neural receptor tyrosine kinase
[2]. Between 50% and 80% of ALCLs have been reported to carry ALK rearrangements and
this led to the definition of ALK-positive (ALK+) ALCL as a new disease entity within non-
Hodgkin’s lymphomas [3]. About 80% of ALK+ ALCLs harbor the t(2;5) rearrangement
encoding for the NPM-ALK fusion protein. Indeed, transgenic expression of NPM-ALK in
CD4+ T lymphocytes induces lymphomagenesis [4]. Subsequently, several groups indepen-
dently identified novel ALK fusions in a minority of ALCLs [5–12]. ALCL accounts for ap-
proximately 15% of pediatric non-Hodgkin lymphomas [13,14], while it is rarer in adults
(2–3% of all cases). Standard treatment is based on multidrug cytotoxic combinations such
as CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or similar, in adults
[15]; for children, the ALCL-99 protocol, which includes high-dose methotrexate, has been
shown to achieve better results [16,17]. Responses to chemotherapy are generally higher in
ALK+ compared to ALK- negative ALCL, resulting in significantly better prognosis [14].
ALK rearrangements were later identified in approximately 50% of patients affected by the
inflammatory myofibroblastic tumor (IMT), a rare soft tissue cancer [12,18–27], suggesting a
broader oncogenic role for the ALK kinase, not restricted to ALCL. As expected, the use of
next generation sequencing technologies led to the identification of ALK involvement in sev-
eral additional cancer types, both hematological and solid: besides non-small cell lung cancer
(see Chapter 2) ALK fusions were found to be oncogenic in rare cases of diffuse large B-cell
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lymphoma (DLBCL) [28–31], spitz tumors [32], anaplastic and medullary thyroid cancer
[33,34], leiomyosarcoma [35], mesothelioma [36], squamous cell carcinoma of the esophagus
[37], renal cancer [38–42], myeloid leukemia [43–45], glioma [46], melanoma [47], breast
carcinoma [48], ovarian cancer [49] and colorectal tumors [48,50–52] (Table 1).
Whatever the type of rearrangement, the common themes among all ALK fusions are: (i)
high aberrant expression driven by the partner gene promoter; (ii) an amino-terminal do-
main, derived from the fusion partner, which dictates subcellular localization and provides
an oligomerization interface that mimics physiological ligand-induced receptor dimerization;
and (iii) a carboxy-terminal tyrosine kinase region derived from the ALK gene, which is
constitutively active as a result of constitutive homotypic interaction.
Besides gene fusions, an alternative mechanism of ALK oncogenic activation in cancer is
represented by activating point mutations. The majority of familial neuroblastoma patients
and up to 10% of sporadic cases harbor mutations in the catalytic domain of the full-length
ALK that activate the receptor in a ligand- independentmanner [73–75]. In a subset of patients,
wild-type ALK is overexpressed, often as a result of gene amplification, again resulting in ex-
cessive kinase activity [76,77]. A third group of neuroblastoma patients expresses ligand-
dependent ALK mutants, whose role as drivers of oncogenesis is doubtful [78]. In general,
ALK point mutations have been validated as therapeutic targets in neural cancers. As ALK
is normally expressed (albeit at low levels) in neural tissue, these cells simply hijack an existing
signalingcircuitry togainaselectivegrowthadvantage.Pointmutationswerealso identified in
thyroid cancers [103] andmyeloidneoplasms [104], although their oncogenic role in thesecases
is not well established. Again, it was suggested that some of these mutants may be ligand-
dependent [105]. Furthermore, deletion mutants have also been reported to be oncogenic: ab-
errant activation of the ALK kinase is caused by genomic amplification of a truncated form of
the receptor in neuroblastoma cell lines and primary tumors [79,80]. Similarly, an in-frame de-
letion of exons 2–17 was identified in an ALCL patient [53]. In both cases, the extracellular do-
main was partially lost and the protein was predicted to retain the transmembrane region.
However, truncated ALK localized to the endoplasmic reticulum, in contrast to plasma
membrane-bound full-length receptor. How these deletion variants undergo constitutive ac-
tivation is unclear, possibly the extracellular portion carries some auto- inhibitory properties.
In a significant fraction of melanoma patients, an aberrant ALK transcript variant was identi-
fied, due to an alternative transcription start site that excludes the whole extracellular domain
sequence, leading to expression of an N-terminally truncated constitutively active form of the
kinase [100]. The transcribed region corresponds to the ALKportion that is retained in fusions
observed in other malignancies. Similarly, aΔ2-17 deletion variant was found in synovial sar-
coma cells, again losing the extracellular domain [101]. Various other exon deletions were
reported inEwing sarcoma,whose significance is unclear [102]. In several soft tissue sarcomas,
ALK is found overexpressed through gene copy number gain [101,102,106]. In alveolar rhab-
domyosarcoma,ALKgenecopygainwasdetected in88%of specimensby in situhybridization
and correlated with poor survival [107]. An alternative mechanism of ALK activation was
reported in glioblastoma multiforme, whereby the co-overexpression of pleiotrophin and
ALKled toan indirect ligand-dependenthyper-activationof thewild-typeALKreceptor,with-
out gene rearrangement or amplification [88–90].
Oncogenic ALK signaling has mostly been studied in ALCL models [108]. The most rele-
vant signals activated by the NPM-ALK fusion include the JAK/STAT, RAS/MAPK and
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TABLE 1 Summary of ALK+ diseases other than NSCLC.
Disease Aberrations Reference
Clinical results:
Drug – outcome (patients) Reference Acquired resistance Reference
ALCL Fusion;
Truncation
[1–12,53] Crizotinib – CR (2/2)
Crizotinib – CR (7/9); PR (1/9); SD (1/9)
Crizotinib – CR (21/26); PR (2/26); SD (3/26)
Crizotinib – CR (9/9)
Crizotinib – CR (8/16); PR (1/16); SD (3/16)
Ceritinib – CR (2/3); PR (1/3)
[54]
[55]
[56]
[57]
[58]
[59]
Crizotinib: L1196M, L1196Q,
I1171N/T/S, R1192P,
G1269A, overexpression,
bypass (IGF-1R)
ASP3026: G1128S, C1156F,
I1171N/T, F1174I, N1178H,
E1210K, C1156F+ D1203N
Brigatinib: F1174V+
L1198F, L1122V+
L1196M, L1122V+
L1196M+G1202R, S1206C,
gene amplification.
Ceritinib: overexpression,
F1174L, T1151M Alectinib:
F1174C
Lorlatinib: G1202R+
G1269A, C1156F+
L1198F, N1178H+
G1269A, I1171T+
E1210K, L1196M, N1178H,
G1202R, G1269A, I1171T,
bypass (PI3K, RAS/MAPK)
[57,60–64]
[65]
[66]
[63,67,68]
[62]
[69]
DLBCL Fusion [28–31] Crizotinib – PR (1/2); SD (1/2)
Crizotinib – SD (1/1)
Crizotinib – PR (3 cases)
[57]
[58]
[70–72]
– –
Neuroblastoma Mutation;
Amplification;
Truncation
[73–80] Crizotinib – CR (1/11); SD (2/11)
Crizotinib – SD (1/2)
Ceritinib – PR (1/1)
ASP3026 – SD (1/1)
Alectinib – CR (1/1)
Alectinib – PR (1/1)
Lorlatinib – CR (1/1)
[55]
[58]
[81]
[82]
[83]
[84]
[85]
Ceritinib: bypass (AXL,
MYCN)
Lorlatinib: bypass (EGFR,
HER4, RAS/MAPK)
[86,87]
[69]
Glioma/
Glioblastoma
Fusion;
Amplification;
Activation
[46,88–90] – – Alectinib: bypass (c-Myc,
RAS/MAPK)
[91]
IMT Fusion [12,18–27] Crizotinib – PR (1/2)
Crizotinib – PR (3/7); SD (4/7)
Crizotinib – CR (5/14); PR (7/14)
Crizotinib – CR (1/9); PR (5/9); SD (3/9)
Ceritinib – PR (1/1)
Brigatinib – PR (1/2); SD (1/2)
Entrectinib – CR (1/1)
[92]
[55]
[56]
[58]
[93]
[94]
[95]
Crizotinib: F1174L, G1128A [96,97]
Colorectal
Cancer
Fusion [48,50–52] Crizotinib – PR (1/1)
Brigatinib – SD (1/1)
Entrectinib – PR (1/1)
[58]
[94]
[95]
– –
Esophageal
Cancer
Fusion [37] – – – –
Thyroid
Cancer
Fusion; Mutation [33,34] Crizotinib – PR (1/1)
Crizotinib – PR (1/1)
Ceritinib/brigatinib – PR (1/1)
[58]
[98]
[99]
– –
Renal Cancer Fusion; Mutation [38–42] Entrectinib – PR (1/1) [95] – –
Breast Cancer Fusion [48] Crizotinib – No response (1/1) [58] – –
Ovarian
Cancer
Fusion;
Amplification
[49] – – – –
Melanoma Fusion;
Truncation
[47,100] Entrectinib – No response [47] – –
Spitz Tumors Fusion [32] – – – –
Myeloid
Leukemia
Fusion; Mutation [43–45] – – – –
Mesothelioma Fusion [36] – – – –
Sarcoma Fusion;
Amplification;
Truncation
[35,101,102] Crizotinib – No response (1/1) [58] – –
Mechanisms of ALK activation, clinical results andmechanisms of acquired resistance to ALK inhibitors are indicated, alongwith references to relevant papers cited in the text.
PI3K/AKT pathways [108–111]. In particular, STAT3 appears as a dominant mediator of cells
survival in ALCL, both ALK fusion-positive (through NPM-ALK [112]) and ALK-negative
(via JAK1 or STAT3 activating mutations [113]). Moreover, PLCγ has been shown to trans-
duce the oncogenic signaling through direct interactionwith NPM-ALK [114]. Also, β-catenin
was found to be constitutively activated in ALK+ ALCL; interestingly, STAT3 was among
its transcriptional targets in these cells [115]. In addition, cytoskeletal regulators such as
the Rho family GTPases Cdc42 and Rac1 [116–118] and the Wiskott-Aldrich syndrome pro-
tein (WASP [119,120]) have been involved in the intricate signaling network triggered by
ALK fusions in ALCL. Finally, tyrosine phosphatases have been involved in the regulation
of ALK- driven pathways [121,122]. Some of the identified downstream pathways are
likely to be cell type-specific. In particular, cytoskeletal proteins governing cell shape
are in line with the anaplastic nature of ALCL, but are not expected to have a significant
role in other ALK-dependent neoplasms. Similarly, the JAK/STAT signaling is typical of
lymphoid malignancies and ALK fusions simply take advantage of its role in T cell biol-
ogy. In contrast, the RAS/MAPK pathway seems to be physiologically activated by wild-
type ALK [123] and it is also a major effector of ALK oncogenes in NSCLC [124] and
neuroblastoma [78].
Tyrosine kinase inhibitors in ALK+ tumors other than lung cancer
First-in-class: Crizotinib
The identification of the NPM-ALK fusion protein in ALCL suggested that specific inhi-
bition of its kinase activitymay be a viable therapeutic option, similar to BCR-ABL1 inhibitors
in chronic myeloid leukemia. Biological validation of NPM-ALK as a therapeutic target was
obtained by siRNA-mediated silencing. NPM- ALK knock-down in ALCL cells led to inhibi-
tion of downstream signaling, cell growth in vitro, and tumor growth in vivo, and synergized
with chemotherapeutic agents [125,126]. The first description of an ALK small molecule in-
hibitor was reported in 2007 by Galkin et al. [127]. The compound was identified through a
cell screening, where NPM-ALK transformed Ba/F3 cells where used as a target and parental
IL3-dependent Ba/F3 cells as a non-target reference. This led to the discovery of a
phenylamino-pyrimidine compound named NVP-TAE684, which showed fairly specific in-
hibition of ALK kinase, in vitro growth inhibition and in vivo regression of ALK+ ALCL and
DLBCL xenografts [127,128]. Unfortunately, TAE684 was not further developed into clinical
use due to unexpected toxicity issues. Soon after, serendipitous discovery of potent anti-ALK
activity by a MET inhibitor opened the era of clinical use of ALK inhibitors: crizotinib (ini-
tially known as PF-2341066, as an anti-angiogenic drug [129]) showed nanomolar inhibition of
NPM/ALK-dependent signaling and cell growth, and exhibited strong anti-tumor efficacy in
ALCL xenografts [130]. Preclinical evaluation of crizotinib in ALK-mutated neuroblastoma
showed that different mutants have differential sensitivity to treatment, introducing the issue
of drug resistance: crizotinib inhibited the growth of cells carrying an R1275QALKmutation,
or an amplified wild-type ALK, while cells with the F1174L mutation were more resistant
[131]. On the basis of excellent preclinical results, crizotinib entered clinical investigation
in NSCLC (see Chapter 2). Within the same initial trial, crizotinib was tested in two IMT
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patients, one of whom was RANBP2/ALK+ [92]. Remarkably, only the ALK+ patient
showed a response to the drug. At about the same time, crizotinib was used off-label in
two ALK+ ALCL patients with excellent outcomes [54]. Interestingly, the value of targeted
ALK inhibition in ALCL was also shown by rapid relapses upon crizotinib discontinuation,
which could be successfully brought to a new remission when treatment was resumed [132].
These case reports indicated that ALK+ tumors (other than NSCLC) are sensitive to ALK in-
hibition and paved the way for larger investigations. A dose finding phase I trial evaluated
pediatric patients with documented genetic alterations in ALK, including 9 ALCL, 11 neuro-
blastoma and 7 IMT cases, recurrent or refractory to chemotherapy [55]. Seven out of nine
ALCLs had a complete response (CR), one achieved a partial response (PR) and one showed
stable disease (SD), achieving 100% disease control (Table 1). In 7 IMT patients, 3 PRs were
observedwhile 4 patients had SD. These data confirmed clinical activity of crizotinib in ALK+
tumors. However, in 11 ALK-mutated neuroblastoma patients, only one CR and two SDwere
observed, in line with poor activity on mutated ALK. A more recent update of this study
reported 88% and 86% overall response rate (ORR) in 26 ALCL and 14 IMT patients, respec-
tively [56]. Further investigation of crizotinib activity in lymphoma patients demonstrated
impressive response rates, with 9/9 ALCL cases obtaining a CR [57]. The cohort included
2 DLBCL patients, with limited clinical benefit (1 PR and 1 SD). Overall survival (OS) at
2years was 73%. A larger phase Ib study evaluating long-term effects of crizotinib in ALK
+ tumors, excluding NSCLC (PROFILE 1013; ClinicalTrials.gov Identifier: NCT01121588),
reported the results in ALK+ lymphoma, IMT and other tumors, with a median follow-up
of 3years [58]. ORR was 56% in ALCL patients (3-year OS, 72%), 67% in the IMT group (3-
year OS, 67%) and only 12% (median OS, 8.3months) in other ALK+ tumors, which included
4 nasopharyngeal cancers, 2 neuroblastomas and single cases of colon, thyroid, pancreatic,
and other cancers. Poor responses in this group may be related to several factors, such as tu-
mor type, genetics, concurrent mutations in other oncogenes, drug-resistant ALK mutants,
which were not evaluated. This study confirmed marked antitumor activity of crizotinib in
ALCL and IMT. Interestingly, in ALCL patients, the progression free survival (PFS) curve sta-
bilized after early relapses, i.e., all relapsing patients progressed within 3months. After that,
no relapses were observed. These data strongly suggest that ALK inhibition induces durable
responses and should be considered as first-line treatment indication in ALCL and IMT
tumors.
Several trials have recently started to fulfill this above need. A phase II trial in patients with
ALK+ ALCL resistant or refractory to standard cytotoxic treatment is reported (NCT02419287)
[133]. Another phase I/II study of crizotinib in relapsed ALK+ ALCL and neuroblastoma is
currently recruiting patients in Japan (UMIN000028075). A larger cross-tumoral phase II
study is enrolling any ALK+ patient, including renal, sarcoma, IMT and ALCL cases
(NCT01524926). By contrast, DLBCL patients seem to respond poorly compared to ALCL,
although there is scarce literature concerning the use of crizotinib in this rare subtype of lym-
phoma: in the PROFILE 1013 study, one ALK+ DLBCL patient only achieved a SD [58]; few
other reports described cases of very short-lived symptoms alleviation [70–72]. Further stud-
ies are needed to determine the clinical activity of ALK inhibitors in other tumors. A patient
with anaplastic thyroid carcinoma harboring an ALK rearrangement showed a remarkable
and durable response to crizotinib [98]. A new trial will evaluate any ALK inhibitor in colo-
rectal cancer patients with ALK mutation (NCT03792568).
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Resistance to crizotinib
As tumors are characterized by high genetic heterogeneity and instability, they adapt to
environmental changes and evolve under selective pressure. Therefore, despite excellent re-
sults, the selection of TKI- resistant disease can be observed in several cases. An in vitro study
analyzed the effects of introducing mutations in key residues, based on homology with other
tyrosine kinases. The authors found that substitution of the gatekeeper leucine to a bulkier
methionine (L1196M) caused marked resistance against two unrelated compounds [60]. In-
deed, the gatekeeper was one of the first described crizotinib-resistant mutants in NSCLC pa-
tients [134]. Analysis of drug-resistant ALCL clones selected in vitro revealed a different
gatekeeper substitution (L1196Q) and a novel I1171N mutation [61]. The I1171N mutant
was later observed also in an ALCL patient relapsing on crizotinib [57]. The structural effect
of a larger gatekeeper amino acid on drug binding is well known from previous experience
with other TKIs: a bulkier side chain reduces the space that would be occupied by the drug,
thus creating steric hindrance to inhibitor binding [135]. The reason for resistance mediated
by I1171N is less obvious. This residue belongs to the αC helix and is part of the R-spine, two
key structural elements of tyrosine kinases, governing enzyme activation [136]. Molecular
modeling studies suggested that mutations at I1171 alter enzyme kinetics, destabilizing drug
binding. The I1171Nmutation was also insensitive to compound TAE684. Additional in vitro
analyses of ALCL cell lines selected by crizotinib identified the emergence of I1171T and
I1171S substitutions [62,63]. These mutants showed moderate resistance to crizotinib and
cross-resistance to other inhibitors. A close amino acid, F1174, situated at the end of the
αC helix, was found mutated in an IMT patient who developed resistance to crizotinib
[96]. The authors showed that a F1174L mutant has higher kinase activity compared with
wild- type ALK and accelerates the growth of RANBP2-ALK transformed cells. Interestingly,
this mutation is also found in neuroblastoma patients at onset, conferring primary resistance
to crizotinib [131]. In some cases, mutations at F1174 appear in neuroblastoma patients after
relapse from chemotherapy, leading to amore aggressive disease [137]. This residue is located
at the center of a hydrophobic cluster of phenylalanine residues involved in DFG positioning
and kinase autoinhibition [138]. Computational analysis confirmed that the F1174L mutant
has higher flexibility within the hinge region and displays weaker crizotinib binding [139].
Moreover, ALK F1174L shows higher affinity for ATP, which contributes to its reduced sen-
sitivity to crizotinib [131]. Another case of IMT with acquired resistance to crizotinib was
found to carry a G1128A mutation [97]. Glycine 1128 is part of the glycine-rich nucleotide-
binding loop; mutations at this position likely alter ATP binding kinetics. The patient was
then shifted to ceritinib with success.
Besides ALK point mutations, the inadvertent activation of alternative survival pathways,
bypassingALK inhibition, can lead to drug resistance. A bypassmechanismwas identified by
Li et al. in crizotinib-resistant ALCL cells harboring a G1269Amutation [64]. Thus, these cells
developed a dual resistance, with both ALK-dependent and -independent coexisting
mechanisms. These data tell about the complexity of the drug resistance problem.
Second- and third-generation ALK inhibitors
The appearance of crizotinib-resistant disease in several settings fostered the search for al-
ternative drugs, collectively referred to as second-generation ALK inhibitors. These include
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alectinib, ceritinib, brigatinib and lorlatinib, that have all reached clinical use inALK+ tumors;
and other compounds such as ASP3026, giltertinib, ensartinib, entrectinib, repotrectinib, and
others, which are still investigational, or have been approved for different indications.
Ceritinib, brigatinib and ASP3026 all have a chemical structure that is very similar to NVP-
TAE684, with little modifications to improve their toxicity profiles. Ceritinib inhibits several
crizotinib-resistant mutants, including I1171T, L1196M and G1269A, and was shown to sup-
press Karpas299 xenograft growth in rats [140,141]. Among over 300 patients treated with
ceritinib in the ASCEND-1 trial, 3 chemoresistant ALK+ ALCL patients were evaluated:
two had a CR and one achieved a PR (95% reduction). These responses were still ongoing
at the time of reporting, with durations >20months [59]. These results confirm excellent
long-term responses in ALCL by ALK inhibition, as described with crizotinib. Efficacy in
other ALK+ tumors remains anecdotal: in a Japanese study, one ALK+ IMT patient, previ-
ously treated with ASP3026, achieved a PR with ceritinib [93]. One case of ALK I1171T neu-
roblastoma achieved a complete response [81]. Recently, an ALK fusion positive thyroid
cancer patient resistant to crizotinib was reported to respond to ceritinib and brigatinib [99].
Brigatinib has been shown to blockmost drug-resistant ALKmutants at clinically relevant
concentrations (i.e., below mean plasma levels) [142] and showed superior in vivo efficacy in
ALK-mutated neuroblastoma compared with crizotinib [143]. In a large phase I-II trial of
brigatinib, 8 patients with malignancies other than NSCLCwere evaluated [94]: four of them,
with confirmed rearranged ALK, achieved a PR and two had SD (one ALK+ IMT and one
colon cancer).
ASP3026 eradicated NPM/ALK+ ALCL xenografts and showed activity against the
L1196M mutant [144,145]. A phase Ib study enrolled one neuroblastoma patient, carrying
an ALK F1174L mutation, who achieved stable disease as best response [82]. Clinical devel-
opment of the drug was subsequently discontinued by Astellas Pharma, for commercial
reasons.
Alectinib, designed by Chugai Pharmaceutical with a completely novel structure, showed
potent antitumor activity against several crizotinib-resistant mutants, including the F1174L
and R1275Q neuroblastoma hotspots, and induced full regression of ALCL and neuroblas-
toma tumors in vivo [146–148]. Trials were only run with NSCLC patients, so reports of clin-
ical activity in other cancers are sporadic; in one case of chemotherapy resistant ALCL,
alectinib was successfully given as a bridge to bone marrow transplantation, leading to a du-
rable complete remission of the disease [83]. Another group reported a case of refractory ALK
F1245C neuroblastoma showing good response to alectinib [84]. In Japan, a non-randomized
non- controlled phase II trial of alectinib is actively recruiting ALCL patients [149].
Lorlatinibwas the last ALK inhibitor to be registered for clinical use in ALK+ NSCLC. It is
usually referred to as third-generation compound. Preclinical evaluation of lorlatinib indicated
sub-nanomolar inhibition and in vivo antitumor activity against most drug-resistant ALKmu-
tants, including the solvent front refractory G1202R variant [150]. In non-NSCLC setting,
lorlatinib showed superior in vitro and in vivo inhibitory activity against neuroblastoma-
associated ALK variants, compared with crizotinib [151,152]. In TKI-resistant ALCL cells
harboring various mutant subclones, lorlatinib suppressed all clones at nontoxic doses [65].
A monocentric phase II clinical trial in ALCL patients is ongoing (NCT03505554) and results
are estimated to be ready by the end of 2020. In a patient with metastatic neuroblastoma car-
rying an unusual Y1278SALKmutation, who progressed on crizotinib, lorlatinib induced com-
plete resolution of symptoms and a confirmed PR [85].
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Entrectinib is a multitarget pan-TRK, ROS1 and ALK inhibitor endowed with potent
antitumor activity in ALK+ ALCL and neuroblastoma models [153,154]. Clinical efficacy
was evaluated in few non-NSCLC patients enrolled in two phase I trials. Three patients with
diverse ALK fusion positive tumors (one renal, one colorectal, one of unknown origin) were
eligible for phase II evaluation: two PR and one SD were observed. In addition, one neuro-
blastoma patient (ALK F1245V) achieved a PR [95]. However, only TKI-naı̈ve patients
showed responses. Clinical benefit was then observed in a DCTN1/ALK+ IMT patient
achieving a durable CR [155].
Ensartinib is a close analogue of crizotinib with 10-fold increased potency against ALK
[156]. It was significantly more effective than crizotinib in subcutaneous neuroblastoma
models [157]. First-in-human results were recently disclosed in a NSCLC cohort, but no data
are available in other ALK+ tumors, yet. An ongoing trial (NCT03213652) will evaluate ac-
tivity in pediatric ALK+ patients after molecular analysis, within the larger NCI-MATCH
study [158].
TSR-011 is a highly selective benzimidazole ALK inhibitor, which induced complete re-
gression of Karpas-299 xenografts inmice and retained activity against the gatekeepermutant
[159]. However, due to initial clinical results that showed lower response rates compared to
approved inhibitors, TSR-011 development has been discontinued.
Repotrectinib is a macrocyclic compound with some structural analogies to lorlatinib,
endowed with activity against the ALK G1202R solvent front mutant [160]. This drug was
shown to inhibit a range of ALK variants found in neuroblastoma and exhibited strong
antitumor activity in neuroblastoma murine models [161].
Resistance to second- and third-generation drugs
Although ALK inhibitors have not reached formal approval by drug agencies for non-
NSCLC tumors, it is clear from the available data that they will eventually have a role in
front-line treatment in these cancers. Nevertheless, drug resistance will inevitably limit their
efficacy, similarly to crizotinib. The impact of this phenomenon will depend on tumor type,
heterogeneity, and stage. Preclinical studies have already identified a number of newmutants
that confer resistance to second-generation inhibitors. ALCL cells selected under pressure by
ASP3026 developed new variants in the P-loop, αC helix and ATP pocket, including a com-
pound C1156F/D1203N mutation that was refractory to all ALK inhibitors [65]. Cross-
resistance analysis of the selected mutants suggested that I1171N/T and E1210K mutants
would also be resistant to alectinib. Several of these variants were later found in NSCLC
patients, indicating that in vitro studies can predict clinical occurrences, and that resistance
profiles of different ALK fusions are similar, as demonstrated by Fontana et al. [162]. Inter-
estingly, in a heterogeneous ASP3026-resistant population in which several mutant clones
co-existed, further treatmentwith second-generation drugs, brigatinib, alectinib and ceritinib,
led to differential clonal selection according to the relative drug sensitivity of the various
mutations, strongly indicating that the precise knowledge of drug-mutation interactions
can allow better treatment choices [65]. Selection in vitro by brigatinib led to the emergence
of two different mechanisms of resistance in ALCL cell lines: SUPM2 cells acquired various
double mutants (Table 1) and even a low frequency triple mutation (L1122V/L1196M/
G1202R), reflecting high potency of this compound that is active against most crizotinib-
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resistant single mutants; in contrast, Karpas-299 cells evolved a very high expression of the
NPM/ALK fusion oncogene, that provided full cross resistance to all tested inhibitors [66].
Intriguingly, ALK kinase overexpression led to a paradoxical phenomenon: cells appeared
to be not only resistant, but even addicted to the presence of the inhibitor, andmassively died
upon drug removal [163]. This was explained by toxicity induced by an excess of signaling,
unleashed by drugwithdrawal. Indeed, cells re-selected in the absence of inhibitor lost NPM/
ALK gene amplification and re-gained sensitivity to the drug. The same effects were also de-
scribed in crizotinib- and ceritinib-resistant ALCL cells by Amin and colleagues, who then
exploited this feature in vivo, by applying a drug holiday schedule leading to long-term con-
trol of tumor growth [67]. Further analysis of drug addiction in lorlatinib-resistant ALCL cells
revealed a mitochondrial stress response triggered by fusion kinase signaling overflow [164].
More recently, a phosphoproteomic analysis suggested the involvement of STAT1 hyper-
activation in toxicity induced by drug withdrawal in ceritinib-addicted ALCL cells and con-
firmed that intermittent dosing can significantly delay tumor relapse [68]. These studies may
lead to a new approach in selected patients who develop ALK gene amplification. However,
caution should be taken before translating these results in human subjects. It is interesting to
note that such mechanism is not restricted to ALK+ cancer [164–166]. Encouragingly, anec-
dotal clinical remissions upon drug discontinuation have been documented in melanoma
patients [167].
Alectinib-resistant ALCL cells developed an F1174C mutation [62], while F1174L and
T1151M mutants were selected by exposure to ceritinib in vitro [63]. Similarly, SH-SY5Y
neuroblastoma cells carrying the F1174L variant showed modest sensitivity to ceritinib
(IC50, 150–180nM) if compared to cells with wild-type ALK. Nonetheless, further resis-
tance to ceritinib occurred in these cells through overexpression of AXL kinase, which
led to ALK-independence and full insensitivity to ceritinib (IC50>1μM) [86]. AXL silenc-
ing by siRNA or inhibition by small molecules resensitized these cells to ALK inhibition.
Mechanisms of target-independent resistance are well documented in targeted therapies,
including ALK-driven NSCLC. Therefore, it is not surprising that it also occurs in other
ALK+ tumors. In another example, neuroblastoma xenografts resistant to ceritinib were
found to upregulate MYCN [87]. To add further complexity, an in vivo study of resistance
to lorlatinib in ALCL xenografts revealed composite mechanisms arising with concomitant
ALK mutations and by-pass pathway activation [69]. The latter included PI3K/AKT and
RAS/MAPK signaling. In the same paper, lorlatinib-resistant neuroblastoma cells (ALK
R1275Q) were found to hyper-activate EGFR and HER4 receptors; in addition, they ac-
quired a nonsense mutation in NF1 gene, leading to constitutive MAPK signal activation.
The RAS/MEK/ERK pathway was also identified as a bypass mechanism in NSCLC cells
[124,168], appearing as a common rescue pathway in ALK+ cancers treated with ALK in-
hibitors. Therefore, drug combination strategies may be devised to block simultaneously
ALK and MAPK signaling in these tumors (see below). In vitro, lorlatinib-resistant ALCL
cells acquired highly overexpressed compound mutants (G1202R/G1269A and C1156F/
L1198F) which rendered them able to survive at high drug concentrations, but made them
again drug-dependent [69].
In ALK+ glioblastoma cells, overexpression of c-Myc and activation of theMAPKpathway
conferred resistance to alectinib. Hence, inhibition of these pathways by a Myc inhibitor or
trametinib overcame resistance and resensitized resistant cells to alectinib [91].
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Finally, a recent intriguing finding by Janostiak et al. shows how kinase signaling can be
interchangeable in tumors, and that we can expect ‘creative’ solutions exploited by cancer
cells to evolve drug resistance: while ALK is in general a therapy target, in this work the au-
thors identified ALK as a by-pass kinase in melanoma cells treated with BRAF inhibitors
[169]. On the other hand, a similar dual role (target/bypass) has been also described for EGFR
in NSCLC [170].
Drug combinations in ALK+ tumors other than lung cancer
The data discussed above, altogether, show that ALK-driven tumors can rely on different
mechanisms to survive ALK-targeted therapy. These include ALK point mutations, ALK
overexpression and several by-pass salvage pathways. While ALK-dependent resistance
can be tackled by drug switch or increase, ALK- independent mechanisms call for alternative
treatments to be combined with ALK inhibition. Therefore, various studies have addressed
the possibility to combine ALK inhibitors and other drugs to achieve superior efficacy. Co-
targeting of ALK and mTOR showed enhanced antitumor activity in ALK-mutated/MYCN-
amplified neuroblastoma mouse models [171,172]. The molecular basis for this result resides
in the necessity to block two cooperating oncogenic signals (ALK and MYCN) in these cells.
Along the same lines, a combination of temsirolimus with ALK inhibitors showed synergistic
effects in ALCL cells in vitro and in vivo, leading to complete regression of relapsed xeno-
grafts [69]. Similar results were observed with everolimus and crizotinib [173]. Since MYCN
is not involved in ALCL pathobiology, the synergy was ascribed in this case to a more pro-
found suppression of oncogenic signaling by the combined treatment, which restrained
resistance.
Mitou and colleagues found that crizotinib induces cytoprotective autophagy in ALK+
ALCL cells [174]. Therefore, targeting autophagy with chloroquine caused an autophagic
switch from cytoprotection to cytotoxicity. Moreover, BCL-2 is involved in the regulation
of this switch and can be targeted in combination with crizotinib to enhance cell killing [175].
Although we are in the era of personalized therapies, cytotoxic chemotherapy is still a
mainstay of cancer treatment. Thus, it could be useful to explore synergism of chemotherapy
with targeted drugs. Such strategy may show superior ability to prevent resistance, due to
unspecific suppression of mutant clones that resist targeted drugs. Indeed, crizotinib was
shown to synergize with chemotherapy in neuroblastoma mouse models, achieving long-
term complete tumor remission, whereas single treatments allowed relapse [176]. The com-
bination was also more effective in neuroblastoma xenografts carrying crizotinib-resistant
mutants (e.g., F1174L). Synergism was ascribed to a potentiated p53 activation. Similarly,
Wang et al. used MDM2 inhibitors in combination with ceritinib to activate p53 and im-
prove antitumor activity [87]. This combination also overcame resistance to single-agent
ceritinib.
In a drug combination screening, Wood et al. identified ribociclib, a dual CDK4/6 inhib-
itor, as a synergistic agent in combination with ceritinib in neuroblastoma cells. Combined
ALK/CDKs inhibition caused complete regressions in xenografts with ALK F1174L and
ALK F1245C mutations and prevented the emergence of resistance [177].
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Histone deacetylase (HDAC) inhibitors have been recognized as promising tools to restore
normal epigenetic regulation in cancer cells and sensitize them to anticancer therapy. The
combination of vorinostat and alectinib was investigated in neuroblastoma cells in vitro
and was shown to cause MYCN down-regulation and induce cell death. However, the com-
bination index was mostly additive, indicating poor pharmacological interaction [178]. Sim-
ilarly, in ALCL cells, we observed no synergism of ALK inhibitors with valproic acid
(unpublished results). Thus, ALK/HDAC dual inhibition needs further investigation before
it can be suggested in ALK+ tumors.
IGF-1Rwas found to interact and cooperate with NPM/ALK, thus enhancing STAT down-
stream signaling inALCL cells. From there, it was an easy step for the cells to switch to IGF-1R
when ALK was blocked by ASP3026. Therefore, dual blockade was needed to suppress
NPM/ALK+ tumor growth in vivo [179].
As noted above, the RAS/MAPK pathway has been often involved in drug resistance.
Thus, dual ALK/MEK inhibition could be a valuable strategy to prevent (or treat) resistant
disease. While several data are available in ALK+ NSCLC, only one study specifically
addressed this point in other ALK+ tumors: Ito et al. [180] combined shRNA-induced
ALK downregulation with UO126, a relatively specific inhibitor of MEK1/2 activation.
The authors found that concomitant ALK and MEK inhibition prevented tumor re-growth
after treatment discontinuation in vivo, suggesting a strong synergy of this combination to
abolish resistance. In lorlatinib-resistant tumors that showed evidence of MAPK activation,
trametinib partially restored sensitivity to lorlatinib [69]. However, as these cells exhibited
complex patterns of intracellular pathways mediating resistance, three-wise drug combina-
tions were necessary to achieve better effects: ALK/PI3K/MEK triple inhibition in ALCL and
ALK/pan-HER/MEK in neuroblastoma cells.
ALCL is characterized by high expression of the CD30 antigen, a TNFR-related transmem-
brane receptor. It has been identified as an attractive target for antibody-based therapy in
ALCL. Brentuximab vedotin is an antibody-drug conjugate which brings the cytotoxic drug
monomethyl auristatin E to CD30+ tumor cells [181]. It is approved for the treatment of re-
lapsed or refractory Hodgkin lymphoma and ALCL. Starting from the observation that re-
lapses occur both in brentuximab-treated and in crizotinib-treated patients, Wang et al.
asked whether combining the two therapies could be an option in ALCL, to improve the out-
come. They demonstrated thatmice treatedwith the combination regimen showed better con-
trol of xenografts growth [182]. Interestingly, the MAPK pathway was identified again as a
key player in this setting.
As a further confirmation of MAPK involvement in ALK+ tumor biology, downstream ef-
fector transcription factors JUN and JUNB (which are stimulated by ERK1/2 activity) have
been implicated in ALCL survival. Indeed, genetic deletion of both factors impaired
NPM/ALK-driven tumor growth in transgenic mice. In this setting, JUN and JUNB were
found to induce the expression of PDGFRB [183]. Interestingly, the combination of the
PDGFRB inhibitor imatinib with ALK inhibitors significantly reduced tumor mass and the
chance of relapses. PDGFRB activation was also observed in some ALCL patients and the au-
thors successfully treated one such PDGFRB+ patient with imatinib monotherapy. Once
again, this observation strengthens the idea that precise medicine requires precise character-
ization of each single tumor.
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Conclusion
Following the medical revolution brought by kinase inhibitors in chronic myeloid leuke-
mia, the discovery of ALK aberrant activation in cancer prompted research efforts to design
specific ALK inhibitors, which took relatively short time to be identified. Indeed, ALK inhib-
itors caused a paradigm change in clinical management of ALK+ patients. Unfortunately, for
obvious reasons, this is mostly true for NSCLC patients, while clinical development in other
ALK+ tumors, including the “original” ALK-dependent disease, is lagging behind. Hope-
fully, things will change soon and ALK targeted drugs will be approved within the next
few years at least for ALCL and IMT patients. However, despite great success of ALK inhib-
itors, tumors find their way to survive therapy, thanks to rapid clonal evolution. This is par-
ticularly true in advanced, heterogeneous disease, where several mutant subclones coexist, or
cells can easily turn on alternative signaling pathways and switch to ALK independence. In
this regard, it is interesting to note that ALK+ ALCL patients display pretty long responses if
they do not relapse in the initial threemonths, which happens in 30–40% of the cases. This is in
contrast to NSCLC patients, who develop resistance in virtually all cases, within approxi-
mately 1 year. Understanding the reasons of this different behavior, identifying the causes
of resistance, and finding clinical or genetic determinants of long-term responses will be
the focus of research in the coming years andwill lead to improved outcome for ALK+ cancer
patients.
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Abstract
ALK tyrosine kinase inhibitors are current standard treatments for patients with ALK-rearranged non-small
cell lung cancer. The development of crizotinib and a newer generation of ALK TKIs like ceritinib, alectinib,
brigatinib and lorlatinib have conveyed prolonged survival outcomes in patients with ALK-driven cancers.
Unfortunately, tumor cells invariably acquire resistance to these drugs through a diverse spectrum of biolog-
ical mechanisms. On- and off-target resistance mechanisms emerge during the evolution of the patients dis-
ease, including ALK kinase domain mutations or ALK amplification and by-pass track activation of oncogenic
signaling pathways. In this chapter, we will discuss the current preclinical and clinical evidences supporting
different treatment strategies aiming to prevent or overcome the biological processes that drive ALK TKI
resistance.
Abbreviations
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Introduction
The discovery of acquired ALK kinase domain mutations as a common mechanism of re-
sistance to the first generation ALK inhibitor crizotinib has fueled the development of a new
generation ALK tyrosine kinase inhibitors (TKIs) [1, 2]. As previously referred in this book,
second- and third-generation ALK TKIs, like ceritinib, alectinib, brigatinib and lorlatinib,
were designed to bind to the ALK kinase domain in the context of specific amino acidic
changes resulting from point mutations that halted crizotinib’s efficacy. These inhibitors,
however, have distinct ALK binding properties and, thus, the potency of these drugs to in-
hibit ALK is dependent on the mutation.
Several research groups have identified ALK inhibitors that can properly bind and impede
ALK phosphorylation in the setting of resistance by a specific single mutation or compound
mutations. This has translated into the development of a clinical strategy that relies on the
sequential administration of ALK TKIs during the patient’s treatment course [3]. This sequen-
tial approach starts with the first-generation inhibitor crizotinib, later moving forward to sub-
sequent treatment with second generation ALK inhibitors like ceritinib, alectinib or brigatinib
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and then to the novel, third-generation inhibitor lorlatinib. Most recently, second-generation
ALK inhibitors have moved to the front line setting, given the increased potency, intracranial
penetration and delay in the onset of resistance.
In addition, off-targetmechanisms of resistance like bypass track activation of downstream
oncogenic signaling and histologic transformation like small-cell, squamous cell transforma-
tion or epithelial mesenchymal transition, also drive disease progression in patients treated
with ALK TKIs [4, 5]. In this context, the molecular diagnosis can be more challenging, given
that many off-target alterations are not detected by DNA or RNA sequencing, but are also
dependent on the expression and activation of non-mutated nor amplified oncogenic effec-
tors. In this context, ALK phosphorylation is properly inhibited by the ALK TKI, but cancer
cell growth becomes independent of ALK, driven by other oncogenic effectors which need
also to be targeted in a dual or combined fashion [6].
The current approval of ALKTKIs by drug regulatory agencies solely requires the presence
of an ALK rearrangement by immunohistochemistry (clone D5F3, Ventana) but, in the setting
of resistance, tissue or blood based biomarkers are not mandatory to select the specific ALK
TKI that could be most beneficial based on genomic profiling. This was mainly due to the
design of the clinical trials with second- and third-generation inhibitors, in which ALK inhib-
itors were studied in patients with clinical progression with a previous generation of ALK
inhibitors, irrespective of the underlying mechanism of resistance [7–9]. However, with
proper biomarker assessment using tissue and/or liquid biopsy NGS, many genomic resis-
tance mechanisms can be identified and help tailor treatments for patients.
In this chapter, we will review the preclinical and clinical therapeutic strategies designed
to overcome on-target resistance like the ALK kinase domain mutations and ALK amplifica-
tion, and the wide range of resistance mechanisms that are ALK-independent also referred as
“off-target” resistance.
Overcoming resistance by the ALK kinase domain mutations
and ALK amplification
ALK kinase domain mutations can affect drug binding or enhance ATP affinity to the ki-
nase domain, which hampers the inhibition of ALK phosphorylation by the ATP-competitive
kinase inhibitors [2, 4, 10]. This has been studied using in vitromodels like Ba/F3 cells infected
with EML4-ALK fusion expressing different mutations and testing the cytotoxic potency of
different ALK inhibitors. In addition, patient-derived cell lines harboring the same ALK mu-
tation than the original tumor sample have also been used to test these compounds[11]. In an
exploratory approach, other assays have been used to try to predict the mutations that can
cause resistance to specific ALK inhibitors, per example, by N-ethyl-N-nitrosourea (ENU)
mutagenesis screens using Ba/F3 [12].
Acquired ALK kinase domain mutations are detected in about 20% and ALK amplifica-
tion can be found in about 8% of patients progressing on treatment with crizotinib [5]. Several
mutations confer resistance to crizotinib including the gatekeeper L1196Mmutation which is
the most common ALK kinase domain mutation in the setting of crizotinib resistance. Other
crizotinib resistance mutations include: I1151T, L1152R, C1156Y, I1171T/N/S, F1174L/C/V,
S1206C/Y, E1210K, G1269A and the solvent front G1202R, D1203N and S1206Y/Cmutations
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[2, 4, 13–16]. The G1269A is frequently acquired with crizotinib, this mutation is located in the
ALKATP-binding pocket [17]. In addition, the L1152P, C1156Y, F1174C/Lmutations lie in N-
terminal region of the kinase domain and do not affect crizotinib binding destabilizing the αC-
helix mobility, enhancing ATP affinity of the kinase by stabilizing its active state [2, 18]. The
G1202R mutation is relatively uncommon in the setting of crizotinib resistance, about 8% of
mutations, and confers resistance to all second-generationALK inhibitors. Thismutation is lo-
cated in the solvent front of thekinaseand impairsbindingof first- andsecond-generationALK
inhibitors by steric hindrance [19]. The type of EML4-ALK variant seems to be associated with
theprobability of acquiringG1202Rmutations, as it hasbeen reported tooccurmore frequently
in variant 3EML4-ALK rearrangements [20]. There is no clear explanation for this observation,
however it could potentially result from enhanced stability of this shorter fusion protein
associated with the loss of the TAPE domain, favoring on-target mutations.
The spectrum of activity of second generation ALK TKIs against crizotinib-resistant mu-
tations differs (Fig. 1A). Ceritinib is an ATP competitive ALK inhibitor active compound
against different crizotinib resistant mutations including: I1171X, L1196M, S1206C/Y,
E1210K and G1269A [18, 21]. However, ceritinib is not active in the setting of ALK I1151X,
L1152P, C1156Y and F1174L/C/V mutations. These later mutations mediate primary resis-
tance to ceritinib if given sequentially after crizotinib, but can be targetable with other second
generation inhibitors such as alectinib and brigatinib. Ceritinib has proven clinical activity in
the setting of resistance to crizotinib with objective response rates reaching about 40% and
median PFS of almost 6 months [22, 23].
Alectinib is a potent ALK inhibitor with high intracranial penetration and central nervous
system (CNS) activity [24]. Alectinib is active againstmost crizotinib resistantmutations includ-
ing: I1151T, L1152P,C1156Y, F1174L/C/V,L1196M, S1206C/Y,E1210KandG1269A.However,
there are twomutationswhich cannot be targeted by this compound, and aremechanisms of in-
nate or acquired resistance to alectinib, the I1171T/N/S and V1180L mutations, which can be
selectively targeted by ceritinib or brigatinib [25] (Fig. 1A). In a biomarker analysis of two
single-arm phase II clinical trials, NP28673 (NCT01801111) andNP28761 (NCT01871805) inclu-
ding 48 patients with detectable post-crizotinib ALK mutations treated with alectinib, median
progression-free survival (PFS) was 5.6 months, and about 50% of patients with on-target resis-
tance achieved responses [26]. In biomarker unselected population, treatment with alectinib in
the setting of crizotinib resistance confers responses in about 37–51% of patients with median
PFS of about 9 months [8, 27]. The ALK G1202R mutation accounts for approximately 30%
of resistance mutations after treatment with a second-generation ALK TKI, being the most
common acquired resistance mutation in patients treated with alectinib [28].
Brigatinib is a potent ALK and ROS-1 inhibitor and also has in vitro activity against other
kinases other kinases like FLT3, EGFR and IGF1R [25]. Brigatinib can overcome resistance
due to acquired kinase domain mutations that confer resistance to crizotinib, ceritinib and
alectinib with the exception of the G1202R mutation (Fig. 1A). Brigatinib was initially devel-
oped to target ALK in the context of the G1202R mutation, with in vitro kinase activity against
this solvent-front mutation and in vivo activity in mouse models [25]. Though plasma levels at
the 180mg dose have been predicted to achieve an IC90 for all ALK mutations, the clinical ac-
tivity of brigatinib against G1202R mutant ALK-rearranged tumors seems suboptimal [29, 30].
Moreover, brigatinib has limited activity against alectinib-resistant ALK-rearranged lung can-
cers, with objective responses seen in about 17% of patients treated with brigatinib after
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alectinib progression, resulting also in a primary progression in a patient with a detectableALK
G1202Rmutation [30]. However, clinical responses have been observed in patientswith tumors
harboring alectinib resistant I1171X and V1180L mutations and should be considered if these
mutations are detected [30]. Besides the G1202R resistance, mechanisms involved in brigatinib
progression are less known given the later development of this compound in respect to other
ALK inhibitors. Compound mutations, when two ALK resistance mutations are present in
the same allele or in cis, have been characterized to confer resistance to brigatinib, including
ALK E1210K/S1203N and E1210K/S1206C [14].Given the differential activity of second gener-
ationALK inhibitors against acquired crizotinib-resistantALKmutations, blood-based or tissue
DNA based NGS can provide useful information that can help better select the proper second-
generationTKI in a sequential treatmentmodality. In anapproach to followabiomarker-guided
ALKTKI strategy, theNCI-NRGALKMaster protocol is enrolling patients and allocating them
to treatment with specific ALK TKIs based on the results of genomic profiling at the time of
resistance to a second generation ALK inhibitor. This trial is currently ongoing and will define
if biomarker selection can improve objective response rates, progression-free survival and
overall survival in patients with ALK-rearranged lung cancer (NCT03737994).
Lorlatinib is a third-generation ALK inhibitor, designed to overcome resistance by all
known single ALKmutations includingALKG1202R [31] (Fig. 1A). Themacrocyclic chemical
design of this compound was achieved by modifying the chemical structure of the first gen-
eration inhibitor crizotinib, to improve blood-brain barrier passage, impede p-glycoprotein
efflux, and allow ALK binding in the presence of single ALK mutations [32]. The in vitro
potency (IC50) in Ba/F3 models against the non-mutant EML4-ALK fusion is about 2–3nM
and varies, within a range of sensitivity, against ALK mutations: I1151T (50nM), C1156Y
(4-15nM), I1171T/N/S (11-41nM), F1174L/C/V (4-8nM), L1196M (34-43nM), S1206C/Y
(3nM), E1210K (1.7nM), G1269A (10nM) [12, 14, 31]. The in vitro potency of lorlatinib in
Ba-F3 cells harboring the G1202R mutation has been reported between 49.9 and 113nM
[12, 14, 31, 33, 34]. In mouse models, lorlatinib also inhibits tumor growth of G1202R mutant
ALK-rearranged tumors, and has also shown significant intracranial activity [31].
Lorlatinib is currently approved for the treatment of patients with metastatic ALK-
rearranged lung cancer who have experienced disease progression on crizotinib and a
second-generation ALK inhibitor, or in patients previously treated upfront with a second-
generation ALK TKI. This approval is based on the results of the phase I/II clinical trial of
lorlatinib, in which patients were enrolled in different cohorts according to the type of treat-
ment received previously (see Chapter 2) [35, 36]. A biomarker analysis of patients included
in this studywas done to understand the impact of genomic alterations studied in plasma and
tissue NGS on lorlatinib outcomes [28]. Among the 198 patients enrolled in the clinical trial,
189 had available plasma and 164 patients had available tissue genotyping prior to lorlatinib
initiation. One or more ALK resistance mutations were found in 24% of plasma, and 24% of
tissue samples. In 28 patientswith detectableALKG1202Rmutations at lorlatinib baseline, the
objective response rate was 57%, the median duration of response with lorlatinib was
7 months and the median progression-free survival was 8.2 months [28]. Concordantly with
preclinical studies, this biologically selected subgroup analysis confirms that lorlatinib is clin-
ically active in the context of detectableALKG1202R mutation and thus, is the standard treat-
ment option in this setting [31]. In this study, the response rate with lorlatinib was higher in
patients with detectable ALK mutations in plasma (62% vs 32%) and in tissue (69% vs 27%)
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compared to patients without detectable ALK mutations. In addition, progression-free sur-
vival was prolonged in patients with detectable ALK resistance mutations in tumor, median
PFS of 11 months compared to 5.4 months, but this benefit was not observed in patients with
detectable ALKmutations in plasma, with a median PFS of 7.3 months versus 5.5 months [28].
Lorlatinib is highly selective in vitro to target tumor cells that harbor ALK resistant muta-
tions. In preclinical studies done in ceritinib resistant patient-derived cell lines, lorlatinib did
not induce cell death in cell lines that did not harbor ALK resistance mutations, suggesting
that lorlatinib is not active in the setting of bypass mechanisms of resistance to second-
generation ALK inhibitors [14]. This is different from bypass resistance in crizotinib resistant
patient derived cell lines, in which tumor cells with less potent bypass activation that still
have co-dependence with ALK signaling undergo apoptosis when treated with second-
generation inhibitors [18]. Hence, we can hypothesis that the responses observed with
lorlatinib in patients without detectable ALKmutations could potentially be due to false neg-
ative results of plasma NGS if ALK resistance mutations would be present at low allele fre-
quencies, or to tumor heterogeneity in patients that underwent tissue sampling [28]. In
addition, it has been documented that a significant proportion of patients may have low plas-
matic effective levels of kinase inhibitors, and hypothetically, the higher potency of lorlatinib
could also compensate low pharmacokinetics levels of previous ALK treatments [37]. In any
case, given that some patients without detectable ALK mutations may respond to treatment
with lorlatinib, to date lorlatinib can be prescribed to all patients who progress to a second-
generation ALK inhibitor. However, if a G1202R mutation is detected upon progression to
any previous generation ALK inhibitor, lorlatinib remains the treatment of choice. Given
at the current dose of 100mg daily, the lorlatinib plasma concentration exceeds the required
dose to inhibit the G1202R mutation and all single ALK mutations [35].
Even when lorlatinib was recently approved, on-target resistance mutations have been
known from some time by studying resistance in patients treated in the phase I/II clinical
trial. The first report on resistance to lorlatinib was in a patient with that experienced progres-
sion by the sequential acquisition in cis of anALKC1156Ymutation with crizotinib and a later
ALK L1198F with lorlatinib exposure [38]. Clonal analysis using whole exome sequencing
data from the patient tumors showed that the cancer cells containing the compoundmutation
at lorlatinib resistance were sub-clones derived from tumor cells that had acquired the
C1156Y mutation with crizotinib. Interestingly, substitution of a leucine for a phenylalanine
in position 1198 led to a steric clash with lorlatinib. Paradoxically, the L1198F mutation in-
creased the affinity binding of crizotinib, resensitizing these cells to treatment with a previous
line of ALK TKI. The patient was treated with crizotinib and experienced a significant re-
sponse. This study provided two novel proof-of-concepts, the discovery of compound muta-
tions conferring lorlatinib resistance and that compoundmutations, like singleALK resistance
mutations, may also have unique features, including re-sensitization to other ALK inhibitors.
Compound mutations acquired with first and second generation ALK inhibitors given se-
quentially have also been reported to drive resistance to brigatinib, like the D1203N/
E1210K, but this compound mutations remain sensitive to lorlatinib inhibition [14].
Several compoundmutations have been later discovered to convey resistance to lorlatinib.
Some have been detected in patients experiencing acquired or primary resistance to lorlatinib
and others have been revealed using in vitro mutagenesis assays with N-ethyl-N-nitrosourea
(ENU) screens with Ba/F3 cells. Some of the compound kinase domain mutations found in
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patients include G1202R/G1269A, I1171M/L1198F, I1171M/D1203N, L1196M/G1202R,
F1174L/G1202R, D1203N/L1196M [12, 33, 34]. The ALK kinase domain mutation L1256F
is predicted in vitro to confer resistance to lorlatinib as a single mutation but is targetable with
alectinib, however this mutation has not been reported clinically [12]. With the exception of
compound mutations that include L1198F mutation, which can be treated with crizotinib,
there are no new novel ALK inhibitors with the capacity to overcome lorlatinib resistance
by compound mutations, especially those that also involve the G1202R mutation. Therefore,
chemotherapy remains the standard treatment option to treat patientswith lorlatinib resistant
ALK-rearranged lung cancer.
Resistance to ALK inhibitors is a dynamic and heterogeneous process, as multiple on-
target and off-target genomic alterations can be found in the same patient. Two biomarker
studies using plasmaNGS have reported that about 7–19% of patients previously treatedwith
first and second generation ALK inhibitors had more than one ALK resistance mutation
detected [29, 39]. In patients progressing on lorlatinib treatment, ALK mutations were found
in 76%, of which two or more ALK mutations were found in 48% of cases. The capacity of
plasma or tissue NGS to detect compound mutations is limited by the size of the amplicons,
as thesemutations need to be found in the same read. Onlymutations that are close enough to
be read in the same amplicon can be called compound mutations.
Moving out of standard approaches to overcome resistance, several research groups are
exploring innovative preclinical strategies to target oncogenic ALK activation, including pro-
tein degraders and EML4 dimerization blockade. Bifunctional proteolysis targeting chimeras
(PROTACs) are novel compounds designed to induce targeted protein ubiquitination and
proteasomal degradation by the cereblon E3 ligase complex [40]. ALK PROTACs are com-
posed of an ALK inhibitor connected by a linker to the cereblon ligand pomalidomide.
Pomalidomide recruits the E3 ubiquitin ligase complex, which proceeds to ALK
ubiquitination and proteasomal degradation. Several ALK PROTACs have been designed
using ceritinib and TAE684 to degrade full ALK receptor with common activating mutations
in neuroblastoma (F1174L/R1275Q) and EML4-ALK in vitro [41, 42]. However, these
PROTACs will not be able to target ALK in the context of lorlatinib-resistant compound mu-
tations, which also confer resistance to ceritinib, thus new ALK binding compounds need to
be designed in this context to induce protein degradation in lorlatinib-resistant cells.
Monomerization of EML4-ALK fusion proteins is another strategy to prevent ALK signal-
ing. In vitro inhibition of spontaneous homodimerization by the EML4 coiled-coil domain is
an attractive strategy to impede ALK kinase domain activation, even in the setting of resis-
tance mutations as most do not confer constitutive kinase activation. A preclinical study has
recently shown that endogenous expression and exogeneous administration of mimicking
peptides of the EML4 coiled-coil domain suppressed ALK-driven tumor growth in vitro
and in vivo by inhibiting EML4 dimerization [43]. There are multiple challenges to develop
this kind of compounds for treatment in humans, however, in the setting of complex ALK
mutations that will difficult the development of novel ALK kinase inhibitors, disrupting other
mechanisms of ALK activation will be necessary in the near future.
ALK amplification is another resistance mechanism reported in about 8% of patients
treated with crizotinib [4, 14]. ALK amplification does not overlap with crizotinib resistance
kinase domainmutations.ALK amplification can be effectively targetedwithmore potent sec-
ond generational ALK inhibitors and has not been described to confer resistance to new gen-
eration ALK TKIs.
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Overcoming resistance by off-target mechanisms
In the absence of ALK mutations or amplification and in the setting of adequate ALK in-
hibition, resistance is probably commanded by other oncogenic effectors like tyrosine kinase
receptors or downstream activation of oncogenic pathways (Fig. 1B) [6]. There is a wide range
of oncogenic bypass pathways that have been implied in resistance to ALK inhibitors. In any
case, in order to effectively overcome resistance in this scenario, effective drug combinations
targeting ALK and the acquired activated effector are needed to induce apoptosis in cancer
cells. Many of these bypass activation pathways can be diagnosed using tumor or plasma
NGS, as some are direct consequence of molecular alterations including activating mutations
or rearrangements in oncogenes, amplification of known oncogenes and truncating muta-
tions in tumor suppressor genes that codify for proteins that regulate oncogenic signaling.
However, many bypass mechanisms of resistance are due to aberrant oncogenic activation
of a non-mutated or amplified driver [6].
MET amplification is a common resistance mechanism to first, second and third gener-
ation EGFR inhibitors, however the role of MET activation in resistance to ALK inhibitors
was less known until recently [44–47] (Fig. 1B). In 207 tissue/plasma samples from patients
treated with next-generation ALK inhibitors, MET amplification was detected by NGS and
fluorescence in situ hybridization (FISH) in about 12% of tumor biopsies at resistance to
second-generation ALK inhibitors and in 22% of lorlatinib-resistant tumors [48]. In addition,
ST7-MET fusions were also reported to be acquired at the time of resistance. MET
rearrangements are rarely found in cancer, but have been reported in NSCLC tumors, in
patients with infantile or adult glioblastomas and in infantile spindle sarcomas [49–53].
In this study, the combination of ALK-MET inhibition led to clinical responses in two pa-
tients: one treated with single agent crizotinib, and in second case with lorlatinib-crizotinib
combination [48]. MET amplification can be assessed by using NGS or FISH and it can be
rapidly adopted into patients clinical care, opening a new opportunity for combinatorial
strategies, as it has been the case for patients with EGFR-mutant and MET-amplified
cancers [54].
Other genomic alterations that can be associated with resistance to ALK inhibitors have
been found using plasma or tissue NGS including KRAS mutations, activating mutations
in PI3K, inactivating PTENmutations,MEKmutations that can suggest that bypass pathways
may be activated in the setting of clinical progression [39, 55].
When bypass track activation cannot be determined by genomic alterations, the study of
off-target resistance mechanisms relies in the development of patient derived xenografts
(PDX) or cell lines. By using different in vitro assays like drug screens, kinase assays and
CRISPR-CAS9 gene editing, several non-genomic bypass mechanisms have been found
and targeted in vitro and in vivowith combination therapies. Several bypassmechanisms have
been discovered using patient derive models involving EGFR, IGFR1, HER2, HER3, MEK,
NF2, PI3K, SHP2 and SRC [6, 14, 34, 56] (Fig. 1B).
By developing patient-derived cell lines, early preclinical studies revealed that these by-
pass track mechanisms of resistance occur frequently. In a patient derived cell line, an ac-
quired MEK K57N mutation was found to confer resistance to ceritinib. This mutation is
one of the hot spot mutations in MEK, leading to constitutive activation of the MAPK path-
way, downstream of RAF and RAS [6]. In vitro and in vivo, the combination of ALK andMEK
inhibition led to significant apoptosis, which was selective for this specific cell line and not
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reproduced in other models that did not harbor MEK mutations. In addition, this cytotoxic
effect was not observed with single MEK inhibition, abrogating for the need to suppress
oncogenic signaling pathways downstream of ALK other than the MAPK pathway like the
PI3K/AKT/mTOR pathway. There are ongoing clinical trials combining ALK and MEK
inhibitors like ceritinib with trametinib (NCT03087448), alectinib with cobimetinib
(NCT03202940) and brigatinib with binimetinib (NCT04005144), translating the observed
interaction in vitro into the clinical practice.
SRC activation has also been recurrently implied in resistance to crizotinib and most re-
cently, in the onset of lorlatinib resistance [6, 34]. In several patient-derived models of
crizotinib resistant cell lines, exposure to crizotinib induced SRC activation and signaling.
SRC can be activated by a number of tyrosine kinase receptors including EGFR, IGFR-1,
PDGFR, VEGFR and ALK, directly activating downstream signaling pathways. SRC is also
involved in cell-to-cell adhesion through focal adhesion kinases, and in the development of
epithelial mesenchymal transition [57]. Combining SRC inhibition using saracatinib
(AZD0530) and ALK TKIs induced apoptosis in patients derived cell lines. In a recent pre-
clinical study of lorlatinib resistance, combining lorlatinib and saracatinib effectively
targeted cells undergoing SRC induced epithelial-mesenchymal transition (EMT) by a direct
cytotoxic effect of this combination [34]. In a second patient with bone oligo-progression in
which partial EMTwas found by high levels of vimentin expression in the biopsy sample, the
patients-derived cell line with EMT phenotype was also susceptible to combined ALK/SRC
inhibition. EMT may be more common than suspected clinically, it has been previously
reported in 40% of tissue samples from 12 ceritinib resistant tumors with E-cadherin loss
and vimentin expression [14]. EMT has also been recently reported in a patient progressing
on several lines of ALK inhibitors like crizotinib, ceritinib and alectinib in the setting of ALK-
refractory disease [58]. The combination of the SRC inhibitor dasatinib and crizotinib was
studied in a phase I trial that did not include patients with ALK-rearranged lung cancers
and had a high rate of adverse events, which does not support this combination [59].
Repotrectinib (TPX-0005) is a potent ROS-1 inhibitor, and can also target ALK and NTRK
and SRC [60]. It was originally designed as a dual ALK/SRC inhibitor, however the
in vitro potency of this inhibitor against ALK was not translated in the clinical setting.
Currently, there are no clinical available combination strategies against ALK/SRC co-
dependence.
As mentioned earlier in this chapter, several phosphokinases can be activated in ALK TKI
resistancemodels. Therefore, preclinical research has been conducted aiming to identify com-
mon signaling activators of intracellular signaling pathways. Src homology region 2 (SH2)-
containing protein tyrosine phosphatase 2 (SHP2) encoded by PTPN11 is a regulator of the
multinetwork of signaling cascades including theMAPK, PI3K/AKT/mTOR and JAK/STAT
[61]. SHP2 inhibition was identified as a hit in ceritinib resistant cell lines using a shRNA
screen [56]. In this study, ERK reactivation was found to be re-induced rapidly after exposure
of cancer cells to ceritinib, and combinedALK and SHP2 inhibition andwas reverted by using
the allosteric SHP2 inhibitor SHP099, which led to enhanced apoptosis in these models in
combination with the ALK inhibitor, proving durable inhibition of ERK1/2 and p90RSK
phosphorylation and inhibition of GTP loading of KRAS isoforms. This study may lead to
the development of SHP2 and ALK combinations, as novel SHP2 inhibitors like TNO155
are being tested in phase I trials (NCT03114319).
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Activation of the ErbB family of receptors like EGFR, HER2 and HER3 are also related to
ALK TKI resistance in vitro due to receptor bypass signaling (217,229,230). EGFR can amplify
downstreamALK signaling through adaptor proteins like GRB (229). In vitro, the combination
of ALK and EGFR inhibitors can restore sensitivity to ALK TKIs (231), and neuregulin expres-
sion can be induced by ALK inhibition. In vitro, ALK dependent cell lines can acquire resis-
tance to ALK TKIs by exposure toNRG1 and this can be reverted by combining ALKTKIwith
lapatinib, a HER2 tyrosine kinase inhibitor (232). Interestingly, de novo co-occurrence of ALK
rearrangements and activating EGFR mutations have been described in case reports [62, 63].
Outside of anecdotal cases, the interactions between ALK and the ERBB family of tyrosine ki-
nase receptors at the time of resistance to ALK TKIs have not been assessed in clinical trials.
Bypass track activation that conveys resistance to crizotinib can be potentially overcome by
second generation ALK TKIs, as it has been well documented in the preclinical models and in
the clinical setting, that tumors without detectable on-target resistance can be targeted by
switching to new generation ALK inhibitors [18]. This suggests that mild bypass signaling
activation can be sufficient to surpass crizotinib inhibition of ALK, however complete and
potent ALK inhibition by new-generation ALK inhibitors can hamper the proliferation of can-
cer cells that still maintain a certain degree of co-dependence in ALK signaling to survive.
Also, second generation ALK inhibitors may provoke off-target inhibition in other effectors
of bypass signaling, like ceritinib with IGFR1 or brigatinib with EGFR and FLT3, which can
also play a role in the efficacy of these agents in crizotinib-resistant models [25].
In the setting of lorlatinib resistance, there is scarce data on potential bypassmechanisms of
resistance to this compound. In a preclinical study using H3122 and H2228 cell lines, incre-
mental doses of lorlatinib induced resistance by EGFR activation in vitro, which has already
been described with other ALK inhibitors in the H3122 cell line [64]. In a neuroblastoma cell
line (CLB-GA) with full length ALK harboring the R1275Q mutation, exposure to lorlatinib
favored the emergence of resistance clones that contained a truncating mutation in NF1,
which was targetable with combination of trametinib and lorlatinib in vitro [64].
More recently, using patient-derived xenografts and cell lines, a bypass mechanism due to
NF2 inactivation was characterized in vitro in a patient progression on lorlatinib with the se-
quential acquisition of deleteriousNF2mutations in different temporo-spatial metastasis [34].
In vitro validation of the effect of NF2 loss in lorlatinib resistance was conducted by CRISPR-
CAS9 NF2 knockout in H3122 cells, showing high levels of pS6 even with adequate ALK in-
hibition, secondary to downstream activation of the PI3K/AKT/mTOR pathway due to loss
of mTOR inhibition by merlin. Combining lorlatinib and the dual mTORC1–2 inhibitor
vistusertib (AZD2014) reverted resistance in vitro and in vivo. More research is needed to bet-
ter understand how to treat patients with off-target resistance mechanisms driving lorlatinib
resistance, as more patients receive this drug in the clinical setting.
Preventing the emergence of resistance: New generation
ALK inhibitors upfront
Given the complexity of on-target resistance with sequential ALK inhibitor treatments,
more potent second- and third-generation ALK inhibitors have been tested upfront in clinical
trials with improved efficacy over crizotinib [3]. In treatment-naı̈ve mice models harboring
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ALK-rearranged tumors, upfront treatment with alectinib or brigatinib conveyed prolonged
disease control by delaying the emergence of resistance [25, 31, 65]. As referred in Chapter 2,
ceritinib, alectinib and brigatinib given in the first line results in prolonged progression-free
survival compared to crizotinib and delays the onset of brain metastasis in patients with met-
astatic ALK-rearranged NSCLC [66–68]. There is scarce data regarding the mechanisms of re-
sistance to first-line treatment with a second-generationALK TKI, however themost common
resistance mutations found in patients receiving front line alectinib are the G1202R and
I1171X mutations, all targetable with lorlatinib [29]. More data will be needed to understand
resistance mechanisms to first line treatment with brigatinib.
Lorlatinib is also predicted to improve outcomes of patients in the first-line setting com-
pared with crizotinib. In a subset of 30 patients treated in the first line with lorlatinib in
the phase I/II trial, 90% achieved a response and intracranial responses were observed in
67% of patients, with sustained PFS benefit [36]. The phase III CROWN trial is currently on-
going, comparing front line treatment with lorlatinib and crizotinib and the results of this trial
showed improved progression-free survival and intracranial activity of lorlarinib over
crizotinib, however longer follow-up is required to see the impact of this approach in overall
survival [69]. Upfront treatment with lorlatinib may favor the delay of on target resistance,
supported by preclinical evidence with ENU mutagenesis screens in which there is absence
of resistantmutations arising in BaF3 cells treatedwith this drug. This further suggests that, in
the first line setting, a predominance of off-target resistance could be expected [33].
Drug combinations to overcome or delay resistance
in ALK-rearranged NSCLC
Other synergic strategies have been explored in the treatment of patients with EGFR-mutant
NSCLC, like the combination of EGFR inhibitors with platinum-pemetrexed chemotherapy
and with antiangiogenic agents, prolonging progression-free survival and overall survival
(only with chemotherapy combinations) in patients treated in the front line [70–72]. In
EGFR-mutant lung cancer there is evidence that resistant clonesmay be pre-existing at the time
of diagnosis, and emerge as dominant clones after treatment selection [73]. This has been
documented for T790M mutations and in the setting of small-cell lung cancer transformation
[74]. Combining TKIs with chemotherapy upfront could target cells that are susceptible to ki-
nase inhibition and clones who are primarily resistant to these compounds, also potentially
diminishing the pool of drug-tolerant or “persister” cells. For the moment, there is scarce data
on combination of chemotherapy with ALK TKIs and it has not been explored in randomized
trials [75]. There is an ongoing clinical trial combining alectinib with bevacizumab, a soluble
VEGFmonoclonal antibody, in patientswithALK-rearrangedNSCLC and untreated and stable
brain metastasis (NCT02521051). This phase I/II trial will assess the safety of this combination,
and additionally, will study the intracranial and systemic objective response rates. If this com-
bination is safe, it will be important to determine whether this can further delay resistance.
In addition to chemotherapy and antiangiogenic agents, programmed cell death-1 (PD-1)
and its ligand (PD-L1) immune checkpoint inhibitors are current standard treatments in pa-
tients with advanced NSCLC. However, they are not effective treatments for patients with
ALK-rearranged NSCLC given as monotherapy, possible due to the low immunogenicity
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of these tumors [76]. In an attempt to improve outcomes in patients with ALK-rearranged
lung cancer, crizotinib was combined with nivolumab in a phase I trial, however this combi-
nation resulted in significant liver toxicities and was discontinued [77]. Alectinib was also
combined with atezolizumab and lorlatinib with avelumab, and though these combinations
showed acceptable toxicity profiles in patients, they did not seem to convey superior clinical
benefit over single agent ALK inhibitors [78, 79]. In patient withALK- or EGFR-driven tumors,
who have progressed on targeted therapies, the combination of the anti PD-L1 monoclonal
antibody atezolizumab with bevacizumab and chemotherapy showed improved overall sur-
vival over the chemotherapy and atezolizumab combination, in a subgroup analysis of the
Impower150 trial [80, 81]. This regimen has been approved in Europe based on a subset anal-
ysis that involved a small group of patients, and though it’s an available option in patients in
which there are no further options of ALK inhibition, prospective studies are needed to val-
idate the use of immunotherapy combinations in this setting. Other research groups are
aiming to improve immune surveillance against ALK-rearranged lung cancer cells, by devel-
oping anti-ALK vaccines, however this approach remains experimental and clinical trials are
awaited [82].
Conclusion
In summary, in this chapter we have reviewed clinical and preclinical strategies to over-
come resistance to ALK inhibitors in patients with lung cancer. The road to the discovery and
characterization of on-target ALK resistance mutations have successfully led to the develop-
ment of effective next-generation ALK inhibitors which have been strategically sequenced to
prolong patients’ survival. On the other hand, treatment strategies to overcome off-target re-
sistance have not translated fast into clinical trial designs, remaining as an unmet need for
patients that require more tailored treatments in this setting. As we approach the frontier
in the development of ALK inhibitors with the approval of lorlatinib, research efforts are
needed to design new drugs and regimens to overcome or prevent novel forms of biological
resistance.With the guidance of translational preclinical research and newdrug development
techniques, innovative strategies are highly awaited to further care for patients with ALK-
driven cancers.
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Abstract
In 1985, a new type of peripheral T-cell lymphoma was discovered using a monoclonal antibody, Ki-1 (anti-
CD30), raised against aHodgkin lymphoma (HL) cell line. It, ultimately named anaplastic large cell lymphoma
(ALCL), was characterized and found to usually contain translocation t(2;5)(p23;q35) fusing nucleophosmin
(NPM) and a “new” gene, anaplastic lymphoma kinase (ALK). The NPM-ALK fusion gene results in a consti-
tutively active ALK tyrosine kinase that drives neoplastic cell growth, in large part through activation of
STAT3 and downstream signaling. ALK positive ALCL is predominantly a disease of children, adolescents,
and young adults, while similar tumors in adults are ALK negative. The discovery of ALK + ALCL occurred
during a time of progress in the treatment of pediatric non-Hodgkin lymphomas (NHL), and it was initially
considered to have a favorable prognosis, with 60–70% event free survival compared to other pediatric NHLs
for which treatment results were less favorable. Since that time, however, progress has occurred in other pe-
diatric NHLs, but has stalled in ALCL. ALK translocations and other abnormalities have subsequently been
found in a number of neoplasms including a portion of non-small cell lung cancers, and ALK tyrosine kinase
inhibitors (TKIs) have been successfully used in their therapy. Tumors often develop resistance to TKIs, lim-
iting their long-term success. TKI therapy is gradually being introduced into the treatment of ALK + ALCL in
efforts to reduce toxicity of chemotherapy while preserving and increasing cure rates. Other targeted modal-
ities are also available to aid in this quest, including the anti-CD30 antibody drug conjugate brentuximab
vedotin, other immune therapies including bi-specific antibodies and immune checkpoint inhibitors, and chi-
meric antigen receptor T-cells (CAR-T).
Abbreviations
ABL Abelson murine leukemia viral oncogene homolog
ADC antibody-drug conjugate
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ALK anaplastic lymphoma kinase
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ATIC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase
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BAG6/BAT3 BAG chaperone 6
BCL B cell lymphoma protein
BCNU carmustine
BCR breakpoint cluster region
BFM Berlin-Frankfurt-Munich cooperative treatment group
BimAb bispecific monoclonal antibody
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CDK cyclin D kinase
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ICH immune checkpoint inhibitor
IGF insulin-like growth factor
IL interleukin
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IRF4 interferon regulatory factor 4
JAK Janus kinase
kDa kilodalton
KIT stem cell factor receptor
KRAS GTPase from Kirsten sarcoma virus
LDM lidamycin
LSA2-L2 early treatment protocol for lymphoid neoplasms
MAPK mitogen-activated protein kinase
MCL1 myeloid cell leukemia 1
MDD minimal disseminated disease
MET Mesenchymal-epithelial transition factor-1
MMAE monomethyl auristatin E
MMAF monomethyl auristatin F
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MRD minimal residual disease
MSKCC Memorial Sloan Kettering Cancer Center
MTOR mammalian target of rapamycin
MTX methotrexate
MYC MYC proto-oncogene
NfkB nuclear factor kappa B
NHL non-Hodgkin lymphoma
NPM nucleophosmin
OS overall survival
PD1 programmed death 1
PDGF platelet derived growth factor
PDL-1/2 programmed death ligand 1/2
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POG Pediatric Oncology Group
PPAR peroxisome proliferator-activated receptor
PTCL peripheral T-cell lymphoma
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PTPN1 protein tyrosine phosphatase non-receptor type 1
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RET RET proto-oncogene
RNA ribonucleic acid
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RT radiation therapy
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SGN-30/35 anti-CD30 and anti-CD30-drug conjugate
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TNFR tumor necrosis factor receptor
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TPM tropomysin
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Introduction
In 1985, Stein et al., reported on a monoclonal antibody, Ki-1, raised against a Hodgkin
lymphoma (HL) cell line [1]. It reacted with cells of HL, lymphomatoid papulosis, some T cell
lymphomas, activated T and B cells, and a group of tumors with anaplastic morphology pre-
viously diagnosed as histiocytic neoplasms. A paraffin-reactive analogue to Ki-1 (BER-H2)
was developed and the antigenwas assigned cluster of differentiation (CD) 30 [2]. The tumors
previously considered histiocytic became recognized as a new entity, Ki-1 positive anaplastic
large cell lymphoma (ALCL) [3, 4]. Soon after the discovery of this “new” tumor, cases of
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histiocytic and large cell lymphomas, mostly in children, were noted to have translocations t
(2;5)(p23;q35). These included about 1/3 of pediatric large cell lymphomas, or approximately
10–15% of pediatric non-Hodgkin lymphomas (NHLs) [4–6].
In 1994, Morris et al. characterized the t(2;5)(p23;q35) translocation as a fusion between a
novel tyrosine kinase gene, anaplastic lymphoma kinase (ALK) at 2p23, with the nucleophos-
min (NPM1) nucleolar phosphoprotein gene at 5q35 [7]. ALK was described as a normal gene
of the insulin receptor kinase subfamily, weakly present in a number of tissues, particularly
fetal brain, but not present in normal hematopoietic cells. The ALK portion of the neoplastic
fusion gene is truncated with a constitutively activated catalytic domain due to a promoter in
the NPMportion.NPMwas subsequently found not to be rearranged [8]. Shiota et al., also des-
cribed theNPM-ALK fusion product, designated as p80, and focused on pathologic aspects [9].
Histologic studies of ALCLwere facilitated by the development of anti-ALK antibodies effec-
tive in paraffin sections, including ALK1 and p80NPM/ALK. These were tested against relatively
large numbers of cases by several cooperative treatment groups, with similar findings across the
studies [10–18]. The majority of cases were found to occur in children and young adults.
Pathology of ALK + ALCL
The pathology of ALK + ALCL was well-described from clinical studies and is now in-
cluded as an entity in the WHO Classification of Haematopoietic Neoplasms [19]. Histology
shows heterogeneous morphology including a common histologic type with the presence of
large cells with indented, reniform, or horseshoe shaped nuclei and abundant cytoplasm.
These are often called “hallmark cells.” Lobated nuclei and multinucleated cells are some-
times seen, and there is frequent involvement of lymph node sinuses (Fig. 1). The
immunophenotype is that of activated T-cells, with expression of CD30 and CD25 (IL2-R),
although T-cell markers are usually incomplete or aberrant. CD45, CD43, CD45RO, CD2
and CD4 are frequent, CD8 less often, HLA-DR typically positive, CD13 often aberrantly pos-
itive, with CD3, CD5, and CD7 variable [20, 21]. The epithelial membrane antigen is frequent,
and histiocyte associated markers including CD68 are sometimes seen [22]. CD30 expression
shows a membrane and Golgi pattern, and both cytoplasmic and nuclear ALK staining are
prototypical, while cytogenetic variants show only cytoplasmic labeling (Fig. 1).
T cellmarkers are absent in up to 30%.Most cases exhibit the T-cell receptor (TCR) alpha gene
rearrangement but not the TCR beta rearrangement. This latter finding may relate to the origin
from an early thymic precursor [23]. Clinically, clonal TCR gamma rearrangement is often
present by PCR. Histologic variants include monomorphic, small cell, lymphohistiocytic,
Hodgkin-like, and composites. All are characterized by the expression of CD30 and ALK. Only
the small cell variant (inwhichmostly perivascular large cells showALK staining), andpossibly
the overlapping lymphohistiocytic variant, are noted to have worse prognosis [19].
Similar ALK+ anaplastic lymphomas also occur, with fusion of ALK to other partner
genes [24, 25]. These partners include tropomysin 3 and tropomysin 4 (TPM3-ALK and
TPM4-ALK), 50aminoamidozole-4-carboxyamide ribonucleotide formyltransferase/IMP
cyclohydrolase (ATIC-ALK), TRK-fused gene (TFG-ALK), myosin heavy chain (MYH9-ALK),
moesin (MSN-ALK), and clatherin-like heavy chain (CLTC-ALK). All but CLTC-ALK have
immunophenotypes similar to those with NPM-ALK except that ALK antibody staining is
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only cytoplasmic in variants, rather than nuclear and cytoplasmic. The CLTC-ALK lymphoma
is associated with B-lineage, similar to some early mouse models with knock-in NPM-ALK,
and, peculiarly, with the absence of both CD30 and CD20 [26, 27].
ALK negative ALCL also deserves mention to limit confusion between it and ALK+ dis-
ease, and there are several distinct types. Systemic ALK  ALCL histologically resembles
ALK+ disease but typically occurs inmiddle age or later. Clinical behaviormay be influenced
by genetic findings. Cases with DUSP22 rearrangement are considered favorable, similar to
ALK + ALCL, while those with TP63 rearrangements (less common) are considered adverse.
Amajority of cases are “triple negative” for ALK, DUSP22, and TP63 abnormalities, and have
intermediate prognosis [28, 29].
Cutaneous ALCL is a subgroup of primary cutaneous CD30+ lymphoproliferative dis-
order, characterized by localized sheets of CD30+ anaplastic large cells in the dermis, without
involvement of the epithelium [19]. This finding is sometimes mimicked by cutaneous
involvement by systemic ALK+ or ALK  ALCL, and thus clinical staging is important. Pri-
mary cutaneous cases are typically relapsing/remitting diseases and frequently indolent,
cautioning against aggressive treatment in absence of systemic disease. Some have DUSP22
rearrangements.
FIG. 1 (A) H&E stained slide showing lymph node sinus involvement by ALK+ALCL (500). (B) Neoplastic cells
showing indented or lobated nuclei with prominent nucleoli and abundant cytoplasm (1000). (C) Anti-CD30
immunohistochemical stain showing Golgi and cytoplasmic positivity. (D) ALK1 immunohistochemical stain show-
ing typical nuclear and cytoplasmic labeling.
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Breast implant ALK  ALCL is a distinct entity involving the region of prior breast
implants. It is usually triple negative but has constitutive activation of STAT3 and expression
of PD1/PD-L1 [30]. Essentially all ALK+ and ALK  ALCLs show STAT3 activation, but in
the ALK negative cases STAT3 is activated by different factors.
To assign targeted therapy for ALK+ ALC, it is important to consider how NPM-ALK acts
as an oncogene. This has been studied and reviewed previously [31, 32]. Principle among the
activities of the NPM-ALK fusion protein as a tyrosine kinase is phosphorylation and acti-
vation of STAT3, both directly and indirectly [32, 33]. The interaction of IL-2, IL-9, IL-21,
and related cytokines with JAK3 plays a role, alongwith Src kinases, SHP1, JAK2, and STAT5.
The PI3K/Akt signaling pathway is constitutively active in ALK + ALCL, and this may be
related to phosphorylation of the negative regulatory tail of PTEN [34]. CD30 expression is
associated with MAPK/JunB signaling, and activation of NFkB [35]. Myc is activated, and
CEBPB, BCL6, PTPN1, MCL1 and SERPINA1 are upregulated [31].
A simplified view of the functions of NPM-ALK fusion protein would be activation of the
JAK3/STAT3, AKT/PI3K, RAS/ERK/MAPK, and sonic hedgehog (SHH/GLI1) pathways,
with coordinated downstream involvement by numerous gene and protein modulations, in-
crease in proliferation, and decrease in apoptosis [36]. Non-coding RNAs, particularly micro
RNAs (miRNAs) are involved, interact with proliferative and apoptotic modulators, and are
involved in differential methylation patterns [37, 38]. NPMmay play a role as well. Although
theNPM-ALK fusion gene is not rearranged, it is likely deregulated. NPMnormally associates
with cyclin D kinases (CDK) and p53 and is important in cell cycle regulation [39]. With
crizotinib-induced ALK inhibition in ALCL cell lines, CDK expressions become down-
regulated, along with many of the other genes annotated to ALK + ALCL [40] (Fig. 2).
Comparative proteomic analysis by mass spectrometry, utilizing cell lines with and with-
out NPM/ALK translocation, has shown analogous findings [41]. Differentially expressed
proteins included those involved in survival, cell cycle regulation, proliferation, growth
factor/cytokine signaling, antiapoptosis, neoangiogenesis, adhesion andmigration. Signaling
pathways represented included those of PI3K/AKT, JAK/STAT, IGF1, IL4, IL6, NFkB, PPAR,
p38/MAPK, ERK/MAPK, FRAP/MTOR, g-protein, PDGF, Wnt/B-catenin, and integrin.
Evolution of standard therapy of ALK + ALCL
Discussion of targeted therapy for pediatric neoplasms also requires discussion of stan-
dard therapies. The first successful treatment protocol for pediatric NHL was LSA2-L2, ini-
tiated in 1971 atMemorial Sloan-Kettering Cancer Center (MSKCC), forNHL of all histologies
(including “reticulum cell sarcoma” or large cell types) [42], and all stages. It utilized nine
chemotherapy agents plus radiation therapy (RT), with induction, consolidation, and main-
tenance phases [43]. Drugs included cyclophosphamide, vincristine, methotrexate, predni-
sone, daunomycin, arabinosylcytosine, thioguanine, L-asparaginase, and BCNU. The first
treatment group included six cases of “diffuse histiocytic” lymphoma, likely including some
of ALCL, and overall actuarial survival in follow-up was 80% [44]. A prior MSKCC protocol
utilizing cyclophosphamide and RT had shown survival of only about 33%. Modifications of
LSA2-L2 have continued to be utilized for lymphoblastic lymphoma [45].
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Around the times that ALCL and NPM-ALK were described, pediatric lymphomas were
being treated in various ways per institutional or regional cooperative treatment group strat-
egies. Initially during that period, patients were separated into lymphoblastic versus non-
lymphoblastic groups [46]. The Pediatric Oncology group found importance in separating
small noncleaved cell (Burkitt) lymphoma from diffuse large cell lymphoma (DLCL), which
included both B and T-cell types, although immunophenotypes were not determined [47].
The Nebraska Lymphoma Study separated peripheral T-cell lymphoma (PTCL), including
ALCL, and found benefit in aggressive treatment [48]. Investigators of Bologna University
treated cases of ALCL, then recently included in the Updated Kiel Classification, with mod-
ified LSA2-L2 and found somewhat favorable 4years event-free survival of 62.9% [49–51].
The Children’s Cancer Study Group compared LSA2-L2 with COMP therapy, finding that
large cell types (both B and T) fared equally with the two therapies, although 5years EFSwere
only 52% and 43%, respectively [52].
FIG. 2 Protein network of genes differentially expressed and associated with apoptosis in ALK+ ALCL cell lines
treated with crizotinib.
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The Berlin-Frankfurt-Munster (BFM) cooperative group reported results from 62 patients
with ALCL on three studies with good results (up to 9years EFS of 83%) using short pulse
chemotherapy. Drugs included prednisone, cyclophosphamide, dexamethasone, methotrex-
ate (MTX), intrathecal chemotherapy, ifosfamide (or cyclophosphamide and doxorubicin),
cytarabine (Ara-C), and etoposide (VP-16) [53]. A subsequent study, BFM-90, further tested
the concepts of short pulse therapy for ALCL in a large prospectivemulticenter trial, stratified
for stage, and found that of 89 patients, the overall 5-year event free survival to be 76%, with
increased risk in patients with B symptoms [54].
The French Society for Pediatric Oncology reported on two protocols for ALCL, HM89 and
HM91. These utilized cyclophosphamide, vincristine, prednisone and doxorubicin as first
line therapy, with heterogenous treatments for relapse. Combined 3years EFSwas 66%, vary-
ingwith stage [14]. A subsequent report from that group showed that relapsedALCL remains
sensitive to vinblastine-based chemotherapy [55].
The Pediatric Oncology Group treated 180 patients of diffuse large cell lymphoma (DLCL),
including 86 ALCL, 75 B-cell (DLBCL), 10 PTCL of other types, and 9 unclassified. Treatment
was APO (doxorubicin, vincristine, prednisone, 6-mercaptopurine, andmethotrexate) versus
APOwith intermediate dosemethotrexate and high dose cytarabine (HiDAC). Overall 4years
EFS was 67.4%, with no significant differences between arms or between DLBCL versus
ALCL [56]. APO was also the backbone of a subsequent Children’s Oncology Group
(COG) trial for ALCL which showed that adding daily vinblastine did not increase efficacy,
but did increase toxicity [57].
A large multi-national multi-institutional trial, ALCL-99, based on the previously men-
tioned BFM-90 protocol showed 2-year event free survival of 352 patients of approximately
74%.The initial report of this studyshowed thatmethotrexate schedulecouldbesafely reduced
from the prior studies, and the results were found particularly favorable because of relatively
good survival combinedwith lower cumulative toxicity than other regimens [58]. Lymphohis-
tiocytic and small cell histologic variants were found to have inferior prognosis [59].
There have been no randomized trials of ALK+ ALCL in adult patients, although the dis-
ease represents about 3% of adult NHL, mostly patients less than 35years, and most adult
treatments have been with anthracycline based CHOP-like therapies [16, 60].
Thus, treatment results fromclinical trials are basedonpediatric studies, and themajority of
patients with ALK + ALCL are from pediatric, adolescent, and young adult populations.
Most trials have shown long-term survivals between 65% and 75%, andALCL99 has emerged
as the most used front line therapy. Identified risk factors include mediastinal or visceral in-
volvement with skin lesions; minimal disseminated disease (MDD) in blood, bone marrow,
and/or CNS; molecular minimal residual disease (MRD) after 4weeks of treatment;
lymphohistiocytic or small cell histology; and low titers of anti-ALK antibodies [61]. Relapsed
patients may be treated by salvage therapy (chemo or RT) followed by autologous bone mar-
row transplantation.Other relapseoptions includepraletrexate (anti-folate agent), romidepsin
(HDAC1 inhibitor), or vinblastine, the latter reported to have immunomodulatory properties
as well as being an anti-tubulin chemotherapy [60, 61].
Results of treatment of ALK + ALCL have not consistently exceeded 70% EFS or 90% OS
(including salvage therapy), and although toxicities have decreased, they remain significant.
Further decrease in toxicity might be achieved by single agent vinblastine as a first line agent,
but this is yet to be tested andwould likely be long-term therapy. Targeted therapy with ALK
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inhibition (i.e., crizotinib or other ALK inhibitors) and/or anti-CD30 antibody-drug conju-
gates (i.e., brentuximab vedotin) also offers promise, but the use such agents is limited by
the relative success of chemotherapy, to some extent by cost of the drugs, and by the lack
of interest by pharmaceutical companies in pursuing this course for a rare disease [62].
ALK tyrosine kinase inhibitors
The first tyrosine kinase inhibitors were developed in the 1980s and 1990s and found to
inhibit products of oncogenes such as v-SRC, v-ABL, and BCR-ABL. One, signal transduction
inhibitor 571 (STI571, imatinib), inhibited PDGFRa, c-KIT, and BCR-ABL [63]. It was found to
be active against cultured chronic myeloid leukemia cells and became a revolutionary treat-
ment for that and other neoplasms as well, including gastrointestinal stromal tumors (GIST),
myeloproliferative neoplasmwith eosinophilia, mast cell neoplasm, and others [63, 64].Many
other TKI’s have also been successful in treating cancer, however, treatment is usually long-
term and emergence of resistance is a generalized function, related in part to ongoing muta-
tions that effect ATP-binding sites with which TKIs interact [63, 65].
Crizotinib, originally known as PF-2341066, was described as an inhibitor of c-MET and of
ALK in 2007 [66, 67]. It inhibits proliferation with G1-S–phase arrest and induces apoptosis in
commonly used ALCL cell lines. Signal transduction effects attributed to NPM-ALK in lym-
phoma, which are mostly up-regulations, are negated by crizotinib at physiologic doses
(Fig. 2). Crizotinib is effective and FDA-approved for treatment of non-small cell lung cancer
(NSCLC) with ALK translocation and for NSCLC with ROS1 rearrangement. Acquired resis-
tance to crizotinib is common in lung cancer treatment due to a variety of mechanism, and
second and third generation ALK inhibitors are often effective in relapse/progression [65].
Crizotinib in pediatric neoplasms
ALK translocation, mutation, or expression has been found in several neoplasms of young
people. These include, in addition to ALCL, familial neuroblastoma due to germline muta-
tions at ALK tyrosine kinase domains G1128A, R1192P, and R1275Q, neuroblastoma without
ALK mutation but with expression on the cell surface, which is nearly ubiquitous, and rhab-
domyosarcoma [68, 69]. ALK translocations also occur in half of pediatric inflammatory
myofibroblastic tumors (IMT). Activity of Crizotinib in refractory/relapsed ALCL and in
myofibroblastic tumors was tested by the Children’s Oncology Group in a phase I/II study,
with complete response in most ALCL and in 36% of IMTs [70].
So the current state of therapy for ALK + ALCL in young people is with treatment
according to ALCL 99, with an overall long-term EFS of about 70%. This outcome has not
changed substantially in 30years, although toxicity is reduced. This is in contrast to results
of treatment of other pediatric lymphomas, for which treatment results have improved dur-
ing this time period, with long-term EFS of overall 80–90% for Burkitt and DLBCL [71]. Over-
all survival (OS) for ALCL in young people is indeed about 90%, with a variety of salvage
therapies, principally autologous BMT. However, salvage therapies impart increased long-
term toxicity, very significant for young people, and those who progress on therapy or fail
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salvage have dismal prognoses. Goals for ALCL, as for other pediatric cancers which have
relatively high long-term survival, include preserving outcomes while reducing toxicity
and increasing quality of life.
Targeted agents including crizotinib and the CD30 antibody-drug conjugate brentuximab
vedotin (BV) are very slowly being introduced into relapse and front-line therapy, but results
are not yet available. These include a COG protocol based on ALCL99 (NCT01979536) that
introduces a randomization of crizotinib versus BV in the treatment of newly diagnosed
ALCL, and a phase II treatment of relapsed refractory ALCL using crizotinib with VBL
(CRISP trial, ITCC053) [62].
As ALK inhibitors such as crizotinib find potential roles in ALCL therapy, acquired
resistance is expected [72]. In a study of 11 patients with relapsed/refractory ALK + ALCL,
progression-free survival at 2years was 63.7%, and all patients who progressed showed
molecular evidence of mutations associated with acquired ALK resistance [73].
Crizotinib in ALK + ALCL
Single agent ALK inhibitor crizotinib has been usedwithmoderate success in patients with
relapsed/refractory ALCL. This approach is difficult to test in front-line clinical trials because
of relatively good success with chemotherapy, limiting availability of patients due to ethical
considerations [62]. Additional study of relapsed/refractory patients may lead to more con-
fidence in this approach, particularly if combined with monitoring prognostic biomarkers.
Single agent therapy, which is likely to be prolonged even when effective, may be difficult
to accept in pediatric oncology, a field in which cure is the over-riding goal, and almost all
curative progress has occurred with combination therapies.
Another approach is to combine ALK inhibitor with chemotherapy. This is currently being
tested in one arm of COG protocol ANHL12P1 (NCT01979536) in a backbone of ALCL99, but
data is not yet available. Accrual has been limited by unexpected toxicity on that arm.
One cell line study suggests that there is antagonism between crizotinib and doxorubicin,
which is a component of ALCL99 and of many chemotherapy regimens. Expression profiling
of treated cell lines showed that while crizotinib restored normal cell signaling to ALK driven
cell lines, with associated apoptosis, doxorubicin disrupted cell signaling and antagonized
apoptosis [40]. Neither brentuximab vedotin (BV) nor vinblastine had significant effects on
cell signaling. BV synergized apoptosis, with vinblastine showing a trend toward synergy.
While it may be surprising that BV and crizotinib could act synergistically since BV is an
anti-CD30 drug conjugate and crizotinib downregulates CD30 [35], drugs in that study were
introduced into cell cultures almost simultaneously, allowing at least an initial CD30 target,
and results were scored at 24h to preserve viable cells for expression analysis. Preliminary
data of apoptosis and growth inhibition for that study had not identified antagonism between
crizotinib and other drugs commonly used in pediatric NHL (unpublished data), so this an-
tagonismmay be specific to doxorubicin (and likely other anthracyclines) rather than being a
general effect of chemotherapy. It has been argued that anthracycline-based therapies (such
as CHOP) are ineffective for peripheral T-cell lymphomaswith the exception of ALK +ALCL,
which responds relatively well [74, 75]. If there is interference between ALK inhibition and
anthracycline, and since ALCL99 is the favored backbone for ALK + ALCL, then regimen
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modifications including timing, dosages, and constituent drugs will be critical for inclusion
of ALK inhibitors, as is usual in therapeutic design. In regard to other chemotherapy,
a European trial (ITCC053) including use of vinblastine in combination with crizotinib in re-
lapsed/refractory ALCL with ALK aberrations was opened but is currently halted. Other
drugs suggested to enhance ALK inhibition include the mTOR inhibitor Everolimus, and a
bromodomain inhibitor, OTX015/MK-8628 [76, 77].
Immune based therapies
Brentuximab vedotin, produced by Seattle Genetics, was the first antibody-drug conjugate
(ADC) to be approved by the US FDA. Approval was granted in 2011 for adults with re-
lapsed/refractory Hodgkin lymphoma (HL) and ALCL. This was extended to first line treat-
ment in combination with chemotherapy (doxorubicin, vinblastine, dacarbazine) in 2018 and
also includes other CD30+ T-cell lymphomas. BV consists of a chimeric monoclonal anti-
CD30 linked to the compoundmonomethyl auristatin E (MMAE), a potent anti-tubulin agent.
The ADC attaches to the tumor cell, is internalized by endocytosis, and its’ effects are focused
on the neoplastic cells with little bystander effect. ADC design revolves around three compo-
nents: the antibody, the linker, and the conjugated drug [78].
Generally speaking, the antibody should be directed to an antigen differentially expressed
on tumor cells to facilitate anti-tumor effect and minimize off-target toxicities, have sufficient
affinity to the target, and be internalized by the cell. Linkers must be stable enough for the
complex to circulate to the tumor, and allow release of the drug; both cleavable and non-
cleavable linkers are in use. The drug component must be sufficiently potent, chemically able
to be attached to the linker, and both soluble and stable under physiologic conditions.
Auristatins such as MMAE are analogs of dolastatin-10, derived from the sea hare Dolabella
auricularia, which inhibit tubulin polymerization with a potency 20–50 times that of vinblas-
tine [78]. Monomethy auristatin F (MMAF) is related but is soluble and thus can diffuse
regionally. Another class of tubulin inhibitor used in ADCs is that of maytansinoids, derived
from the bark of an African shrub and which acts similarly to vinca alkaloids. These include
ermtansine/mertansine (DM1), ravtansine/soravtansine (DM4), and ansamitocin [79].
A third class of drug is derived from the potent antibiotic calicheamicin, which cleaves double
stranded DNA, and those of a fourth commonly used class, the duocarmycins, are DNA
alkylating agents [78].
ADCs developed for the treatment of lymphoma and leukemia are predominantly targeted
toward B-cells, for use in acute lymphoblastic leukemia (ALL) and B-cell lymphomas. These
include naratuximab emtansine, a CD37 ADC for NHL, polatuzumab vedotin, a CD79b ADC
for treatment of diffuse large B-cell lymphoma, coltuximab ravtansine, a CD19 specific anti-
body labeled with DM4, denintuzumab mafodotin, a CD19 antibody conjugated to MMAF,
inotuzomab ozogamicin, anti-CD22 ADC useful for B ALL, and others including those spe-
cific for CD25 [80, 81]. Anti-CD25 ADCs could presumably be utilized for ALCL, since many
or most ALCL are positive for CD25. Anti-CD25 ADCs have previously been tested on other
lymphomas including HL and adult T-cell leukemia/lymphoma, with promising results
[82, 83]. Gemtuzumab ozogamicin is an anti-CD33 ADC useful in treatment of acute myeloid
leukemia [84].
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CD30 is an ideal target for ADC immune therapy. It is highly expressed on tumor cells of
ALCL, HL, and some other lymphomas, but is normally only expressed on activated lym-
phocytes with limited distribution, predominantly in lymph node perifollicular regions,
and in the paracortex in infections such as Epstein Barr Virus (EBV), thus limiting potential
toxicity. It is a member of the tumor necrosis factor receptor (TNFR) superfamily and is in-
tegral to the pathobiology of both ALCL and HL, however, it’s cell signaling functions vary
with tumor type and cell lines studied. It is also released as circulating CD30 in lymphoma
and in infections [85].
A variety of unconjugated anti-CD30 monoclonal antibodies have been tested against
CD30+ lymphomas, eachwith differing immunologic effects. One chimeric (murine/human)
anti-CD30 antibody, cAC10, was tested and found safe in phase I trials, but without demon-
strated subsequent efficacy. This drug, SGN-30, was modified with conjugation to MMAE,
and became SGN-35 (BV) [85].
Bi-specific monoclonal antibodies (BimAbs) offer another potential option for targeted
immune therapy which may be combined with other relevant treatments. These antibodies
are engineered to have two binding sites, one for tumor cells, and another for T-cell
costimulatorymolecules. These bring activated T-cells to the tumor cells to facilitate tumor cell
killing [86, 87]. Blinatumomab, an anti-CD19 bi-specific, has shown promise in treatment of B-
ALL andB-cell lymphomas. Several anti-CD30BimAbs have been tested inpreclinical studies.
Neither unconjugated antibodies nor BimAbs have thus far shown the efficacy of BV [85].
Chimeric antigen receptor T-cells (CAR-T) have also found a role in the treatment of B-ALL
and B-cell NHL [86]. CD30-specific CAR-T have been tested in patients with ALCL and HL,
found to be safe, with 5 of 7 HL patients and 1 of 2 ALCL patients showing CR of variable
durations in one study [88]. Another study of 17 patients with HL and 1 with cutaneous
ALCL, showed the treatment to bewell tolerated, with 7 partial remissions (PR) and 6 patients
with stable disease (SD) [89].
At this time, BV is the principle ADC and principle immune based therapy available for
ALCL. It was tested in phase I and phase II trials of adult ALCL, both ALK positive and
ALK negative, and other CD30+ lymphomaswhich had failed therapy, with favorable results
(up to 64% 4years OS) [72, 90]. BVwas approved by the FDA in 2011 for treatment of ALCL in
relapse/progression after failure of at least one multi-agent chemotherapy protocol. Multiple
trials have been performed on HL in adults, with promising results, and one protocol
combining BV and chemotherapy for pediatric HL is ongoing (active, not recruiting;
NCT02166463). The BV arm of COG ANHL12P1 (NCT0179536), trialing BV or crizotinib in
a backbone of ALCL99 has completed accrual [72]. BV has large molecular weight
(150kDa) and likely does not easily penetrate the blood brain barrier. It has been described
in a case study, however, in combination with intrathecal methotrexate, to successfully treat
CNS progression of ALK + ALCL on front line therapy of ALCL99 [91]. Whether BV contrib-
uted substantially is difficult to know.
A novel anti-CD30 ADC has recently been described that is conjugated to lidamycin
(enediyne containing antibiotic) and performedwell on CD30 cells lines in vitro and inmouse
models [92]. Another utilizing a novel anti-CD30 antibody conjugated to DMI was found ac-
tive in ALCL cell lines in xenographs [93]. Yet another anti-CD30 lidamycin (LDM) conjugate
was produced and found to synergize with crizotinib in xenographs of Karpas 299 and
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SUDHL-1 ALCL cell lines [94]. These cell lines, incidentally, are utilized in virtually all cell
line studies of ALK+ ALCL reported in this review. Another ADC utilizes an ALK antibody
(CDX-0125) labeled with thienoindole (TEI) DNA alkylating agent, and found to be active
against ALK+ neuroblastoma cell lines [95]. This may be helpful in those cases of ALK+
ALCL that express surface ALK, on the order of possibly 33% [21].
Immunotherapy utilizing immune checkpoint inhibitors including those targeting
programmed cell death 1 (PD1), it’s ligands PD-L1 and PD-L2, and CTLA-4, may also be use-
ful to augment other therapy. ALK+ ALCL is positive for PD-L1 in approximately 76% of
cases [96]. This appears to be mediated through STAT3 activation and subsequent action
of IRF4 and BATF3 on the enhancer region of CD274 (PD-L1). This suggests that ALCL
may be amenable to treatment with PD1/PD-L1 blockade [97]. Immune checkpoint blockade
has shown some success in HL, and nivolumab (anti-PD1) is currently being evaluated in a
phase II trial of pediatric and adult relapsed/refractory ALK+ ALCL [98].
Introduction of immune checkpoint inhibitors to front-line treatment of ALK+ALCL faces
thesamechallengesasdoothernovel therapies inadiseasewhichusually responds tostandard
therapies and for which there are few refractory/relapsed patients to test. Pre-clinical screen-
ing for potential efficacy ofmixedmodality targeted therapy ismore complicated than screen-
ing cell lines for drug effects, in that immune therapies often require an intact immune system.
In-vitro systems to assess immune response, such as using allogeneic or autologous immune
cells tomeasure anti-tumor effects aswell as to effect therapy, are advancing [99].ALK+ALCL
are ideal candidates for these advances since theyhave strong immune components, including
eliciting antibody responses, and having high levels of PD-L1 expression [100].
Conclusion
In the future, we may test patient tumor cells for treatment sensitivities similarly to how
bacterial diseases are tested for antibiotic sensitivity. Eventually, combinations of targeted
therapies with increased efficacy and less toxicity than chemotherapy will likely emerge.
In the short term, clinical trials of targeted therapy for ALK+ ALCL will proceed on re-
lapsed/refractory patients, and as promising combinations are found, and as risk factors
for treatment failure are clarified, these therapies may move to the front line. ALK inhibitors
might best be used transiently, but if use is prolonged enough for development of resistance,
the experience obtained from NSCLC will provide invaluable guidance.
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Abstract
Alterations in the ALK gene are found in 8% of familial and sporadic neuroblastoma cases. The frequency of
ALK aberrations in high-risk neuroblastomas is 14% (10% point mutation and 4% amplification) at the time of
diagnosis, with increasing number of aberrations at tumor relapse (Bresler et al., 2011). Despite recent advance-
ments in ALK-targeted therapies, ALK inhibitor potency eventually diminishes, and drug resistance emerges
after initial successful treatment. To improve drug efficacy and overcome resistance to ALK inhibitors, com-
bined regimens with chemotherapy or other targeted therapies showed superior anti-tumor effects in preclin-
ical and early clinical studies, making it a promising strategy for neuroblastoma treatment.
Abbreviations
ALCL anaplastic large-cell lymphoma
ALK anaplastic lymphoma kinase
ATRX alpha thalassemia/mental retardation syndrome X-linked
CDKN2A cyclin dependent kinase inhibitor 2A
CR complete response
CTX cyclophosphamide
DDR discoidin domain receptor
161Therapeutic Strategies to Overcome ALK Resistance in Cancer # 2021 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/B978-0-12-821774-0.00003-6
EFS event free survival
ERK extracellular signal-regulated kinase
FOXM1 forkhead box M1
IGF1R insulin-like growth factor-1 receptor
INRG International Neuroblastoma Risk Group
INSR insulin receptor
JAK Janus Activated Kinase
MAPK mitogen-activated protein kinase
MDM2 mouse double minute 2 homolog
MET mesenchymal epithelial transition
MS mass spectrometry
MTC medullary thyroid cancer
MTD maximum tolerated dose
NSCLC non-small cell lung cancer
PI3K phosphoinositide 3-kinase
PK pharmacokinetics
RET Ret proto-oncogene
ROS1 ROS proto-oncogene 1
RP2D recommended phase 2 dose
RPTOR regulatory associated protein of MTOR complex 1
SD stable disease
STAT signal transducer and activator of transcription
TKI tyrosine kinase inhibitor
TOPO topotecan
TRK tropomyosin receptor kinase
Conflict of interest
No potential conflicts of interest were disclosed.
Introduction
Neuroblastoma
Neuroblastoma is the most common extracranial pediatric solid tumor originating from
the sympathoadrenal lineage of the neural crest. Primary tumors usually initiate in the adre-
nal glands, but can also develop in the neck, chest, abdomen, or spine. The International Neu-
roblastoma Risk Group (INRG) Task Force has established a classification system to stratify
neuroblastoma patients into four categories: very low-risk, low-risk, intermediate-risk, or
high-risk. Classification is based on different prognostic factors: the stage of the disease
according to the INRG staging system, age at time of diagnosis, tumor histology/differenti-
ation, MYCN amplification, Chromosome 11q status, and tumor cell ploidy. Low- and
intermediate-risk forms of neuroblastoma are highly curable, while the survival rate of
high-risk disease is only 40% despite aggressive multimodal therapy. Survivors of high-risk
disease also often suffer from severe side-effects associated with drug toxicities [1, 2]. With a
greater understanding of tumor biomarkers and molecular aberrations in neuroblastoma,
targeted therapies are being developed to explore novel, less toxic, and potentially more
efficacious treatments for this malicious disease [3]. However, relapse and fatality may
occur due to de novo or acquired drug resistance, especially in high-risk neuroblastoma
patients [4, 5].
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Recent genome-wide sequencing analyses in large neuroblastoma patient cohorts contrib-
ute to spotlighting the genetic basis of neuroblastoma. Next-generation sequencing-based
genomic profiling identified the most frequent alterations including MYCN (26.5%), ALK
(17.8%), ATRX (6.5%), CDKN2A (4.8%), and RPTOR (4.8%) in 230 neuroblastoma patient
samples. [6–10].
ALK variants in neuroblastoma
In 2008, several groups discovered ALK mutations, including germline missense muta-
tions and somatically acquired mutations, in high-risk neuroblastoma patients [11–13]. Mu-
tated kinases were autophosphorylated and displayed increased kinase activity compared
with thewild-typeALK. So far, more than 35ALK variants, predominantly pointmutations,
have been detected in neuroblastoma [14], with fewer cases involving a truncated extracel-
lular domain [15, 16] and BEND5-ALK fusion protein [10]. Almost all cases of familial
neuroblastoma (<2% of all neuroblastoma) bear ALK mutations [17]. Three common path-
ogenic variants, p.Arg1275Gln (R1275Q), p.Gly1128Ala (G1128A) and p.Phe1174Leu
(F1174L), were identified in familial neuroblastoma patients, among which R1275Q ac-
counts for 45% of ALK germline mutations [7, 11]. ALK mutations have also been reported
in 6–10% of sporadic neuroblastoma cases [18]. Twelve different ALK active mutations have
been identified to associate with sporadic neuroblastoma, including two of the most com-
mon ALK variants, F1174L and R1275Q [19]. ALK amplifications have also been reported in
2% of primary neuroblastoma tumors [7]. More interestingly, ALK mutations appear to be
further enriched in relapsed patients, either through subclonal mutation selection or addi-
tional mutations acquired during therapy [20–22].
In neuroblastoma, most of ALK pathogenic variants are found within the tyrosine kinase
domain of ALK and cause constitutive autophosphorylation and activation of the ALK pro-
tein and downstream cellular pathways, including the MAPK and RAS-related protein 1 sig-
nal pathways [23, 24], the PI3K (phosphatidylinositol 3-kinase)/Akt [25], and the JAK/STAT
(Janus activated kinase/signal transducer and activator of transcription) [26] pathways.
ALK inhibitors in neuroblastoma
Crizotinib is the most extensively studied ALK inhibitor in neuroblastoma. It is an oral
small-molecule tyrosine kinase inhibitor, originally developed as a c-MET inhibitor, and later
found to be an inhibitor for ALK phosphorylation [27, 28]. In vitro studies demonstrated that
crizotinib was potent in neuroblastoma cell lines with ALK amplification or the R1275Q
mutation, one of themost commonALK variants in neuroblastoma [29], whereas cells bearing
F1174Lmutation are relatively crizotinib-resistant [11, 12, 30, 31]. In vivo, crizotinib treatment
causes complete and sustained regression of xenografts with R1275Q mutation, but it has
limited effects on the growth of F1174L-positive tumors [14]. Single agent crizotinib has been
tested for the treatment of pediatric solid tumors through a COG Phase 1/2 trial which
determined the RP2D to be 280mg/m2/dose twice daily [32]. From the 11 enrolled patients
with ALK mutations and rearrangements, only one patient had a CR and two had SD. Drug
resistance becomes a real challenge with crizotinib.
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In order to address secondary resistance to crizotinib, new generations of ALK TKIs,
including ceritinib, AP26113, alectinib, ensartinib (X-396), entrectinib (RXDX-101), belizatinib
(TSR-011) and lorlatinib (PF06463922) have been developed in clinical use for adult patients
[33, 34]. Lorlatinib, a selective next-generation ROS1/ALK inhibitor, has high potency across
ALK variants, R1275Q, F1174L and F1245C mutations. It induces complete tumor regression
in both crizotinib-resistant and crizotinib-sensitive neuroblastoma xenograft models, as well
as in patient-derived xenografts [34]. A pediatric phase 1 trial of lorlatinib (NCT03107988) is
underway in patients with relapsed/refractory neuroblastoma. Lorlatinib will be utilized
both as a single agent and in combination with chemotherapy with cyclophosphamide and
topotecan. A new ALK/IGF1R inhibitor AZD3463 is designed by AstraZeneca to overcome
the acquired resistance to crizotinib. This new drug suppresses cell proliferation of
neuroblastoma cell lines with wild-type ALK as well as ALK-activating mutations (F1174L
and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway. In addition,
AZD3463 also exhibits significant therapeutic effects on the growth of the neuroblastoma
tumors bearing an ALKF1174L mutation in orthotopic xenograft mouse models [35]. A novel
ALK inhibitor alectinib (5-chloro-2,4-diaminophenylpyrimidine) has been tested in neuro-
blastoma preclinical models and shows substantial inhibitory effects against tumors
with ALKmutations, including ALKL1152R, ALKF1174L, and ALKD1091N [36, 37]. Most recently,
the next-generation inhibitor repotrectinib (TPX-0005), which targets the active kinase confor-
mations of ALK, ROS1 and TRK receptors, is capable of inhibiting signaling activity of a range
of ALKmutant variants and reducing tumor growth in a neuroblastoma xenograftmodel [38].
Combined therapy with ALK inhibitors
It is becoming increasingly clear that monotherapy simply inhibiting a single upstream tar-
get, in many cases, is not enough to hinder cancer cell growth. In a Children’s Oncology
Group phase 1 consortium study, 11 patients with neuroblastoma with known ALK muta-
tions were treated at doses ranging from 100 to 365mg/m2 per dose. Out of 11 patients, only
one had a complete response (9%), and two had stable disease [39], which suggests that
crizotinib monotherapy is not efficient to treat neuroblastoma. Combined therapy with other
antitumor agents may help to maximize treatment benefit and overcome the limitations of
single-agent ALK inhibitors for neuroblastoma.
In addition, similar to other small-molecule tyrosine kinase inhibitors (TKI), crizotinib in-
variably loses its potency, and drug resistance emerges after initial successful crizotinib treat-
ment in neuroblastoma patients, which has also occurred in other types of cancer [40, 41].
Crizotinib resistance may develop as a consequence of secondary mutations in the ALK ty-
rosine kinase domain, or amplification of the ALK locus, which is also called ALK-dependent
resistance [42, 43]. In other cases, crizotinib resistancemay also arise from pre-existingminor-
ity ALK variant populations with drug resistance due to intratumor heterogeneity in neuro-
blastoma tumors. Another mechanism of ALK inhibitor resistance is ALK-independent, by
which tumor cells switch to alternative signaling pathways to evade ALK inhibitor-induced
apoptosis.
To overcome drug resistance to ALK inhibitors, alternative treatment approaches would
be required, such as increased dose of ALK inhibitors, transition to newer generations of
ALK inhibitors, or addition of inhibitor(s) to the alternative pathways into existing ALK
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inhibition therapy. Unfortunately, with increased dose of crizotinib or newer generations of
ALK inhibitors, despite exhibiting more potent initial response to ALK inhibition, many
patients eventually develop resistance with secondary mutations. Therefore, targeting these
bypass mechanisms becomes crucial to enhancing treatment efficacy and reversing drug re-
sistance, by which a superior anti-tumor activity and reduction of tumor relapse could be
achieved in neuroblastomas with ALK mutations. Several alternative signaling pathways
and oncogenic drivers have been identified in neuroblastoma, including cyclin-dependent
kinase, p53, PI3K-mTOR, MEK/ERK, ALK-ETV5-RET axis, insulin-like growth factor-1 re-
ceptor (IGF1R)/INSR, etc. [22].
Crizotinib and chemotherapies
Topotecan alone and in combination with chemotherapies such as cyclophosphamide, has
been studied in several single andmulti-institutional phase I and II trials and proved tolerable
and effective in relapsed and newly diagnosed neuroblastoma [44–46]. In the Children’s On-
cology Group (COG) study, 57 patients were treated with topotecan and cyclophosphamide
(TOPO/CTX), and 62 patients were treated with topotecan alone for up to 1year. TOPO/CTX
proved superior to TOPO in PFS, with a trend toward superior response rate, but no improve-
ment in OS. Currently, TOPO/CTX regimens are also being incorporated into several phase I
and II trials as backbones to combine with targeted therapies for the treatment of high-risk or
refractory neuroblastoma.
ALK inhibitor in combination with TOPO/CTX was also studied in neuroblastoma.
Krytska et al. [47] combined crizotinib with TOPO/CTX in human neuroblastoma-derived
cell lines and patient-derived xenograft models. In their study, combined regimen showed
enhanced cytotoxic effects compared to crizotinib or chemotherapy alone in vitro. In vivo,
combined therapy not only induced rapid and sustained tumor regression with improved
EFS, but also restored sensitivity in preclinical models harboring ALK aberrations (both
ALK mutation and amplification). Complete responses were maintained even 24weeks after
treatment was completed. Another preclinical study tested crizotinib combined with low-
dose metronomic topotecan in neuroblastoma and demonstrated that single-agent crizotinib
showed limited anti-tumor activity in ALKF1174L-mutated neuroblastoma xenograft models.
However, when combined with low-dose metronomic administration of topotecan, signifi-
cantly delayed tumor development was observed. In addition, relapsed tumors remained re-
sponsive to combined therapy [48]. This enhanced anti-tumor activity was probably achieved
through targeting hypoxia-related pathways. Hypoxia regulates tumor cell proliferation, mi-
gration, and invasiveness through the expression of a group of transcription factors called
hypoxia-inducible factors (HIFs) [49, 50]. Topotecan, especially daily metronomic topotecan,
induces oxidative stress and down-regulates HIF-1 alpha expression in cancer cells [51–53]. It
was also demonstrated that ALK specifically regulates HIF-1α expression under hypoxia con-
ditions in both ALCL and NSCLC [54]. A COG phase 1 trial of crizotinib in combination with
dose intensity TOPO/CTX has been conducted in children with relapsed and refractory solid
tumors. The RP2D of crizotinib was 215mg/m2/dose twice daily when combined with che-
motherapy (NCT01606878) [41]. A phase 3 clinical trial is underway to determine whether the
addition of crizotinib to standard therapy improves the survival of patients with newly-
diagnosed high-risk neuroblastoma (NCT03126916).
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ALK inhibitor ceritinib and CDK4/6 inhibitor ribociclib
Ribociclib (LEE011) is an orally bioavailable, small molecule inhibitor of both CDK4 and
CDK6. In vitro, ribociclib caused cell-cycle arrest and cellular senescence with reduced phos-
phorylation of the retinoblastoma (Rb) protein and the transcription factor FOXM1. In vitro
screening of a panel of more than 500 cell lines constituting the Novartis Cancer Cell Line
Encyclopedia identified neuroblastoma to be among the most sensitive cell lines to ribociclib
treatment [55]. Ribociclib significantly reduced cell proliferation in 12 out of 17 human
neuroblastoma-derived cell lines, and caused tumor growth delay in vivo [56]. From a Phase
1 clinical trial [57], ribociclib demonstrated acceptable safety and pharmacokinetics (PK) in
pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors.
MTD (470mg/m2) and RP2D (350mg/m2) were equivalent to those in adults.
Wood and colleagues [58] investigated the combination of ceritinib and ribociclib against
17 comprehensively characterized human neuroblastoma-derived cell lines. In their study,
the combination of ribociclib and the ALK inhibitor ceritinib demonstrated synergistic
antitumor effects in cell lines with ALK mutations. Compared to single-agent treatment,
combined therapy significantly reduced cell proliferation, enhanced cell cycle arrest, and
caspase-independent cell death. In vivo, combination therapy induced complete regression
in xenograft models with ALK-F1174L and F1245C mutations. For ceritinib-resistant SH-
SY5Y xenografts, combined ceritinib and ribociclib treatment also achieved complete and
sustained regressions, and prolonged event-free survival (EFS) compared to either of the sin-
gle agents. Their synergistic antitumor activity was achieved by targeting both the receptor
tyrosine kinase ALK and cell cycle oncogenic network. Based on this study, The Children’s
Hospital of Philadelphia recently initiated Next Generation Personalized Neuroblastoma
Therapy (NEPENTHE) trial (NCT02780128), a Phase 1 clinical trial, to study the combination
therapy of ceritinib and ribociclib in relapsed or refractory neuroblastoma patients. Their
qualified participants with ALK mutations are selected based on genetic sequencing results
from tumor biopsy.
ALK inhibitor ceritinib and p53 activation
Another drug combination study targeting both ALK and p53 pathways also showed
prominent anti-tumoral potential in p53 wild-type neuroblastoma. In p53 wild-type tumors,
p53 function is frequently impaired by two major negative regulators, MDM2 and its homo-
log MDMX. MDM2 induces p53 degradation via its E3 ligase activity. It can also bind to the
N-terminal transactivation domain of p53, blocking its transcriptional activity [59]. Small
molecules targeting MDM2, such as NVP-CGM097, block the p53-binding site of MDM2
and prevents its interaction with p53. Thus, NVP-CGM097 exerts its antitumor activity by
stabilizing p53 and activating the p53 pathway.
Wang et al. [60] examined the anti-proliferative effect of the MDM2 inhibitor NVP-
CGM097 in a panel of neuroblastoma cell lines, including five TP53 mutant and six TP53
wild-type cell lines. Consistent with the molecular mechanisms of MDM2 inhibitors, the
TP53 wild-type neuroblastoma cell lines were significantly more responsive to NVP-
CGM097 treatment than the TP53 mutant cell lines.
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In their in vivo study, NVP-CGM097 alone at 50mg/kg/day demonstrated no inhibition of
tumor growth, while the combination of ceritinib with NVP-CGM097 promoted apoptosis in
the ALK mutant/TP53 wild-type neuroblastoma. Combination therapy also induced com-
plete and durable tumor regression and prolonged animal survival in neuroblastoma xeno-
graft models. More interestingly, combined therapy overcomed acquired ceritinib resistance
caused by MYCN upregulation in an ALK-driven neuroblastoma model. This group also
investigated the molecular mechanism of synergy between the ALK and MDM2 inhibitor.
Ceritinib inhibited phospho-ALK, phospho-AKT and phospho-ERK signaling, which dem-
onstrated effective ALK pathway inhibition. NVP-CGM097 treatment resulted in an increase
in p53 expression and induction of its target genes, including p21,MDM2 and PUMA, in TP53
wild-type neuroblastoma cells, while p53 protein or its downstream effectors were not af-
fected in TP53-mutant cells. Thus, ceritinib andNVP-CGM097 target two complementary sig-
nal pathways, both anti-proliferative and apoptosis-stimulating signals, which causes
synergistic antitumor effects and overcomes ceritinib drug resistance [60].
Targeting MYCN signals
ALKF1174L is the most aggressive ALK mutations in neuroblastoma. It possesses high
transforming potential and is often accompanied by theMYCN oncogene amplification. Both
ALK andMYCN genes are located in chromosome 2p, a chromosomal alteration identified as
a statistically significant prognostic factor [61]. It has been shown that ALK and MYCN drive
tumor malignancy cooperatively. Activation of ALK increases the expression of MYCN by
enhancing the activity of the MYCN promoter and stabilizing MYCN protein likely via acti-
vation of the AKT and ERK pathways [24, 25, 62]. In vivo, compared to ALKF1174L andMYCN
alone, co-expression of these two oncogenes leads to the development of neuroblastoma tu-
mors with earlier onset, higher penetrance and enhanced lethality [25, 63, 64]. In our study,
neuroblastoma cells harboring both ALKF1174L mutation and MYCN amplification showed
less response to an ALK inhibitor crizotinib than to other variants [48].
Directly targeting MYCN has proven to be technically challenging due to a lack of appro-
priate surfaces on its DNAbinding domain for small molecule binding [65]. Also, sinceMyc is
predominantly located in the cell nucleus, targeting Myc with monoclonal antibodies is tech-
nically impractical. Alternative approaches to indirectly abrogate Myc functions are being in-
vestigated. The PI3K/AKT/mTOR pathway appears to play an important role in MYCN
stabilization, therefore, targeting the PI3K/AKT/mTOR pathway becomes a good option
to attenuate MYCN signals.
Moore et al. [66] showed that in ALKF1174L/MYCN-amplified neuroblastoma cells,
crizotinib alone did not affect mTORC1 activity as evidenced by persistent RPS6 phosphor-
ylation. Combined treatment with crizotinib and an ATP-competitive mTOR inhibitor,
Torin2, inhibited RPS6 phosphorylation, enhanced antitumor activity and prolonged survival
in ALKF1174L/MYCN-amplified neuroblastoma models compared to single-agent treatment.
However, in MYCN wild-type tumors, this combination induced mTORC1 downregulation,
but at the same time caused upregulation of PI3K activity. Therefore, no synergistic or
additive cytotoxicity was observed in MYCN wild-type neuroblastoma. To overcome the
limitation of this selective mTOR inhibitor in MYCN wild-type tumors, Moore et al. tried
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to block both mTOR and PI3K signals with PF-05212384, a dual inhibitor against both mTOR
and PI3K, and combined PF-05212384 with crizotinib treatment. As expected, synergistic ac-
tivity was achieved in neuroblastoma cells with non-amplified MYCN. As indicated in this
study, understanding themolecular basis of drug resistance is crucial for designing new com-
bination strategies to improve antitumor activity and overcome ALK-TKI drug resistance.
Targeting both ALK and its downstream signals
Here is another strategy to enhance the treatment efficacy and avoid ALK-TKI resistance
by blocking both ALK activity and its downstream signals together. In ALK-positive tumors,
several downstream signal pathways have been reported in ALK activation, including ERK5,
RET, IGF1R/INSR, PI3K-AKT-mTOR, RAS-MAPK, etc. [66–70].
Extracellular signal-regulated kinase 5 (ERK5) serving as a downstream target in the ALK
pathway, is known as big mitogen-activated protein kinase 1 (MAPK1), a member of the
MAPK family. ERK5 has autophosphorylation activity, which phosphorylates MEK5 and
activates downstream transcription factors. ERK5 is required for epidermal growth factor
(EGF)-induced cell proliferation, cell cycle promotion, and cellular transformation [71]. In
neuroblastoma, ERK5 activation was also required for ALK-induced transcription of the on-
cogene MYCN and the stimulation of cell proliferation [69]. Umapathy and colleagues
showed that treatment with either crizotinib or PI3K pathway inhibitors diminished the
levels of phosphorylated ERK5 in the nucleus and reduced MYCN expression, which indi-
cates that ALK-driven ERK5 activation is mediated by the PI3K-AKT pathway [72]. With
ALK-positive, MYCN-amplified neuroblastoma cell lines, in vitro studies showed inhibition
of cell proliferation by either the ERK5 inhibitor XMD8-92 or ERK5 siRNA. Combined treat-
ment with crizotinib and XMD8-92 synergistically suppressed neuroblastoma cell prolifer-
ation. Further in vivo, dual inhibition of ALK and ERK5 abrogated tumor growth
synergistically and resulted in reduced expression of MYCN in tumor cells. These findings
suggest that concomitant ALK and ERK5 inhibition may provide another effective regimen
to suppress oncogenic MYCN signaling, and potentially overcome crizotinib resistance in
ALK-positive neuroblastoma.
The oncogene RET has also been reported as a molecular target of ALK activation in both
human neuroblastoma cell lines and primary tumors [73, 74]. Cazes et al. developed a neu-
roblastoma mouse model with endogenous expression of mutated ALK in a MYCN trans-
genic context (MYCN/ALKmut). They compared transcriptomic profiling between mouse
MYCN/ALKmut and MYCN/ALK wild-type tumors and found that the RET oncogene
was upregulated in ALK-mutated tumors [73, 74]. They further demonstrated a strong cor-
relation between RET and ETV5 expressions and showed that ALK activation induced ETV5
protein upregulation in a MEK/ERK-dependent manner. Inhibition ETV5 with siRNA de-
creased RET expression both at the protein and mRNA levels. Therefore, RET upregulation
by activated ALK was achieved through an ALK-ETV5-RET axis. With ChIP-seq analysis,
Cazes and colleagues further confirmed that ETV5 took part in the transcriptional regulation
of the RET gene by binding on the RET promoter and acted as an upstream enhancer. In
mouse models, tumor growth of MYCN/ALKmut tumors was inhibited by a RET inhibitor,
vandetanib, indicating RET as a potential therapeutic target in ALK-mutated neuroblastoma.
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They also investigated the effect of the crizotinib/vandetanib combination therapy after al-
lograft of a MYCN/AlkF1178L tumor in nude mice. Tumor-bearing mice were treated with ve-
hicle, crizotinib (100mg/kg/day) or a combination of crizotinib (100mg/kg/day) and RET
inhibitor vandetanib (30mg/kg/day). A strong reduction in tumor growth was observed
in mice treated with the combination agents compared to the vehicle control, and this effect
wasmore potent than each single agent. A prolonged event-free survival was also achieved in
mice treated with the combination therapy. There is an ongoing multicenter phase 1/2 trial
with LOXO-292, a highly selective RET inhibitor, in patients with advanced solid tumors, in-
cluding RET fusion-positive solid tumors,medullary thyroid cancer (MTC), and other tumors
with RET activation (NCT03157128). Although pediatric neuroblastoma is not included in
this study. Once the drug safety profiles, pharmacokinetic properties and initial treatment
responses are determined in RET activated tumors, it would provide another treatment
option for ALK-resistant neuroblastoma.
Combined therapy directed by proteomics or genomic profiling
The rapid advances in proteomics-based technologies, especially quantitative proteomic
research, provide us great opportunities to identify drug targets and their downstream
signals. To identify downstream signaling components regulated by ALK network in neuro-
blastoma cells, Eynden et al. [75] performed phosphoproteomics and RNA-sequencing
(RNA-seq) analysis after exposing neuroblastoma cells to the first- and third-generation
ALK TKIs, crizotinib and lorlatinib, and generated both phosphoproteomic and gene expres-
sion signatures reflecting ALK signaling events in different neuroblastoma cell lines. From
Mass Spectrometry (MS)-based phosphoproteomic analysis, with ALK positive cell lines,
crizotinib treatment resulted in a specific inhibition of tyrosine phosphorylation in ALK,
whereas lorlatinib treatment caused decreased phosphorylation of discoidin domain receptor
1 (DDR1), DDR2, and insulin-like growth factor-1 receptor/insulin receptor (IGF1R/INSR) in
addition to ALK inhibition. Neither the selective DDR1 inhibitor DDR1-IN-1 nor the selective
EGFR inhibitor afatinib affected the growth of neuroblastoma cells, which left IGF1R/INSR as
a potential drug target. Emdal and colleagues selected neuroblastoma cell lines with different
ALK profiles: CLB-BAR (gain of function, Δexon4–11 truncated ALK), CLB-GE (gain of func-
tion, ALKPhe1174Val mutation), IMR-32 (wild-typeALK, ligand-dependent activation), and SK-
N-AS (wild-typeALK) for further drug evaluation. All cell lines were treatedwith either ALK
inhibitor (crizotinib or lorlatinib), or an IGF1R/INSR inhibitor (linsitinib), or the combination
of both. It was shown that linsitinib treatment reduced growth of all neuroblastoma cell lines,
whereas crizotinib and lorlatinib were active only in ALK positive CLB-BAR and CLB-GE
cells. Furthermore, linsitinib had an additive effect on the cell proliferation inhibition compar-
ing to the single-agent crizotinib or lorlatinib treatment. Although in vitro results showed
promising effects by targeting both ALK and IGF1R/INSR in ALK positive neuroblastoma
cells, further in vivo studies are required to validate this regimen.
Genome-wide CRISPR activation (CRISPRa) screening was also used to identify bypass
mechanisms of resistance to ALK inhibitors in ALK-positive neuroblastomas. Trigg and
colleagues [76] conducted genome-wide CRISPRa screens in two ALK mutant NB cell lines
SH-SY5Y (ALKF1174L) and CHLA-20 (ALKR1275Q) exposed to brigatinib or ceritinib for
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14days. They identified PIM1 as a putative resistance gene which is often associated with
high-risk disease and poor survival outcomes in neuroblastoma. They further confirmed that
overexpression or knockdown of PIM1 induced resistance or sensitization to ALK inhibitors,
respectively. These findings suggested that combining ALK inhibitors with AZD1208, a
small-molecule pan-PIM inhibitor, may overcome ALK drug resistance. To evaluate the
efficacy of combined ALK and PIM inhibition in vivo, both MYCN wild-type and MYCN-
amplified neuroblastoma cells were tested in their xenograft models. Superior antitumor ac-
tivity was achieved in ceritinib and AZD1208 combination therapy compared to single-agent
ceritinib or AZD1208 treatment. A significant increase in event-free survival was also
observed in animals with combined treatment relative to single-agent therapies. In addition,
combined PIM and ALK inhibition is effective independent of MYCN status in
neuroblastoma cells.
Conclusion
Among all identified oncogenic mutations in neuroblastoma, ALK is the second most fre-
quent alterations afterMYCN. It is also one of the most well-studied druggable molecular tar-
gets. During the last decades, considerable advances have been made to understand the
association between ALK genetic aberrations and disease prognosis in neuroblastoma. Incor-
poration of ALK alteration into neuroblastoma stratification may help predict the risk of
recurrence or progression, guide standard therapeutic strategies for neuroblastoma and pro-
vide greater clinical benefit for patients.
For neuroblastoma treatment, ALK inhibitors and their combination with chemotherapeu-
tic drugs are being evaluated at the different stages of clinical trials. Those clinical data pro-
videmore andmore evidence about the development of ALKmutations during the treatment
with ALK inhibitors. Molecular profiling of tumor tissues before and after a tyrosine kinase
inhibitors (TKIs) exposure have been a common method to monitor therapy response and
identify drug resistance mechanisms. Therefore, repeated biopsy of neuroblastoma tumors
at recurrence is critical to understand the underlying molecular changes causing acquired
resistance to ALK-TKI. Also, given the growing number of genetic alterations detected, small
sequencing panels that focus on a limited number of genes may not be sufficient, especially
in highly heterogeneous neuroblastoma tumors. Indeed, molecular profiling with next-
generation sequencing (NGS), RNA-seq or Mass spectrometry-based proteomics could be
used as a standard approach to discover new oncogenic drivers and identify novel drug
targets in neuroblastoma. Of course, tumor molecular profiling for each individual patient
at different stages of treatment will assist physicians choosing more-efficient therapeutic
interventions or adding a second-line treatment to overcome ALK-TKI resistance.
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Abstract
The clinical success of ALK inhibition through targeted therapies is manifestly evident in ALK-rearranged
non-small cell lung cancer (NSCLC). Deciphering resistance mechanisms to targeted agents in ALK-positive
NSCLC has been crucial to develop novel inhibitors and novel treatment strategies, with a continued and re-
ciprocal exchange of evidence between clinical and preclinical research. With the advent of the third-
generation ALK inhibitor lorlatinib in the clinical setting, as well as with the availability of second-generation
agents (e.g., alectinib) in the upfront treatment of ALK-rearranged NSCLC, novel scenarios of resistance have
recently emerged. In parallel, moving ALK inhibition in disease setting earlier than the advanced/metastatic
one would likely demand new concepts and methodologies.
Whereas the evidence of resistance mechanisms to ALK inhibitors are scarce in ALK-dependent tumors
other than lung cancer, biological and clinical specificities can be recognized. The relevant results obtained
in NSCLC should serve as an example for other ALK-driven diseases.
Abbreviations
ALK anaplastic lymphoma kinase
NSCLC non-small cell lung cancer
ACLC anaplastic large cell lymphoma
IMT inflammatory myofibroblastic tumor
TKI tyrosine kinase inhibitor
EGFR epidermal growth factor receptor
PFS progression-free survival
OS overall survival
HR hazard ratio
CI confidence interval
NR not reached
CNS central nervous system
ctDNA circulating tumor DNA
PD-L1 programmed death-ligand1
CT computed tomography
PET positron emission tomography
HSCT hematopoietic stem cell transplantation
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Introduction
Over the last 25years, the understanding of the biological underpinnings of the ALK on-
cogene has led to parallel major clinical improvements for patients affected by ALK-driven
cancers.
Firstly, the identification of ALK rearrangements and mutations allowed to identify spe-
cific pathological-molecular entities across tumor types. This is the case for ALK-rearranged
non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ACLC), inflammatory
myofibroblastic tumor (IMT) and ALK-mutant neuroblastoma. Of note, taking into account
the detection of activating events involving ALK in additional malignancies at lower frequen-
cies, virtually every solid tumor type can be characterized by a subset driven by ALK. ALK-
positive diseases can be globally defined as raremolecular entities of common-to-rare cancers
(NSCLC, lymphomas, pediatric malignancies and other), acquiring a relevant epidemiologic
significance if taken together [1]. With the broad diffusion of next-generation sequencing
techniques, hopefully no cancer harboring an ALK-driven event should be missed. Even
more importantly, the identification of ALK driver events holds clinical and therapeutic re-
percussions in every single patient, as an eminent example of precision medicine.
Secondly indeed, the intrinsic physiological nature of ALK as a receptor tyrosine kinase,
together with its constitutive activation in case of molecular oncogenic events, boosted the
development of specific tyrosine kinase inhibitors (TKIs). The clinical results obtained since
the introduction of these targeted agents are recapitulated by the outstanding achievements
observed in patients suffering from ALK-rearranged, advanced/metastatic NSCLC. With re-
gard to these patients, the quest for longer survival outcomes has been made possible by the
rapid availability of several ALK-TKIs and by novel strategies regulating the timing of their
administration (sequential versus more-potent TKI upfront) [2]. The mentioned ALK-driven
tumors other than advanced NSCLC are characterized by their predominance in younger
ages and by potential curability (see Chapter 4). In this setting, the integration of ALK inhib-
itors into the treatment armamentarium should aim to increase the rate of cure, with reduced
long-term toxicities.
As approached in the previous Sections, deciphering the ways ALK-driven tumors escape
to targeted agents is the pillar for achieving the best outcomes for today’s and tomorrow pa-
tients, with a continuous and reciprocal interaction between preclinical research and clinical
practice (Fig. 1).
In this last Chapter, we resume the current state of the art, the benchmark for further
developments and applications in the field of ALK resistance mechanisms.
Dealing with resistance in ALK-rearranged NSCLC: Actualities and perspectives
After the unrevealing of EGFR activating mutations as the responsible for major responses
to EGFR-TKIs [3,4], ALK rearrangements are the second targetable driver events in NSCLC,
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both in terms of their frequency and the chronological availability of active ALK-TKIs [5].
Considering the impressive survival outcomes observed in ALK-positive advanced NSCLC
patients, this subset of disease represents, thus far, themost successfulmodel of targeted ther-
apy at least in lung cancer, outdoing the initial successes of EGFR inhibition and representing
a model for other molecular entities (e.g., ROS1, BRAF, MET, RET, HER2, NTRK). Since the
clinical availability of crizotinib, huge scientific efforts have been in parallel addressed to
identify resistance mechanisms. Sequential biopsies performed at the progression on ALK-
TKIs allowed to detect genomic events putatively in cause of resistance [6]. The functional
studies in engineered cellular models (e.g., Ba/F3), the establishment of primary cell cultures
and in vivo experiments, validating genomic analyses insights and providing independent
evidence, represent the cornerstone of ALK resistance research [7–13]. These elements are
moreover the bases for the virtuous harmony between clinical and preclinical research aiming
to improve patients’ outcomes, making of ALK the best example in the oncology field.
The global achievements in the field of ALK-rearranged NSCLC are recapitulated by the
updates of PROFILE-1014 andALEX trials (see Chapter 2) [14,15], fromwhichwe take a cue to
provide a global vision of the study of resistance in ALK-positive cancers.
State of the art in sequential treatment strategy: From clinical results
to resistance mechanisms
In PROFILE-1014, the first-generation inhibitor crizotinib was compared to platinum/
pemetrexed chemotherapy in the first-line setting [16]. After having demonstrated its positiv-
ity satisfying its primary objective progression-free survival (PFS), the study resulted infor-
mative providing overall survival (OS) data. Formally, a trend for longer OS was observed
for crizotinib experimental arm compared to chemotherapy [hazard ratio (HR) 0.760; 95%
confidence interval (CI), 0.548–1.053; P ¼ .0978)], with OS medians not reached (NR; 95%
CI: 45.8months-NR) and 47.5months (95% CI: 32.2-NR), respectively [14]. This is in line with
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other trials of targeted agents compared to standard-of-care chemotherapy,when crossover to
the targeted therapy is allowed at progression to cytotoxic treatment [17,18]. When virtually
adjusting for crossover indeed (modeling the lack of cross-over to crizotinib from the chemo-
therapy arm and vice-versa), OS resulted significantly better in the experimental arm [HR
0.346; 95% bootstrap CI: 0.081–0.718; medianOS 59.8 (46.6-NR) and 19.2 (13.6-NR)months, re-
spectively [14]. Besides reinforcing the role of ALK-TKIs in the first-line setting (already incor-
porated into guidelines), the trial update was informative for other aspects of interest. As
envisaged and confirmed by the data, the administration of post-study novel-generation TKIs
dramatically impacted on survival, with better results observed for patients in the crizotinib
arm receiving subsequent targeted agents. This represents indeed the sequential strategy of
ALK-TKIs adopted in the clinical practice, made possible by the availability of several gener-
ation of drugs developed on the basis of preclinical/translational evidence on resistance
mechanisms [19].
All second- (ceritinib, alectinib, brigatinib) and third-generation (lorlatinib) approvedALK
inhibitors share indeed four peculiar characteristics making them more performant com-
pared to the previous generation:
(1) Higher potency in inhibitingALK allowing the complete abrogation of its direct signaling,
useful in the case of bypass/downstream pathway activation, not sufficient per se of
maintaining cell viability, but still requiring a contribution from ALK signaling.
(2) Activity against the largest spectrum of ALK resistance mutations.
(3) Pharmacokinetics properties in terms of penetration of the blood-brain-barrier, with
regard to the frequent CNS (central nervous system) localizations of ALK-rearranged
disease, both at diagnosis and at progression to early-generation ALK-TKIs [20,21].
(4) Increased specificity for ALK, in order to avoid off-target adverse events.
These features, progressively incorporated in the second-generation ALK-TKIs, are reca-
pitulated at their higher degree in the third-generation inhibitor lorlatinib [9]. CNS progres-
sion represented a major issue when only first- or second-generation inhibitors were
available. With its impressive blood-brain penetration, as its concentration in the cerebrospi-
nal fluid is the 75% of that in the blood, lorlatinib allows a relevant control of brain disease and
“relegates” CNS progression after the extra-CNS, systemic one [22,23]. Dealing with this lat-
ter, two major molecular responsible have been identified.
First, bypass/downstream pathway activations are responsible for both primary and
acquired resistance to lorlatinib [11,13]. If their role in acquired resistance can be easily trans-
posed from other inhibitors and targets, de novo resistance requires some peculiar understand-
ing. If theonset ofabypass track is the responsible for resistance toa second-generation inhibitor,
the higher potency against ALK exerted by lorlatinib cannot be useful, as direct ALK signaling
has already been completely abrogated by the second-generation TKI itself.
Second, cancer cells find the way to acquire new ALK mutations able to elude lorlatinib
inhibition, still acknowledging that the third-generation TKI is active against all known single
mutants (including the recalcitrant G1202R) [11–13]. Both in vitro experiments and in clinical
samples, cancer cells and patients exposed of sequential generations of ALK-TKIs can ind-
eed develop complex mutations, named compound mutations, occurring on the same
ALK allele modifying the structure of the ALK-rearranged receptor, preventing lorlatinib
binding and activity. Of major interest, the occurrence of compound mutations in in vitro
and in vivo models responsible for lorlatinib resistance seems to require exposure to
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first- and second-generation inhibitors, as a pre-existing single mutation is the prerequisite to
develop additional ones [11].
Dealing with resistance to lorlatinib caused by bypass/downstream pathways activation,
the putative combination of lorlatinib with an additional inhibitor is meant to be the strategy
of choice. Nevertheless, despite increasing preclinical validation [13], such combinatorial
treatments have not really taken place yet in the clinics thus far. Identifying specific, recurrent
alterations in patient-derived samples at lorlatinib progression could hopefully boost the de-
velopment of such strategies, as seen for EGFR-driven NSCLC [24–26]. The implementation
of circulating tumor DNA (ctDNA) in ALK-rearranged diseases, already useful in detecting
simple and compound mutations involving ALK, will ostensibly power the recognition of
such molecular events [27].
With regard to compoundmutations, only anecdotical reports havewitnessed the potential
re-sensitization to crizotinib exerted byALK compoundmutants (namely the ones containing
L1198F mutation) engendering resistance lorlatinib and to second-generation ALK TKIs [28].
Developing a fourth-generation inhibitor, capable to act against variety of compoundmutants
potentially emerging during lorlatinib treatment, appears to be a relevant challenge.
This brings us to consider the other treatment strategy currently adopted in the clinics
(novel generation ALK-TKIs upfront) and its implications in approaching ALK resistance.
State of the art in new generation-upfront strategy: Improving clinical results,
waiting for evidence on resistance mechanisms
As seen for the EGFR-mutant NSCLC, moving novel-generation ALK-TKIs upfront fulfills
two major goals: to make ALK-positive NSCLC patients live longer and with a reduced tox-
icity burden [29].When administered as the first-line treatment, as expected, the three second-
generation inhibitors ceritinib, alectinib and brigatinib achieved longer PFS compared to
crizotinib [15,30,31]. Taking into account the current wide upfront administration of alectinib
in the clinical practice, the careful methodology used (with particular regard to the evaluation
of CNS disease at screening and systematically during the study), and the recent update,
ALEX trial comparing alectinib with crizotinib is the best example of the benefits of this treat-
ment strategy [15,20].
After having set amedian PFS at 34.8months (versus 10.9 in the crizotinib arm), the estima-
tions on OS, exploratory and still immature, are impressive, as median OS was NR and
57.4months (95%CI34.6–NR)withalectinib andcrizotinib, turningout ina5-year survival rate
of 62.5% and (95% CI: 54.3–70.8) and 45.5% (95% CI: 33.6–57.4), respectively [15]. Despite no
cross-over to alectinib was formally allowed within the study to patients progressing on
crizotinib, the majority of them had access to second-line targeted agents, recapitulating a se-
quential treatment strategy. Of interest, dealingwith chronic treatments, the toxicity spectrum
was in favor of alectinib with regard both to mild and serious adverse events. In addition to
these observations, alectinib features of action against and prevention of CNS metastases
vouch for its administration as first-line treatment in ALK-positive NSCLC patients [32,33].
Acknowledging these utmost results, no evidence is thus far available with regard to the
resistance mechanisms to alectinib in the upfront setting. It can be envisaged that the repar-
tition between on-target (i.e., ALK mutations) and off-target (i.e., bypass/downstream path-
ways activation) mechanisms may recapitulate the one observed when second-generation
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TKIs are administered after crizotinib, with an enrichment in the first ones (namely with re-
gard to G1202R mutation) [10]. This knowledge will put the bases to assess lorlatinib sensi-
tivity and resistance in this new setting (see previous paragraph).
Another tempting strategy is to directly move the “best-in-class” of ALK-TKI, lorlatinib,
directly upfront, as currently evaluated in the phase III CROWN trial (NCT03052608). Besides
providing a formal comparison between the third-generation inhibitor and crizotinib, this
study will allow to estimate the PFS of first-line lorlatinib. With regard to resistance mecha-
nisms awaited, we take advantage of both clinical evidence from the pretreated setting and
from preclinical work. CNS progression, relatively rare when lorlatinib is administered
within a sequential treatment approach [23], appears even less probable in mouse models
of brain metastases when given upfront [9]. Similarly, no compound mutation is expected
to raise in the lack of a pre-lorlatinib single ALK mutant [11]. Therefore, if our expectations
are correct, activation of bypass/downstream tracks will likely be identified as major players
in lorlatinib resistance. Countermoves in terms of combinatorial treatments development
would then be a putative solution to overcome (or to prevent) lorlatinib resistance.
Moving ALK inhibitions in NSCLC settings other than advanced disease:
Implications for resistance
In the last years, targeted agents have shown their role in early stages, as EGFR-TKIs as
adjuvant treatment in EGFR-driven lung cancer [34–36]. The implementation of ALK-TKIs
in the adjuvant setting is still exploratory, but the positive results observed in oncogene-
driven disease sustain this possibility, also considering that the administration of a brain-
penetrating ALK inhibitor could prevent or at least delay the occurrence of CNS relapses,
compared to chemotherapy, after the surgical removal of the tumor. Dealing with locally-
advanced NSCLC potentially suitable of radical cure, several case reports have reported
the potential role of ALK-TKIs as neoadjuvant treatment before surgery [37–41], and also in-
duction treatment with such inhibitors may be envisaged in order to reduce tumor burden
before (chemo)radiotherapy administration. These observations will require a systematic
evaluation of the ALK status (thus far limited to the advanced/metastatic NSCLC setting)
even in resectable and locally-advanced stages. Of note, these two are setting of current pe-
culiar interest: the first, as the spread of lung cancer screening programs will hopefully move
the NSCLC epidemiology towards more early stages [42], the second as the locally-advanced
diseases have recently seen the improvement since the introduction of immunotherapy con-
solidation with durvalumab (an anti-PD-L1 agent) [43]. Given the low activity and efficacy of
immune checkpoint inhibitors in the advanced setting of oncogene-addicted diseases [44], it
should be discussed if locally-advanced ALK-positive NSCLC would better benefit from a
treatment strategy involving ALK TKIs.
Still dealing with advanced-metastatic NSCLC, the “oligometastatic” disease entity has re-
cently came into the spotlight [45,46], since dedicated treatment strategies have been proposed
[47,48]. Thevariable and complexdefinitions of oligometastaticNSCLCarebeyond theobjective
of this chapter, nevertheless the application of this knowledge in ALK-driven lung cancer may
foster research in the field of resistance mechanisms research. Patients suffering from ALK-
rearranged NSCLC experiencing isolated progression under ALK-TKIs can benefit from local
treatments (surgery, radiotherapy, interventional radiology techniques), while maintaining
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the same TKI, in the scenario of oligoprogressive disease [49,50]. The oligometastatic disease,
on the other hand, represents advanced lung cancers whose limited number or metastases
allows to envisage a local treatment of all disease sites, once systemic therapy guarantees dis-
ease control. This strategy has been mainly tested with chemotherapy agents, but its potential
with targeted agents, namely ALK inhibitors, is promising.
These settings of early/locally advanced/oligometastatic ALK-rearranged NSCLC may
drive the concept of resistance to new directions [51]. These clinical situations indeed imply
that local treatment will be combined to ALK-TKIs in order to act locally against every mac-
roscopic site of the disease identified at CT and PET scans. Novel clinical scenarios will there-
fore need to be faced to assess resistance (Fig. 2):
(1) early disease undergoing surgical resection and adjuvant ALK-TKI will stimulate the
study of molecular factors on the resected tumor that could affect disease relapse.
(2) early or locally advanced disease undergoing neoadjuvant ALK-TKI will allow the
availability of large surgical samples of ALK-positive tumors after targeted treatment,
boosting to get insights on cancer cells which still remains vital.
(3) locally advanced NSCLC patients who undergo induction ALK-TKIs before (chemo)
radiotherapy could be sequentially biopsied in order to seek differential molecular
features engendered by targeted agents and radiotherapy.
(4) local treatment of oligometastic ALK-positive disease, concomitantly to (in the case of
surgery) or preceded by tumor biopsy (in the case of radiotherapy or interventional
radiology techniques) would allow to compare the molecular status of the different
disease sites after ALK-TKI exposure.
These four clinical scenarios, still hypothetical but hopefully achievable, will share some
relevant aspects of research on ALK resistance mechanisms. Indeed, thus far the molecular
evidence (still extremely precious) has been developed from genomic analyses performed
mainly on biopsy tumor samples obtained at progression to ALK-TKIs (Fig. 2A). Moving
ALK inhibition into early stageswill allow to deal with larger amounts of tumormaterial (sur-
gical resections) obtained at the moment of disease response. Although counterintuitive, this
approach could be strategic in obtaining insights on the prediction of following disease re-
lapse/progression through complexmolecular analyses. These latter would likely encompass
genomic, epigenomic, proteomic, metabolomics analyses, likely to be connected with clinico-
radiological information (e.g., disease- and progression-free survivals, risk of brain disease
localizations) into deep-learning algorithms [52]. In parallel, focusing into these novel scenar-
ios will require particular attention towards the cells of origin of potential relapse or progres-
sion (“drug-tolerant cells”) [53–56], and the concept of minimal residual disease. This latter,
with the refinement of ctDNA detecting techniques, will be ostensibly monitored with liquid
biopsy analyses, potentially informative of the presence of micro-metastatic disease before its
clinical-radiological manifestations [57,58].
State of the art and perspective on ALK-dependent malignancies other that
lung cancer
Tumors other than NSCLC that are often driven by ALK (namely ACLC, IMT and neuro-
blastoma) share some characteristics that impact on their treatment and on the study on ALK
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resistance mechanisms (see Chapter 4). Both for their main occurrence in pediatric patients
and for their clinical features, curative intent is always the primary objective to be pursued,
with a growing attention towards the reduction of long-term toxicity. The treatment back-
bones of the three entities are represented by “traditional” therapies: cytotoxic agents, sur-
gery, radiotherapy and hematopoietic stem cell transplantation (HSCT). Nevertheless, as
seen in previous chapters, ALK-TKIs find a role in these diseases, mainly as second-choice
treatments and in combination with the mentioned treatments, providing their contributions
by increasing curative rates. Moreover, compared to chemotherapy, ALK inhibitors carry an
inferior burden of long-term toxicities. The lack of awider incorporation of ALK-TKIs in these
diseases can be mainly attributed to the relative success of standard therapy (70–80% of cure
in pediatric ACLC) [59], to the challenging design of randomized clinical trials in such rare
diseases and to the scarce interest these raremalignancies evoke in pharmaceutical industries.
Although evidence concerning resistance to ALK inhibitors in patients suffering from ma-
lignancies other than NSCLC are scarce, insights can nevertheless be driven. ACLC patients
receiving ALK-TKIs inhibitors as progressing after standard chemotherapy undergo disease
response, frequently complete, in the majority of the cases [60,61]. Nevertheless, once treat-
ment with either crizotinib or ceritinib is interrupted, disease invariability recurs [62], leading
to the incorporation of ALK inhibitors as bridge therapies towards HSCT. The rapid onset of
disease progression after targeted treatment discontinuation suggests targeted treatment can-
not eliminate every single tumor cell. Identifying the molecular features of resistant clones
could potentially lead to decipher peculiar pharmacologic vulnerabilities, to be targeted to-
gether with ALK in order to avoid HSCT with its potential toxicities. In addition, almost all
the cases of disease progression while on ALK-TKIs (crizotinib, ceritinib and alectinib) oc-
curred in ACLC patients who experienced primary drug resistance [61,63,64]. This imply that
ALK-positive ACLC can be dichotomized into a disease that respond or not to ALK-TKIs.
Again, the molecular underpinnings of the differential clinical behavior are of major rele-
vance to allow non-responsive diseases to be sensitive to combinatorial treatment strategies.
Of note, this kind of differential responses are not recorded in ALK-rearranged NSCLC,
where TP53 status and BIM polymorphisms may impact on PFS and on duration of response
[65,66], but not on the initial sensitivity to ALK-TKIs.
In IMT, ALK-TKI are administered in order to reduce disease burden and allow complete
tumor removal, as radical surgery is the treatmentmainstay. Themajority of patients respond
to targeted agents and, of note, overcoming resistance with novel generation inhibitors has
been reported [67–70]. Obtaining an in-depth view of the molecular events responsible for
resistance to ALK-TKI in IMT is nevertheless awaited.
Differently from the cancer types approached thus far, in neuroblastoma ALK is not acti-
vated by gene fusion but by point mutations. This likely explains the unsatisfactory results of
crizotinib in this disease, as the first-generation inhibitor is known to act a wild-type kinase
domain and mutations occurring into kinase active sites are responsible for acquired
crizotinib resistance in NSCLC [61]. Given the relatively frequency and the potential severity
of this disease, the novel-generation ALK-TKIs now being tested, mainly as combinatorial
strategies, will hopefully confirm ALK-mutant IMT as a suitable target of ALK inhibition.
Severalother tumortypescanbefoundtoharborALKrearrangements (seeChapter1)andthey
canbenefit fromALK-TKI administration. In linewith theACLC, IMTandneuroblastoma,ALK-
positive NSCLC remains themodel to follow, concerning both the clinical use of targeted agents
and linked resistance, with peculiarities dependent from specific tumor types and localization.
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Conclusions
The wide and profound knowledge generated on the biology of resistance to ALK-TKI in
ALK-positive NSCLC are the main responsible for the major clinical achievements obtained
through the availability of several generations of ALK inhibitors and the development of
novel treatment strategies. Data concerning molecular events entailing resistance in this set-
ting have been mainly obtained from clinical samples of patients progressing on ALK-TKIs
administered sequentially. These lessons are extremely precious now that the clinical practice
is shifting towards the second- (andmaybe third-) generation inhibitors given upfront, to sug-
gest how tumors can evade direct inhibition. With the positioning of ALK inhibitors even in
the early, locally advanced and oligometastatic stages of NSCLC, new areas of research will
likely develop, in order to identify biologic features potentially responsible for relapse or pro-
gression, from clinical samples obtained at the moment of disease remission. The scientific
methodology adopted to assess ALK resistance in lung cancer should be translated in other
ALK-driven diseases, still acknowledging the biological and clinical peculiarity of the tumor
type of origin.
In conclusion, insisting on dissecting ALK resistance mechanisms has provided dramatic
improvements in the management of ALK-rearranged NSCLC. Both in lung cancer and in
other ALK-driven diseases, chasing better survival outcomes relies on the understanding
of biologic events.
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